Drug, bio-affecting and body treating compositions patents - Monitor Patents
FreshPatents.com Logo    FreshPatents.com icons
Monitor Keywords Patent Organizer File a Provisional Patent Browse Inventors Browse Industry Browse Agents



USPTO Class 514  |  Browse by Industry: Previous - Next | All     monitor keywords
08/2010 | Recent  |  14:  | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan | 13: Dec | Nov | Oct | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan | 12: Dec | Nov | Oct | Sep | Aug | July | June | May | April | Mar | Feb | Jan | 11: Dec | Nov | Oct | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan | 10: Dec | Nov | Oct | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan |  | 09: Dec | Nov | Oct | Sep | Aug | Jl | Jn | May | Apr | Mar | Fb | Jn |  | 2008 | 2007 |

Drug, bio-affecting and body treating compositions August inventions list 08/10

Below are recently published patent applications awaiting approval from the USPTO. Recent week's RSS XML file available below.
Listing for abstract view: USPTO application #, Title, Abstract excerpt,Patent Agent. Listing format for list view: USPTO National Class full category number, title of the patent application.
  
08/26/2010 > patent applications in patent subcategories. inventions list

20100216689 - Cytotoxic t cell activator comprising ep4 agonist: P

20100216688 - Peptidomimetic macrocycles: The present invention provides biologically active crosslinked polypeptides with improved properties relative to their corresponding precursor polypeptides, having good cell penetration properties and reduced binding to human proteins. The invention additionally provides methods of identifying and making such improved polypeptides.... Agent: Wilson, Sonsini, Goodrich & Rosati

20100216692 - Acidic insulin preparations having improved stability: The invention relates to a pharmaceutical formulation comprising a polypeptide selected from the group consisting of insulin, an insulin metabolite, an insulin analog, an insulin derivative and combinations thereof; a surfactant or combinations of two or more surfactants; optionally a preservative or combinations of two or more preservatives; and optionally... Agent: Andrea Q. Ryan Sanofi-aventis U.s. LLC

20100216690 - Pegylated single-chain insulin: The present invention is related to a single-chain insulin comprising the B- and the A-chain of human insulin or analogues thereof connected by a connecting peptide having from 3-35 amino acid residues, wherein the single-chain insulin comprises at least one PEG group attached to at least one lysine residue in... Agent: Novo Nordisk, Inc. Intellectual Property Department

20100216691 - Protease stabilized, pegylated insulin analogues: Novel PEGylated insulin analogues exhibiting resistance towards proteases can, effectively, be administered pulmonary or orally. The insulin analogues contain B25H and A14E or A14H. The PEGylation is at B29K.... Agent: Novo Nordisk, Inc. Intellectual Property Department

20100216694 - Antidiabetic tricyclic compounds: Tricyclic compounds containing a cyclopropanecarboxylic acid fused to a bicyclic ring, including pharmaceutically acceptable salts, are agonists of G-protein coupled receptor 40 (GPR40) and are useful as therapeutic compounds, particularly in the treatment of Type 2 diabetes, and of conditions that are often associated with this disease, including obesity and... Agent: Merck

20100216693 - Compositions and methods of treating diabetes: The invention features compositions comprising insulin and C-peptide and methods for treating diabetes, using such compositions. The invention further features compositions comprising insulin analogues and C-peptide and the uses thereof for treating diabetes.... Agent: Global Patent Group - Cbx

20100216695 - Second generation low oxygen affinity pegylated hemoglobins as oxygen-carrying plasma expanders: Provided are hemoglobins having at least two chemical modifications that lower oxygen affinity, hemoglobins chemically modified by the addition of glyceraldehyde-3-phosphate, and hemoglobins having at least two specific chemical modifications. PEGylated versions of these hemoglobins are also provided, as are certain tetraPEGylated and diPEGylated hemoglobins. Methods of modifying a hemoglobin... Agent: Amster, Rothstein & Ebenstein LLP

20100216696 - Compounds and methods for treating cancer: The present invention provides a method of treating cancer involving administering an insulin-like growth factor-1 receptor (IGF-1 receptor) agonist and an anti-cancer chemotherapeutic agent. Also provided are compounds for treating cancer comprising an IGF-1-receptor ligand coupled to an anti-cancer chemotherapeutic agent. Also provided are compounds for treating cancer comprising an... Agent: Hugh Mctavish Mctavish Patent Firm

20100216698 - Liquid formulations of g-csf: Provided are pharmaceutical liquid formulations of G-CSF, which are stable over a long time period and substantially free of excipients, as well as ready-to-use syringes containing such formulations and corresponding kits.... Agent: Latimer Intellectual Property Law, LLP

20100216697 - Pharmaceutical composition, substrate comprising a pharmaceutical composition, and use of a pharmaceutical composition: o

20100216699 - Semi-synthetic glycopeptides having antibacterial activity: Semi-synthetic glycopeptides having antibacterial activity are described. Also described are processes of preparing such semi-synthetic glycopeptides by chemical modification of a glycopeptide (Compound A, Compound B, Compound H or Compound C) or the monosaccharide made by hydrolyzing the disaccharide moiety of the amino acid-4 of the parent glycopeptide in mild... Agent: Jones Day

20100216700 - Methods of treating ocular disorders: This invention is directed to treatments of ocular disorders using emulsions and molecular dispersions in the form of a gel comprising a hydrophobic ocular agent.... Agent: Brian S. Boyer, Ph.d.

20100216718 - Cancer classification and methods of use: The present invention relates to methods of classifying cancer cells based on the presence, absence or level of a tyrosine kinase or a phosphorylated tyrosine kinase. The present invention also relates to methods of treating cancer using cancer classification. The present invention further relates to methods of determining the effectiveness... Agent: Nancy Chiu Wilker, Ph.d. Chief Intellectual Property Counsel

20100216716 - Cell-permeable peptide inhibitors of the jnk signal transduction pathway: The invention provides cell-permeable peptides that bind to JNK proteins and inhibit JNK-mediated effects in JNK-expressing cells.... Agent: Morgan Lewis & Bockius LLP

20100216707 - Cosmetic use of apolipoprotein d type proteins: The subject of the present invention is the use, in particular the cosmetic and/or therapeutic use, of the apolipoprotein D, of polypeptides derived from this protein or of analogues thereof, of a nucleic sequence encoding such a polypeptide or of an agent modulating the activity or of the expression of... Agent: Oliff & Berridge, PLC

20100216715 - Fgf21 derivatives with albumin binder a-b-c-d-e- and their use: The present invention relates to Fibroblast Growth Factor 21 (FGF21), more in particular to derivatives of FGF21 compounds having an albumin binder of the formula A-B-C-D-E- covalently attached. The invention also relates to novel FGF21 analogues, as well as to the pharmaceutical use of these FGF21 derivatives and analogues, in... Agent: Novo Nordisk, Inc. Intellectual Property Department

20100216708 - Fibronectin type iii domain based scaffold compositions, methods and uses: A protein scaffold based on a consensus sequence of fibronectin type III (FN3) proteins, such as the tenth FN3 repeat from human fibronectin (human Tenascin), including isolated nucleic acids that encode a protein scaffold, vectors, host cells, and methods of making and using thereof have applications in diagnostic and/or therapeutic... Agent: Philip S. Johnson Johnson & Johnson

20100216706 - Ghrelin protects substantia nigra dopamine neurons: A method of treating neurodegeneration of substantia nigra pars compacta (SNpc) dopamine neurons and compositions therefor are provided.... Agent: Drinker Biddle & Reath Attn: Intellectual Property Group

20100216705 - Human growth hormone formulations: Formulations containing complexed human growth hormone crystals are described. Also described are needleless injection systems for crystalline proteins.... Agent: Lando & Anastasi, LLP

20100216717 - Hypoallergenic mutant polypeptides based on fish parvalbumin: The present invention relates to non-naturally occurring polypeptides derived from fish allergens such as parvalbumin Cyp c 1.01 from carp. The polypeptides display reduced allergenic activity and are useful as allergy vaccines for treatment of sensitized allergic patients and for prophylactic vaccination.... Agent: Arent Fox LLP

20100216703 - Inhibitors of pde4 and methods of use: The inventors have succeeded in discovering that the p75 neurotrophin receptor (p75NTR) is directly involved in the degradation of cAMP via interaction of its intracellular domain with phosphodiesterase 4A4/5 (PDE4A4/5). Provided herein are methods and compositions for the treatment of conditions of PDE4A4/5 and p75NTR expression (such as pulmonary disease... Agent: Spencer Fane Britt & Browne LLP

20100216710 - Methods for stimulating nervous system regeneration and repair by regulating arginase i and polyamine synthesis: This invention relates to the novel identification of arginase as an enzymatic activity which can reverse inhibition of neuronal regeneration in the central and peripheral nervous system. Assays to monitor the effects of various agents on arginase expression and thus on neuronal regeneration and repair and to identify agents which... Agent: Fish & Richardson P.C. / Cuny Research Foundation Of The City University Of New

20100216714 - Natriuretic compounds, conjugates, and uses thereof: Modified natriuretic compounds and conjugates thereof are disclosed in the present invention. In particular, conjugated forms of hBNP are provided that include at least one modifying moiety attached thereto. The modified natriuretic compound conjugates retain activity for stimulating cGMP production, binding to NPR-A receptor, and in some embodiments an improved... Agent: Moore & Van Allen PLLC

20100216713 - Novel compositions and methods in cancer associated with altered expression of prlr: The present invention relates to novel sequences for use in diagnosis and treatment of carcinomas, especially breast cancers. In addition, the present invention describes the use of novel compositions for use in screening methods. The invention provides compositions and methods associated with altered expression of PRLR in cancer.... Agent: Mcdermott Will & Emery LLP

20100216704 - Novel genes and proteins that home to developing microvessels: Described herein are polypeptides that home to developing microvasculature, (also referred to as developing microvessels), such as newly developing microvasculature in mammals, particularly in humans, and to DNA that encodes such polypeptides. These polypeptides are referred to herein as developing microvasculature homing polypeptides. In a specific embodiment, the homing peptides... Agent: Wolf Greenfield & Sacks, P.C.

20100216712 - Nucleic acid codifying for a utrophin transcription specific regulating protein, protein codified thereby and uses thereof: The present invention relates to a nucleic acid molecule comprising a nucleotide sequence codifying for a protein characterized in having at least four zinc finger domains and in modulating the transcription of the utrophin gene by binding to a nucleotidic sequence comprised in a utrophin gene untranscribed regulatory sequence. Protein... Agent: Lucas & Mercanti, LLP

20100216711 - Protease-stable, cell wall-lysing enzymes: The present invention relates to a modified polypeptide with a biological activity to lyse cell walls of bacteria, wherein the polypeptide has no caspase, clostripain, enterokinase, factor Xa, granzyme B, staphylococcus peptidase I (V8 Protease), plasmin, streptopain, bacillolysin and/or thrombin cleavage site. The invention further relates to nucleic acids with... Agent: Fulbright & Jaworski L.L.P.

20100216701 - Protein kinase c inhibitors for prevention of insulin resistance and type 2 diabetes: The present invention provides peptides and peptide analogs capable of inhibiting the activity of protein kinase C. The invention discloses use of such peptides and analogs for preparation of pharmaceutical compositions and methods for prevention, delay, suppression or treatment of type 2 diabetes using such compositions.... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20100216719 - Soluble fiber combinations for weight control and improving parameters of cardiovascular health: A food or pharmaceutical agent is provided for treating or offsetting the risks of a disease or disorder such as a cardiovascular disease, a hypercholesterolemia disorder, a low serum high density lipid (HDL)/low density lipid (LDL) ratio, a hypertriglyceridemia disorder, and diabetes includes a pharmaceutical carrier, and a composition including... Agent: Chalker Flores, LLP

20100216709 - Systemic insulin-like growth factor-1 therapy reduces diabetic peripheral neuropathy and improves renal function in diabetic nephropathy: The present invention provides methods of treatment of patients suffering from the complications of blood sugar disorders: diabetic peripheral neuropathy and diabetic nephropathy by administration of IGF-1 via protein therapy or gene therapy. It relates to methods of treating an individual having a diabetic disorder or a hyperglycemic disorder, comprising... Agent: Robins & Pasternak

20100216702 - Vegf analogs and methods of use: Modified VEGF proteins that inhibit VEGF-mediated activation or proliferation of endothelial cells are disclosed. The analogs may be used to inhibit VEGF-mediated activation of endothelial cells in angiogenesis-associated diseases such as cancer, inflammatory diseases, eye diseases, and skin disorders.... Agent: Cooley LLP Attn: Patent Group

20100216720 - Antibodies to troponin i and methods of use thereof: The subject invention relates to antibodies to troponin I as well as methods of use thereof. In particular, such antibodies may be used to detect Troponin I in a patient and may also be used in the diagnosis of, for example, a myocardial infarction or acute coronary syndrome.... Agent: Paul D. Yasger Abbott Laboratories

20100216721 - Inhibition of hiv-1 infection by potent metallocene conjugated peptide through conformational entrapment of envelope gp120: The invention provides a peptide triazole conjugate and derivatives thereof, and methods of its use.... Agent: Drinker Biddle & Reath Attn: Intellectual Property Group

20100216722 - Use of the peptide pro-gly-thr-cys-glu-ile-cys-ala-tyr-ala-ala-cys-thr-gly-cys as a therapeutic agent: The present invention is directed to the use of the peptide compound Pro-Gly-Thr-Cys-Glu-Ile-Cys-Ala-Tyr-Ala-Ala-Cys-Thr-Gly-Cys-OH as a therapeutic agent for the prophylaxis and/or treatment of cancer, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurodegenerative diseases, infectious diseases, lung diseases, heart and vascular diseases and metabolic diseases. Moreover the present invention relates to pharmaceutical... Agent: Winstead PC

20100216723 - Neuroprotection using nap-like and sal-like peptide mimetics: This invention relates to NAP-like and SAL-like peptide mimetics, polypeptides, or small molecules derived from them, and their use in the treatment of neuronal dysfunction, neurodegenerative disorders cognitive deficits, neuropsychiatric disorders, and autoimmune disease.... Agent: Townsend And Townsend And Crew, LLP

20100216724 - Use of fibronectin fragment (196-203 ) as a therapeutic agent: The present invention is directed to the use of the peptide compound Ser-Arg-Asn-Arg-Cys-Asn-Asp-Gln-NH2 as a therapeutic agent for the prophylaxis and/or treatment of cancer, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurodegenerative diseases, infectious diseases, lung diseases, heart and vascular diseases and metabolic diseases. Moreover the present invention relates to pharmaceutical... Agent: Winstead PC

20100216725 - 4-amino-4-oxobutanoyl peptides as inhibitors of viral replication: and the pharmaceutically salts and hydrates thereof. The variables R, R1, R6-R8, R16, R18, R19, M, n, T, Y, and Z are defined herein. Certain compounds of Formula I are useful as antiviral agents. The 4-amino-4-oxobutanoyl peptides disclosed herein are potent and/or selective inhibitors of viral replication, particularly Hepatitis C... Agent: Cantor Colburn, LLP

20100216726 - Substituted-quinoxaline-type piperidine compounds and the uses thereof: The invention relates to Substituted-Quinoxaline-Type Piperidine Compounds, compositions comprising an effective amount of a Substituted-Quinoxaline-Type Piperidine Compound and methods to treat or prevent a condition, such as pain, comprising administering to an animal in need thereof an effective amount of a Substituted-Quinoxaline-Type Piperidine Compound.... Agent: Dechert LLP

20100216727 - Carbohydrate-metallocene-antimalarial conjugates: An antimalarial conjugate according to a non-limiting embodiment of the present invention may include a metallocene, a carbohydrate, and an antimalarial agent. The metallocene may include two cyclopentadienyl rings bound to a central metal atom. The carbohydrate and the antimalarial agent may be appended to at least one of the... Agent: Harness, Dickey & Pierce, P.L.C

20100216729 - Cancer cell growth inhibition by black bean (phaseolus vulgaris l) extracts: A group of phytochemical compounds extracted from whole germinated or not germinated black beans (Phaseolus vulgaris L) and/or their dry milled fractions such as seed coats or hulls and cotyledons is described. These phytochemicals are classified as phenolics, such as polyphenols, flavonoids, coumarins, and tannins, triterpenes such as saponins, phytosterols... Agent: Frommer Lawrence & Haug

20100216728 - New use of specific cyklolignans: The invention refers to the use of specific cyclolignans, wherein the carbon atoms in positions 9 and 9′ have cis configuration, for inhibition of the insulin-like growth factor-1 receptor. Said compounds can be used for treatment of IGF-1R dependent diseases, such as cancer, psoriasis, artherosclerosis and acromegaly. A preferred compound... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, L.L.P.

20100216730 - Sprayable controlled-release, male annihilation technique (mat) formulation and insect control: A male annihilation insecticide formulation, having a viscosity appropriate for use in aerial or backpack spray applications and suitable for on-crop or off-crop uses, comprises an insect toxicant and a male-specific attractant, such as a parapheromone, for a target insect species, such as fruit fly, dispersed and entrapped in an... Agent: Dow Agrosciences LLC

20100216732 - Azithromycin for the treatment of nodular acne: Azithromycin, administered systemically, is an effective treatment for nodules associated with acne vulgaris.... Agent: Howard Eisenberg, Esq.

20100216731 - Process for the preparation of macrolide antibacterial agents: Described herein are processes for the preparation of compounds of formula (I): and pharmaceutically acceptable salts, solvates, and hydrates thereof.... Agent: Barnes & Thornburg LLP

20100216734 - Modulation of neurogenesis by nootropic agents: The instant disclosure describes methods for treating diseases and conditions of the central and peripheral nervous system by stimulating or increasing neurogenesis. The disclosure includes compositions and methods based on use nootropic agents, optionally in combination with one or more other neurogenic agents, to stimulate or activate the formation of... Agent: Sughrue Mion, PLLC

20100216733 - Use of inhibitors and antisense oligonucleotides of btk for treating proliferative mastocytosis: The present invention relates to a method for treating proliferative mastocytosis comprising administering a Bruton tyrosine kinase (BTK) inhibitor, a BTK antisense to a mammal in need of such treatment. The invention is more particularly suited for treating category II, III and IV mastocytosis.... Agent: Birch Stewart Kolasch & Birch

20100216867 - Methods of treatment of a bcl-2 disorder using bcl-2 antisense oligomers: The present invention is directed to the use of bcl-2 antisense oligomers to treat and prevent bcl-2 related disorders. These disorders include cancers, tumors, carcinomas and cell-proliferative related disorders. In one embodiment of the invention, a bcl-2 antisense oligomer is administered at high doses. The present invention is also directed... Agent: Diehl Servilla LLC

20100216865 - Microrna compositions in the treatment of vegf-mediated disorders: The invention provides methods of treating diseases caused by the over-production of a VEGF polypeptide by administering miRNA or miRNA inhibitor compositions to decrease at least one activity of a VEGF polypeptide.... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.c

20100216864 - Rna antagonist compounds for the modulation of pcsk9: The present invention provides compounds, compositions and methods for modulating the expression of PCSK9. In particular, this invention relates to oligomeric compounds, such as oligonucleotide compounds, which are hybridisable with target nucleic acids encoding PCSK9, and methods for the preparation of such oligomeric compounds. The oligonucleotide compounds have been shown... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20100216866 - Rnai modulation of apob and uses thereof: The invention relates to compositions and methods for modulating the expression of apolipoprotein B, and more particularly to the downregulation of apolipoprotein B by chemically modified oligonucleotides.... Agent: Alnylam/fenwick

20100216863 - Susceptibility gene for myocardial infarction, stroke, and paod; methods of treatment: Polymorphisms in the FLAP and LTA4H gene are shown by genetic association analysis to be susceptibility markers for myocardial infarction (MI) and ACS, as well as stroke and PAOD. Pathway targeting for treatment and diagnostic applications in identifying those who are at risk of developing MI, ACS, stroke or PAOD,... Agent: Marshall, Gerstein & Borun LLP

20100216868 - Agents, compositions and methods for treating pathologies in which regulating an ache-associated biological pathway is beneficial: The present invention provides agents which are capable of regulating the function of a micro-RNA component which can be used to regulate an AChE-associated biological pathway. In addition, the present invention provides methods and pharmaceutical compositions for the treatment of various pathologies related to AChE-associated biological pathways such as apoptosis,... Agent: Martin D. Moynihan D/b/a Prtsi, Inc.

20100216735 - Gpcr enhanced neuroprotection to treat brain injury: Disclosed are methods of preventing or treating neuronal damage associated with oxidative stress and/or neuronal injury. The method comprises administering to a patient a pharmaceutical composition comprising a purinergic P2Y receptor ligand, in an amount effective to increase the extracellular concentration of said agonist in the brain of the subject... Agent: Meyertons, Hood, Kivlin, Kowert & Goetzel, P.C.

20100216737 - Inactivation of mir-34a by abberant cpg methylation in cancer: The present application refers to methods for cancer diagnosis and treatment, particularly in types of cancers associated with aberrant CpG methylation of the miR-34a promoter.... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20100216736 - 2'-cyanopyrimidine nucleoside compound: [wherein one of X and Y is cyano and the other is hydrogen; and i) R1 is hydrogen, and R2 is alkyloxycarbonyl wherein the alkyl moiety is straight or branched C5-12 alkyl (the alkyl may be substituted), or alternatively, ii) R1 is alkyloxycarbonyl wherein the alkyl moiety is straight or... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20100216738 - Acaricidal active substance combinations: The present invention relates to the use of active substance combinations which consist firstly of a known dihydrofuranone derivative and secondly of further known pesticidal active substances, which active substance combinations are used for controlling animal pests, in particular from the order of the mites.... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20100216740 - Cereal-based infant nutrition with fibre: Cereal-based semi-liquid and/or semi-solid compositions suitable for supporting the transition period wherein the infant changes from a diet consisting of breast milk or liquid infant formula to solid adult foods, comprising uronic acid carbohydrates with a degree of polymerisation (DP) between 10 and 300 and also uses thereof are disclosed.... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20100216739 - Method of promoting muscle tissue repair: A method of treating a muscle tissue which is effected by providing the muscle tissue with an effective amount of a sterile polymer solution being essentially devoid of free multivalent cations and being capable of self-gelling following deposition in or around the muscle tissue.... Agent: Hoffmann & Baron, LLP

20100216741 - Ophthalmic composition: The present invention provides an ophthalmic composition which stabilizes the tear film during wearing contact lens, prevents eye dryness, imparts a favorable sensation in using, is highly convenient with no risk of misuse and shows a high efficiency in the course from manufacturing to sales. More specifically, the present invention... Agent: Birch Stewart Kolasch & Birch

20100216742 - Soluble fiber combinations for weight control and improving parameters of cardiovascular health: A food or pharmaceutical agent is provided for treating or offsetting the risks of a disease or disorder such as a cardiovascular disease, a hypercholesterolemia disorder, a low serum high density lipid (HDL)/low density lipid (LDL) ratio, a hypertriglyceridemia disorder, and diabetes includes a pharmaceutical carrier, and a composition including... Agent: Chalker Flores, LLP

20100216743 - Therapy-enhancing glucan: This invention provides a method for introducing substances into cells comprising contacting a composition comprising orally administered beta-glucan with said cells. This invention also provides a method for introducing substances into a subject comprising administering to the subject an effective amount of the above compositions. The substance which could be... Agent: Law Offices Of Albert Wai-kit Chan, PLLC

20100216744 - Thickener/gellant for oily substance: The purpose of the invention is to provide a thickening and gelling agent that is easily dispersed into an oily substance such as a silicone oil in a small addition amount, is free of liquid separation, stably forms a thickened material or a gel state, and can prepare a thickened... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, L.L.P.

20100216745 - Novel cephem compounds useful for the treatment of bacterial infections: The present invention relates to new cephem compounds useful for the treatment of bacterial infections. The invention also relates to methods of preparing the compounds, pharmaceutical compositions comprising the compounds, and to methods of treatment using the compounds. The new cephem compounds are stable, exhibit good solubility, and are particularly... Agent: Forest Laboratories, Inc. Attn: Charles S. Ryan

20100216746 - Chemical compounds: The present invention relates to compounds that are a non-nucleoside reverse transcriptase inhibitors, and to processes for the preparation and use of the same. Specifically, the present invention includes methods of using such compounds in the treatment of human immunodeficiency virus infection.... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B482

20100216747 - Preventive agent or therapeutic agent for disease caused by abnormal bone metabolism: An object of the present invention is to provide a preventive drug and a therapeutic drug for diseases caused by abnormal bone metabolism, especially osteoporosis, which is more effective than conventional drugs. Combined use of N-hydroxy-4-{5-[4-(5-isopropyl-2-methyl-1,3-thiazol-4-yl)phenoxy]pentoxy}-benzamidine, or a salt thereof; and at least one compound selected from the group consisting... Agent: Sughrue Mion, PLLC

20100216748 - Pyrrole derivatives and their methods of use: The invention relates to a series of substituted pyrrole derivatives, compositions comprising the same, and methods of treating conditions and disorders using such compounds and compositions.... Agent: Paul D. Yasger Abbott Laboratories

20100216749 - Combination therapy for neuroprotection: The present invention relates to combination therapy of a pyruvoyl derivative and an anti-oxidant, which is characterized by significant increase of the activity of microglia, inhibition of brain tissue damage by the activation of inflammatory cytokines, improvement of motor skill and recovery effect of neuronal damage. Compared to single treatment... Agent: The Webb Law Firm, P.C.

20100216750 - Tricyclic inhibitors of fatty acid amide hydrolase: A series of substituted oxazole compounds having an alpha keto side chain at the 2 position and an aromatic, heteroaromatic or heterocycle substituent at the 5 position are disclosed. These compounds exhibit inhibition of fatty acid amid hydrolase and arc useful for treatment of malconditions involving that enzyme.... Agent: Schwegman, Lundberg & Woessner, P.A.

20100216751 - Liquid bevirimat dosage forms for oral administration: The present application discloses and claims liquid pharmaceutical compositions comprising bevirimat dimeglumine as a drug substance, methods of treatment comprising administering such compositions to a subject in need thereof, and the use of such compositions in the manufacture of medicaments.... Agent: Myriad Pharmaceuticals, Inc. C/o Cpa Global

20100216752 - Use as medicaments of derivatives of cholest-4-en-3-one, pharmaceutical compositions containing them, novel derivatives and their preparation process: e

20100216755 - Anti-tumor agent:

20100216754 - Compositions for the treatment of inflammation of the gastrointestinal tract: Provided herein are methods for treating the symptoms of and inflammation associated with gastroesophageal reflux disease (GERD) and other conditions. Also provided herein are pharmaceutical compositions useful for the methods of the present invention.... Agent: Wilson, Sonsini, Goodrich & Rosati

20100216753 - Controlled release of drugs into/through the skin: The slow and sustained, controlled release of a drug into and through the skin includes topically applying onto the skin of an individual in need of such treatment, a composition containing at least one solubilized drug, at least one film-forming silicone, and at least one volatile solvent.... Agent: Buchanan, Ingersoll & Rooney PC

20100216756 - Compositions and methods for suppressing endometrial proliferation: The subject matter of the instant invention is pertinent to the field of hormone therapy. More specifically, the subject matter of the instant invention concerns methods of treating estrogen-dependent conditions such as endometrial hyperplasia and endometrial cancer in a female undergoing estrogen and/or selective estrogen receptor modulator (SERM) therapy. The... Agent: Howrey LLP - East

20100216757 - Sprayable compositions comprising pharmaceutical active agents, volatile silicones and a non-volatile oily phase: A process for improving the penetration of at least one pharmaceutical active agent into the skin, including formulating at least one volatile silicone, a non-volatile oily phase and a pharmaceutically acceptable alcoholic vehicle herewith, and spraying the formulation onto the skin of an individual in need of such treatment.... Agent: Buchanan, Ingersoll & Rooney PC

20100216759 - Novel 2-azetidinone derivatives and their use as cholesterol absorption inhibitors for the treatment of hyperlipidaemia: Compounds of formula (I) (wherein variable groups are as defined within) pharmaceutically acceptable salts, solvates, solvates of such salts and prodrugs thereof and their use as cholesterol absorption inhibitors for the treatment of hyperlipidaemia are described. Processes for their manufacture and pharmaceutical compositions containing them are also described.... Agent: Pepper Hamilton LLP

20100216761 - Novel azetidinones useful as inhibitors of elastase: The invention is directed to novel azetidinones selected from 2-(S)-[4-(((2-(Dimethylamino)ethyl)ethylamino)carbonyl)phenoxy]-3,3-diethyl-N-[1-(R)-(4-(trifluoromethoxy)phenyl)butyl]-4-oxo-1-azetidin ecarboxamide, 2-(S)-[4-(((2-(Dimethylamino)ethyl)ethylamino)carbonyl)phenoxy]-3,3-diethyl-N-[1-(R)-(4-(trifluoromethyl)phenyl)butyl]-4-oxo-1-azetidinecarboxamide, and analogs thereof, and pharmaceutically acceptable salts thereof, and their use in the treatment of diseases associated with an excess of elastase, including emphysema, bronchial inflammation, chronic bronchitis, cystic fibrosis, acute respiratory distress syndrome, rheumatoid arthritis, osteoarthritis; glomerulonephritis,... Agent: Merck

20100216762 - Agonists and antagonists of the s1p5 receptor, and methods of use thereof: Disclosed are compounds that are agonists or antagonists of the S1P5 receptor, compositions comprising said compounds, and methods of using said compounds and compositions. In certain embodiments, said compounds are 1-benzylazetidine-3-carboxylic acid derivatives. In certain embodiments, said methods relate to the treatment of neuropatic pain and/or a neurodegenerative disorder. In... Agent: Abbott Bioresearch

20100216763 - Heteroaryl amide derivatives: Heteroaryl amide derivatives are provided, of the Formula: wherein variables are as described herein. Such compounds are ligands that may be used to modulate specific receptor activity in vivo or in vitro, and are particularly useful in the treatment of conditions associated with pathological receptor activation in humans, domesticated companion... Agent: Lundbeck Research Usa, Inc. Attention: Stephen G. Kalinchak, Legal

20100216766 - Inhibitors of vegf receptor and hgf receptor signalling: The invention relates to the inhibition of VEGF receptor signaling and HGF receptor signaling. The invention provides compounds and methods for inhibiting VEGF receptor signaling and HGF receptor signaling. The invention also provides compositions and methods for treating cell proliferative diseases and conditions... Agent: Wood, Phillips, Katz, Clark & Mortimer

20100216765 - Kinase inhibitors: e

20100216764 - Soluble guanylate cyclase activators: and pharmaceutically acceptable salts thereof which are soluble guanylate cyclase activators. The compounds are useful for treatment or prevention of cardiovascular diseases, endothelial dysfunction, diastolic dysfunction, atherosclerosis, hypertension, pulmonary hypertension, angina pectoris, thromboses, restenosis, myocardial infarction, strokes, cardiac insufficiency, pulmonary hypertonia, erectile dysfunction, asthma bronchiale, chronic kidney insufficiency, diabetes, or... Agent: Merck

20100216760 - Novel compounds as cannabinoid receptor ligands: d

20100216758 - Pyridone compounds: [wherein R1 and R2 represent a lower alkyl group, a C3-6 cycloalkyl group or the like, X1 and X2 represent methine, an Ar—Y1—Y2—Y3-substituted methine or the like, however either of them is an Ar—Y1—Y2—Y3-substituted methine, X3 to X8 represent methine, —N— or the like, Y1 and Y3 represent a single... Agent: Merck

20100216768 - N-substituted azaindoles and methods of use: The invention relates to N-substituted azaindolyl compounds of Formula I with anti-cancer and/or anti-inflammatory activity and more specifically to N-substituted azaindolyl compounds which inhibit MEK kinase activity. The invention provides compositions and methods useful for inhibiting abnormal cell growth or treating a hyperproliferative disorder, or treating an inflammatory disease in... Agent: Genentech, Inc.

20100216767 - Quinazolines for pdk1 inhibition: The invention provides novel compounds that are inhibitors of PDK1. Also provided are pharmaceutical compositions including the compounds, and methods of treating proliferative diseases, such as cancers, with the compounds or compositions.... Agent: Novartis Institutes For Biomedical Research, Inc.

20100216770 - Inhibitors of the interaction between mdm2 and p53: e

20100216769 - Substituted glycinamides, process for their manufacture and use thereof as medicaments:

20100216771 - Method oftreating demyelination diseases: The present invention relates to a method of treating demyelination diseases, such as multiple sclerosis, comprising administration of an atypical antipsychotic drug, such as quetiapine or an analog thereof, to a subject in need thereof.... Agent: Bereskin And Parr LLP/s.e.n.c.r.l., S.r.l.

20100216772 - Novel phenantridine analogues and uses thereof: e

20100216774 - Cyclopropyl fused indolobenzazepine hcv ns5b inhibitors: The disclosure provides compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV.... Agent: Louis J. Wille Bristol-myers Squibb Company

20100216773 - Phenanthroindolizidine analogues: Treatment of coronavirus infection with phenanthroindolizidine analogues.... Agent: Occhiuti Rohlicek & Tsao, LLP

20100216775 - Adamantanamines and neramexane salts of thiomolybdic and thiotungstic acids: This invention concerns adamantanamines (e.g. memantine, amantadine, and rimantadine) and neramexane salts of thiomolybdic and thiotungstic acids, including their preparation and pharmaceutical compositions, as dual acting drugs. These salts are used to treat or potentially arrest the neurodegenerative pathophysiology, clinical signs and symptoms of dementia of the Alzheimer's type, Parkinson's,... Agent: Technology Law, PLLC

20100216776 - Assays for s100 inhibitors: Provided are methods of determining whether a compound is an inhibitor of an S100 protein. The methods utilize a biosensor that comprises the S100 protein that has a covalently bound fluorescent dye at an amino acid residue of the S100 protein that becomes less exposed to the aqueous solution upon... Agent: Amster, Rothstein & Ebenstein LLP

20100216777 - Aminopyrazine analogs for treating glaucoma and other rho kinase-mediated diseases and conditions: Methods for using aminopyrazine analogs to treat rho kinase-mediated diseases or rho kinase-mediated conditions, including controlling intraocular pressure and treating glaucoma, are disclosed. Ophthalmic pharmaceutical compositions useful in the treatment of eye diseases such as glaucoma, and additionally useful for controlling intraocular pressure, the compositions comprising an effective amount of... Agent: Alcon

20100216778 - Pain remedy containing rock inhibitor: Since a ROCK inhibitor exerts a potent analgesic effect by a single dose after the onset of a cartilage-related disease such as osteoarthritis, and can regenerate or suppress destruction of cartilage tissue and alleviate pain associated with cartilage diseases by multiple doses, administration of an therapeutically effective amount of the... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, L.L.P.

20100216779 - Imidazopyridine kinase inhibitors: The present invention provides imidazopyridine compounds, compositions containing the same, as well as processes for the preparation and methods for their use as pharmaceutical agents.... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B482

20100216780 - Novel 1,4-diaza-bicyclo[3.2.2]nonyl oxadiazolyl derivatives and their medical use: Due to their pharmacological profile the compounds of the invention may be useful for the treatment of diseases or disorders as diverse as those related to the cholinergic system of the central nervous system (CNS), the peripheral nervous system (PNS), diseases or disorders related to smooth muscle contraction, endocrine diseases... Agent: Birch Stewart Kolasch & Birch

20100216781 - Mtor kinase inhibitors for oncology indications and diseases associated with the mtor/pi3k/akt pathway: wherein R1-R4 are as defined herein, compositions comprising an effective amount of a Heteroaryl Compound and methods for treating or preventing cancer, inflammatory conditions, immunological conditions, neurodegenerative diseases, diabetes, obesity, neurological disorders, age-related diseases, or cardiovascular conditions, comprising administering an effective amount of a Heteroaryl Compound to a patient in... Agent: Jones Day

20100216783 - Compositions, synthesis, and methods of utilizing arylpiperazine derivatives: The present invention provides arylpiperazine derivatives which can be advantageously used for treating schizophrenia and related psychoses such as acute manic, bipolar disorder, autistic disorder and depression.... Agent: Fenwick & West LLP

20100216784 - Compounds for inhibiting beta-amyloid production and methods of identifying the compounds: Provided are compounds useful for treating diseases associated with a cerebral accumulation of Alzheimer's amyloid, such as Alzheimer's disease. Also provided are methods for screening for such compounds, by measuring capacitative calcium entry in cells which optionally overexpress APP or a fragment thereof. Also provided are methods of treating or... Agent: Bryan Cave LLP

20100216782 - Hydroxybenzamide derivatives and their use as inhibitors of hsp90: o

20100216785 - Pharmaceutical compositions:

20100216786 - New compounds: within them favourably to the antagonists, to their salts, solvates, N-oxides and isomers, to the pharmaceutical compositions containing the compounds of the general formula (I), their salts, solvates, N-oxides and isomers, to the use of the compounds of the general formula (I), their salts, solvates, N-oxides and isomers, to the... Agent: Andrea Q. Ryan Sanofi-aventis U.s. LLC

20100216787 - Thiazole derivative: t

20100216788 - Fused heterocyclic compound:

20100216790 - Imidazopyridine-derivatives as inducible no-synthase inhibitors:

20100216789 - Rho-kinase inhibitors: Disclosed are compounds and derivatives thereof, their synthesis, and their use as Rho-kinase inhibitors. These compounds of the present invention are useful for inhibiting tumor growth, treating erectile dysfunction, and treating other indications mediated by Rho-kinase, e.g., coronary heart disease.... Agent: Millen, White, Zelano & Branigan, P.C.

20100216791 - Pyridinylquinazolinamine derivatives and their use as b-raf inhibitors: The invention relates to chemical compounds of the formula (I) or pharmaceutically acceptable salts thereof, which possess B-Raf inhibitory activity and are accordingly useful for their anti cancer activity and thus in methods of treatment of the human or animal body. The invention also relates to processes for the manufacture... Agent: Astrazeneca R&d Boston

20100216792 - Pesticidal arylpyrrolidines: e

20100216793 - Heteroaryl substituted pyridazinone derivatives:

20100216794 - Pyridine derivatives useful as glucokinase activators:

20100216795 - Tnik inhibitor and the use:

20100216796 - N-hydroxy-naphthalene dicarboxamide and n-hydroxy-biphenyl-dicarboxamide compounds as histone deacetylase inhibitors: The present invention relates to a novel class of N-hydroxy-naphthalene dicarboxamide and N-hydroxy-biphenyl-dicarboxamide derivatives. The N-hydroxy-naphthalene dicarboxamide and N-hydroxy-biphenyl-dicarboxamide compounds can be used to treat cancer. The N-hydroxy-naphthalene dicarboxamide and N-hydroxy-biphenyl-dicarboxamide compounds can also inhibit histone deacetylase and are suitable for use in selectively inducing terminal differentiation, and arresting cell... Agent: Merck

20100216797 - Preparation of thioarabinofuranosyl compounds and use thereof: wherein X is selected from the group consisting of hydrogen, fluorine, alkoxy, alkyl, haloalkyl, alkenyl, haloalkenyl, alkynyl, amino, monoalkylamino, dialkylamino, cyano and nitro. The above compounds also inhibit DNA replication in mammalian cells.... Agent: Connolly Bove Lodge & Hutz LLP

20100216798 - Fused heterocycles as lck inhibitors: e

20100216799 - Phthalazine and pyrido[3,4-d]pyridazine compounds as h1 receptor antagonists:

20100216804 - Long circulating nanoparticles for sustained release of therapeutic agents: The present disclosure is directed in part to a biocompatible nanoparticle composition comprising a plurality of non-colloidal long circulating nanoparticles, each comprising a α-hydroxy polyester-co-polyether and a therapeutic agent, wherein such disclosed compositions provide a therapeutic effect for at least 12 hours.... Agent: Goodwin Procter LLP Patent Administrator

20100216805 - Modulation of neurogenesis using d-cycloserine combinations: The disclosure provides compositions and methods for treating diseases and conditions of the central and peripheral nervous system by stimulating or increasing neurogenesis. The disclosure provides compositions and methods based on the use of D-cycloserine in combination with the neurogenic agent, which synergistically stimulates or activates the formation of new... Agent: Sughrue Mion, PLLC

20100216803 - Ornithine derivative: e

20100216802 - Pteridine derivatives as polo-like kinase inhibitors useful in the treatment of cancer: wherein R1 and R2 are hydrogen, or an optionally substituted (C1-C6)alkyl, (C2-C6)alkenyl, (C2-C6)alkynyl or (C3-C6)cycloalkyl group; R3 and R3′ are independently selected from hydrogen, —CN, hydroxyl, halogen, optionally substituted (C1-C6)alkyl, (C2-C6)alkenyl, (C2-C6)alkynyl or (C3-C6)cycloalkyl, —NR5R6 or C1-C4 alkoxy, wherein R5 and R6 are independently hydrogen or optionally substituted (C1-C6)alkyl; ring... Agent: Banner & Witcoff, Ltd.

20100216801 - Thiazolones for use as pi3 kinase inhibitors: Invented is a method of inhibiting the activity/function of PI3 kinases using substituted thiazolones. Also invented is a method of treating one or more disease states selected from: autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, allergy, asthma, pancreatitis, multiorgan failure, kidney diseases, platelet aggregation, cancer, sperm motility, transplantation rejection,... Agent: Glaxosmithkline Global Patents -us, Uw2220

20100216800 - Treatment of type 2 diabetes with a combination of dpiv inhibitor and metformin or thiazolidinedione: This invention relates to a therapeutic method for glycaemic control, in particular to a method for the treatment of type 2 diabetes, comprising the administration of a DPIV inhibitor together with metformin or a thiazolidinedione.... Agent: Osi Pharmaceuticals, Inc.

20100216806 - Ortho aminoamides for the treatment of cancer: i

20100216807 - Heterocyclic compounds as serotonergic and / or dopaminergic agents and uses thereof: which exhibit a dopamine receptor (preferably a D4 receptor) and/or a serotonine receptor (preferably 5HTA1 agonistic activity), processes of preparing same, pharmaceutical compositions containing same and uses thereof in the treatment of medical conditions associated with the dopaminergic and/or serotonergic systems (e.g., sexual disorders, dyskinesia, anxiety) are disclosed.... Agent: Martin D. Moynihan D/b/a Prtsi, Inc.

20100216808 - Substituted pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors: Pyrazolo-quinazoline derivatives of formula (I) as defined in the specification, and pharmaceutically acceptable salts thereof, process for their preparation and pharmaceutical compositions comprising them are disclosed; the compounds of the invention may be useful, in therapy, in the treatment of diseases associated with a disregulated protein kinase activity, like cancer.... Agent: Scully Scott Murphy & Presser, PC

20100216809 - Piperidine/piperazine derivatives: The invention further relates to a DGAT inhibitor of formula (I), including any stereochemically isomeric form thereof, wherein A represents CH or N; the dotted line represents an optional bond in case A represents a carbon atom; X represents —NRx—C(═O)—; —Z—C(═O)—; —Z—NRx—C(═O)—; —S(═O)p-; C(═S)—; —NRx—C(═S)—; —Z—C(═S)—; —Z—NRx—C(═S)—; —O—C(═O)—; —C(═O)—C(═O)—; R1... Agent: Philip S. Johnson Johnson & Johnson

20100216810 - Heterocyclic compound and use thereof: e

20100216811 - Furo[3. 2-b] pyrrol derivatives: The present invention relates to compounds of formula (I), and pharmaceutically acceptable salts thereof, wherein: R3 is tert-butylmethyl, sec-butyl or tert-butyl; X is CH or N; and R4 is optionally substituted C1-8 alkyl or optionally substituted C3-8 cycloalkyl. The invention further relates to pharmaceutical compositions comprising compounds of formula (I),... Agent: Edwards Angell Palmer & Dodge LLP

20100216812 - Cyclopropyl amide derivatives: Disclosed herein is at least one cyclopropyl amide derivative, at least one pharmaceutical composition comprising at least one cyclopropyl amide derivative disclosed herein, and at least one method of using at least one cyclopropyl amide derivative disclosed herein for treating at least one histamine H3 receptor associated condition therewith.... Agent: Astra Zeneca Pharmaceuticals Lp Global Intellectual Property

20100216815 - N-substituted oxindoline derivatives as calcium channel blockers: A series of N-substituted oxindole derivatives represented by Formula I, or pharmaceutically acceptable salts thereof. Pharmaceutical compositions comprise an effective amount of the instant compounds, either alone, or in combination with one or more other therapeutically active compounds, and a pharmaceutically acceptable carrier. Methods of treating conditions associated with, or... Agent: Merck

20100216816 - Pyrazinyl amide-t type calcium channel antagonists: The present invention is directed to pyrazinyl amide compounds which are antagonists of T-type calcium channels, and which are useful in the treatment or prevention of disorders and diseases in which T-type calcium channels are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use... Agent: Merck

20100216814 - Pyrido[4,3-b]indoles containing rigid moieties: This disclosure is directed to pyrido[4,3-b]indoles having rigid moieties. The compounds in one embodiment are pyrido[4,3-b]indoles having an unsaturated hydrocarbon moiety. The compounds in another embodiment are pyrido[4,3-b]indoles having a cycloalkyl, cycloalkenyl or heterocyclyl moiety. Pharmaceutical compositions comprising the compounds are also provided, as are methods of using the compounds... Agent: Morrison & Foerster LLP

20100216813 - Pyrrolidineanilines: The present invention relates to a compound represented by the following formula I or a pharmaceutically acceptable salt thereof; wherein R1, R2, and y are defined herein. The present invention further relates to compositions that include the compound of the present invention as well as a method of treating a... Agent: Glaxosmithkline Global Patents -us, Uw2220

20100216817 - Antitumoral tetrahydro-pyrimidines: Antitumoral compounds of the formula (I) wherein X is O, S, or NRa, obtained from a maze coral of the family Meandrinidae, genus Meandrina, species meandrites, or derivatives thereof are useful as antitumoral agents.... Agent: King & Spalding

20100216818 - Inhibitors of post-amadori advanced glycation end products: The present invention provides compounds, pharmaceutical compositions, and methods for treating or inhibiting development of AGE- and/or ALE-associated complications in subjects in need thereof.... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20100216819 - Thiazolopyrimidines for use in therapy: Use of a compound of formula (I) wherein R is an alicyclic group; an arylethyl group; or phenyl or benzyl substituted by halogen, lower alkyl, alkoxy, OH, NH2, NHalkyl, N(alkyl)2, CN or NO2; in the manufacture of a medicament for the therapy of hyperalgesic pain conditions and their symptoms.... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20100216820 - Thienopyrimidiones for treatment of inflammatory disorders and cancers: The current invention provides compounds of formula (1): wherein: one of Q1, Q2 and Q3 is S, and the other of two of Q1, Q2 and Q3 are —CR1—, which are inhibitors of PI3K-delta. These compounds are useful for treatment of conditions mediated by PI3K-delta, such as hematopoietic cancers, immune... Agent: Morrison & Foerster LLP

20100216821 - Benzimidazoles with a hetero spiro-decane residue as npy-y5 antagonists: e

20100216822 - Nucleotide analogue prodrug and the preparation thereof: (R)-9-[2-bis[pivaloyloxymeihoxy]phosphinoylmethoxypropyl]adenine (being abbreviated bis-POMPMPA, TD), the derivative and the use thereof. Also including the synthetic process of TD and the procedure for manufacturing solid TD, as well as the composition containing TD and the procedure for manufacturing the composition.... Agent: GlobalIPServices

20100216823 - Spirocyclic derivatives: )

20100216824 - Anti-cancer cyclopenta [g]quinazonline compounds:

20100216825 - Fungicidal compositions: A composition for control of diseases on useful plants or on propagation material thereof caused by phytopathogens, comprising (A) a compound of formula (I) or a tautomer of such a compound; and component (B) and component (C) are pesticides as described in claim 1.... Agent: Syngenta Crop Protection , Inc. Patent And Trademark Department

20100216826 - Polymorphisms in voltage-gated sodium channel alpha 1-subunit as markers for therapy selection: A method for determining whether a patient in need thereof will respond to chemotherapy by screening a suitable sample isolated from the patient for a pre-selected polymorphism present in the VGSC gene.... Agent: Foley & Lardner LLP

20100216827 - Aryl gpr120 receptor agonists and uses thereof: Aryl GPR120 agonists are provided. These compounds are useful for the treatment of metabolic diseases, including Type II diabetes and diseases associated with poor glycemic control.... Agent: Metabolex, Inc. C/o Swiss Tanner, P.C.

20100216828 - Methods and compositions for treating cancers: This invention provides a combination of antagonists of the hedgehog signaling pathway with a BCR-ABL inhibitor. The combination of the present invention may be used for treating cancers known to be associated with protein tyrosine kinases such as, for example, Src, BCR-ABL and c-kit.... Agent: Novartis Corporate Intellectual Property

20100216829 - Method and compositions for deterring abuse of opioid containing dosage forms: This invention relates to an abuse deterrent dosage form of opioid analgesics, wherein an analgesically effective amount of opioid analgesic is combined with a polymer to form a matrix.... Agent: Morgan, Lewis & Bockius LLP

20100216830 - Oral composition comprising a cooling agent: The present invention relates to a formulation comprising an endothermic cooling agent selected from the group consisting of xylitol, sorbitol, mannitol and erythritol having a heat of enthalpy between −10 cal/g and −100 cal/g, and one or more active agents wherein the endothermic agent is present in the formulation at... Agent: Troutman Sanders LLP 5200 Bank Of America Plaza

20100216831 - Desloratadine crystalline forms mixtures having a low level of residual solvents: Provided are desloratadine mixtures, comprising a low level of residual solvents and processes for the preparation thereof.... Agent: Merchant & Gould PC

20100216832 - method for assaying fto (2-oxoglutarate dependent oxygenase) activity: The present invention provides a method for assaying oxygenase activity, the method comprising monitoring oxygenase activity of FTO.... Agent: Clark & Elbing LLP

20100216833 - Tetrahydrocarbazoles and derivatives: wherein R1, R2, R3, R4, R5, X1, X2, X3, X4, n, and k are defined in the description and claims, and pharmaceutically acceptable salts and/or pharmaceutically acceptable esters thereof. The compounds are useful for in the treatment and prophylaxis of diseases which are modulated by LXRα and/or LXRβ agonists, including... Agent: Hoffmann-la Roche Inc. Patent Law Department

20100216834 - Hiv integrase inhibitors: Stereoisomers of compounds of Formula I are disclosed: wherein V1, V2, R5a, R5b, R5c, R8 and R9b are defined herein and wherein the stereoisomer contains 2 chiral centers in the 8-membered ring and one of the chiral centers is due to the presence of a chiral ring carbon. The isomers... Agent: Merck

20100216835 - Method for modulating microbial quorum sensing: The present invention provides compositions and methods for modulating bacterial quorum sensing using antagonist or agonist compounds. Further, the present invention provides methods of treating or preventing microbial damages and diseases, in particular for diseases where there is an advantage in inhibiting quorum sensing regulated phenotypes of pathogens.... Agent: Quarles & Brady LLP

20100216836 - 2,3-dihydrobenzo(1,4) dioxin-2-ylmethyl derivatives as alpha2c antagonists for use in the treatment of peripheric and central nervous systeme diseases: wherein X, Z, R1-R4, and m are as defined in the claims, exhibit alpha2C antagonistic activity, and are thus useful as alpha2C antagonists. Methods for the treatment of diseases and conditions of the peripheric system and the central nervous system are also disclosed.... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20100216837 - Glycine transport inhibitors: The present invention relates to compounds of formula (I), or salts or solvates thereof, their use in the manufacture of medicaments for treating neurological and neuropsychiatric disorders, in particular psychoses, dementia or attention deficit disorder. The invention further comprises processes to make these compounds and pharmaceutical formulations thereof.... Agent: Glaxosmithkline Global Patents -us, Uw2220

20100216838 - Fexofenadine base polymorphic forms: The invention relates to novel crystalline forms of fexofenadine base, a process for the preparation thereof and the use thereof in therapy.... Agent: Young & Thompson

20100216839 - Pim kinase inhibitors and methods of their use: The present invention relates to new compounds of Formulas I and II, their tautomers, stereoisomers and polymorphs, and pharmaceutically acceptable salts, esters, metabolites or prodrugs thereof, compositions of the new compounds together with pharmaceutically acceptable carriers, and uses of the new compounds, either alone or in combination with at least... Agent: Novartis Institutes For Biomedical Research, Inc.

20100216840 - Benzimidazolidinone derivatives as muscarinic agents: Benzimidazolidinone derivative compounds, which increase acetylcholine signaling or effect in the brain, and highly selective muscarinic agonists, particularly for the M1 and/or M4 receptor subtypes, pharmaceutical compositions comprising the same, as well as methods of treating psychosis using these compounds are disclosed.... Agent: Knobbe Martens Olson & Bear LLP

20100216841 - 4-fluoro-piperidine t-type calcium channel antagonists: The present invention is directed to 4-fluoro-piperidine compounds which are antagonists of T-type calcium channels, and which are useful in the treatment or prevention of neurological and psychiatric disorders and diseases in which T-type calcium channels are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and... Agent: Merck

20100216842 - Narcotic emulsion formulations for treatment of cancer pain: Methods and compositions of treating a subject for cancer pain are provided. In the subject methods, a subject is treated for cancer pain by administering to the subject an effective amount of a narcotic emulsion, e.g., fentanyl elmulsion, formulation. In certain embodiments, the emulsion formulations include a narcotic active agent,... Agent: Bozicevic, Field & Francis LLP

20100216843 - Novel salt 628: 6-Methyl-5-(1-methyl-1H-pyrazol-5-yl)-N-{[5-(methylsulfonyl)pyridin-2-yl]methyl}-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridine-3-carboxamide 4-methylbenzenesulfonate and a novel crystalline form thereof are disclosed together with processes for preparing such salt and form, pharmaceutical compositions comprising such a salt and form, and the methods of treatment using such a salt and form.... Agent: Connolly Bove Lodge & Hutz, LLP

20100216844 - Carboxamide compounds and their use as calpain inhibitors: and R1, R2, R3a, R3b, Y1, Y2, Y3, Y4, X, Q, m, k, Rw and Rw* have the meanings mentioned in the claims, the tautomers thereof and the pharmaceutically suitable salts thereof. Of these compounds those are preferred wherein Y1, Y2, Y3 and Y4 are CRy, or one or two... Agent: Abbott Laboratories C/o Polsinelli Shughart PC

20100216845 - Isoxazoles / o-pyridines with ethyl and ethenyl linker: wherein R1, R2, R3 and L are as described herein, as well as pharmaceutically acceptable salts and esters thereof. The active compounds of the present invention have affinity and selectivity for GABA A α5 receptor. Further the present invention is concerned with the manufacture of the active compounds of formula... Agent: Hoffmann-la Roche Inc. Patent Law Department

20100216846 - Trisubstituted 1,2,4 triazoles: e

20100216847 - Nornicotine for the treatment of pain: This invention relates to the use of R(+)-, S(−)- or racemic nornicotine for the treatment of pain.... Agent: Crowell & Moring LLP Intellectual Property Group

20100216848 - Liquid pharmaceutical compositions for parenteral administration of a substituted amide: A liquid pharmaceutical composition comprising N-[1S,2S]-3-[(4-chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl]-2-methyl-2-{[(5-trifluoromethyl)pyridine-2-yl]oxy}propanamide is disclosed, together with processes of preparing the liquid pharmaceutical composition, preparing a vessel containing the liquid pharmaceutical composition, the use of the composition for treating and preventing diabetes or obesity and a method of treating or preventing diabetes or obesity comprising administration to... Agent: Merck

20100216849 - Biphenylcarboxamides: l

20100216850 - Insecticidal compounds: A compound of formula (I) wherein A1, A2, A3, A4, G1, G2, R1, R2, R3, R4, Q1, Y1, Y2, Y3 and Y4 are as defined in claim 1; or a salt or TV-oxide thereof. Furthermore, the present invention relates to processes and intermediates for preparing compounds of formula (I), to... Agent: Syngenta Crop Protection , Inc. Patent And Trademark Department

20100216851 - 1,2,4-oxadiazole benzoic acid compositions and their use in bioassays: Novel 1,2,4-oxadiazole benzoic acid compounds, methods of using and pharmaceutical compositions comprising an 1,2,4-oxadiazole benzoic acid derivative are disclosed. The methods include methods of treating or preventing a disease ameliorated by modulation of premature translation termination or nonsense-mediated mRNA decay, or ameliorating one or more symptoms associated therewith.... Agent: Jones Day

20100216853 - Methods and compositions for modulating p300/cbp activity: The present invention relates to a method for identifying compounds that modulate the activity of p300/CBP. Compounds of the invention are identified by designing or screening for a compound which binds to at least one amino acid residue of the newly identified lysine-CoA inhibitor binding site, L1 loop, electronegative pocket,... Agent: Licata & Tyrrell P.C.

20100216852 - Methods for screening antimicrobial and antiviral compounds and uses thereof: The invention features compounds that have antibacterial activity, their use for the treatment of bacterial infections, screening methods that use whole animals or plant seedlings to identify compounds that inhibit a pathogen in the animal or plant, and screening methods to identify compounds that increase the lifespan of an organism.... Agent: Clark & Elbing LLP

20100216854 - 1,3 and 1,3,5 substituted imidazoles as antihypertensives: The present invention provides novel 1,5 and 1,3,5-substituted imidazole compounds of formulas (I), (IIa), (IIIb) in hydrophilic or lipophilic form, which are useful as angiotensin II AT1 receptor antagonists with sympathetic suppressant properties. In particular, the invention provides pharmaceutical compositions containing the pharmacophoric groups of Losartan and Clonidine as well... Agent: Brinks Hofer Gilson & Lione/ann Arbor

20100216855 - Imidazaolone derivatives,preparation thereof and biological use of same: e

20100216856 - Protective agent for retinal nerve or optic nerve: wherein X represents a halogen atom or a hydrogen atom, R1 and R2 independently represent a hydrogen atom or an optionally substituted C1 to C6 alkyl group, or R1 and R2, together with a nitrogen atom bound thereto, or optionally another nitrogen atom or an oxygen atom, are combined to... Agent: Burr & Brown

20100216857 - Method of treating motor disorders with 4-(1-(2,3-dimethylphenyl)ethyl)-1h-imidazole-2(3h)-thione: Disclosed herein is a method of treating motor disorders comprising administering to a subject in need of such treatment 4-(1-(2,3-dimethylphenyl)ethyl)-1H-imidazole-2(3H)-thione.... Agent: Allergan, Inc.

20100216858 - Bendamustine cyclopolysaccharide compositions: The present invention is directed to pharmaceutical compositions comprising: (a) bendamustine, (b) a charged cyclopolysaccharide, and (c) a stabilizing agent having a charge opposite to that of the cyclopolysaccharide. Such composition provides unexpectedly desirable stability in reactive environments such as plasma, coupled with unexpectedly desirable anticancer activity. Such compositions are... Agent: Cynthia Soumoff Porzio, Bromberg & Newman, P.C.

20100216859 - Curcumin analog compositions and related methods: Novel curcumin-analog compounds are disclosed that are antioxidants useful in inhibition of pro-inflammation, angiogenic, and vascular permeability factors and elimination of reactive oxygen species. The curcumin compounds specifically inhibit VEGF and are useful in treating various diseases that are mediated through the oxidative stress pathway, including those that are characterized... Agent: Foley Hoag, LLP Patent Group, World Trade Center West

20100216860 - Novel compounds: Indazole compounds, processes for their preparation, intermediates usable in these processes, pharmaceutical compositions containing such compounds and their use in therapy.... Agent: Glaxosmithkline Global Patents -us, Uw2220

20100216861 - Amino arylsulfonamide compounds and their use as 5-ht6 ligands: The present invention relates to novel amino arylsulfonamide compounds of the formula (I), their derivatives, their stereoisomers, their pharmaceutically acceptable salts and pharmaceutically acceptable compositions containing them: The present invention also relates to a process for the preparation of above said novel compounds, their derivatives, their stereoisomers, their pharmaceutically acceptable... Agent: Iphorgan, Ltd.

20100216862 - Pyrrole derivatives as therapeutic compounds: Novel pyrrole derivatives are disclosed as Aβ42-lowering agents for the treatment and prevention of neurodegenerative disorders characterized by the formation or accumulation of amyloid plaques comprising the Aβ42 peptide.... Agent: Myriad Pharmaceuticals, Inc. C/o Cpa Global

20100216869 - Artemisinin derivatives for the treatment of melanoma: wherein A and B are as defined in the specification. Compounds (I) have proved able to inhibit cell proliferation, in particular of uveal melanoma cells, and can therefore be used, either alone or in association with other antitumoral drugs, for the preparation of medicaments intended for the treatment of malignant... Agent: Young & Thompson

20100216870 - Novel genes encoding a nystatin polyketide synthase and their manipulation and utility: The invention provides a nucleic acid molecule comprising: (a) a nucleotide sequence as shown in SEQ ID No. 35; or (b) a nucleotide sequence which is the complement of SEQ ID No. 35; or (c) a nucleotide sequence which is degenerate with SEQ ID No. 35; or (d) a nucleotide... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20100216871 - Use of compounds having ccr antagonism: It is intended to provide preventives/remedies for graft-versus-host disease and/or rejection in organ or bone marrow transplantation, rheumatoid arthritis, autoimmune diseases, allergic diseases, ischemic cerebral cell injury, myocardial infarction, chronic nephritis and arteriosclerosis. The above object can be achieved by preventives/remedies for graft-versus-host disease and/or rejection in organ or bone... Agent: Wenderoth, Lind & Ponack, L.L.P.

20100216872 - Plant extract from low-thc cannabis for the treatment of disease: The present invention relates to a plant extract from a low-tetrahydrocannabinol (THC) variety of Cannabis sativa subsp. sativa for the treatment of disease. The invention further relates to the production of the extract and pharmaceutical compositions comprising said extract and the uses thereof.... Agent: Patent Central LLC Stephan A. Pendorf

20100216873 - 5-hydroxy-2-methyl-4h-pyran-4-one esters as novel tyrosinase inhibitors: Skin brightening compositions based on esters of 5-hydroxy-2-methyl-4H-pyran-4-one. Also disclosed are methods of making the compositions as well as methods of using the compositions.... Agent: Tammye Taylor

20100216874 - Hydroxytyrosol-rich composition from olive vegetation water and method of use thereof: The invention provides olive-derived hydroxytyrosol. According to one aspect of the invention, vegetation water is collected from olives. Acid is added to stabilize the vegetation water and prevent fermentation. The mixture is incubated to allow oleuropein to convert to hydroxytyrosol, and then fractionated to separate hydroxytyrosol from other components. The... Agent: King & Spalding LLP

20100216875 - Methods of treating alzheimer's disease: The invention is directed to a method of treating Alzheimer's disease. The method comprises administering a cysteine protease inhibitor to a patient and thereby affecting the disease. In a preferred method, the cysteine protease inhibitor is a cathepsin B inhibitor. A preferred method causes a reversal in the progression of... Agent: Cooley Godward Kronish LLP

20100216876 - Antidiarrhetic composition, product containing the same and method of preventing diahhrea: An antidiarrhetic composition is provided which is efficacious against diarrhea, in particular, the predominant secretory diarrhea; an antidiarrhetic medicinal composition containing the same is also provided; a food containing the antidiarrhetic composition is also provided; and a method of preventing diarrhea using the same is also disclosed. The composition for... Agent: Abelman, Frayne & Schwab

20100216877 - Storage stable prostaglandin product: A prostaglandin composition comprising prostaglandin and a low-density polyethylene container are disclosed. The prostaglandin compositions are stable in polyethylene containers over longer period of time.... Agent: Pauly, Devries Smith & Deffner, L.L.C.

20100216878 - Amino acid derivatives: The compound 3,3-dimethyl-butyric acid 4-((S)-2-amino-2-methoxycarbonyl-ethyl)-2-(3,3-dimethyl-butyryloxy)-phenyl ester of formula (I) has dopaminergic properties.... Agent: Banner & Witcoff, Ltd.

20100216879 - Resveratrol ferulate compounds and compositions: Resveratrol ferulate compounds and compositions.... Agent: The Estee Lauder Cos, Inc

20100216880 - Transdermal compositions for anticholinergic agents: The present invention relates generally to compositions or formulations for transdermal or transmucosal administration of anticholinergic agents such as oxybutynin. The invention utilizes a novel delivery vehicle and is a substantially malodorous-free and irritation free transdermal formulation which is substantially free of long chain fatty alcohols, long-chain fatty acids, and... Agent: Winston & Strawn LLP Patent Department

20100216881 - Enhydrazone esters for treating asthma, allergy and inflammation: e

20100216882 - Aspirin-triggered lipid mediators: Aspirin triggered lipid mediators (ATLMs) are disclosed which are useful for the treatment of prevention of inflammation associated with diseases, including ischemia.... Agent: Fulbright & Jaworski L.L.P. Attn: MnIPDocket

20100216883 - Method of using abscisic acid to treat and prevent diseases and disorders: Methods and compositions for treating inflammatory bowel disease, gastrointestinal inflammation and maintaining normal gut health are described. These methods of the invention involve the administration of abscisic acid in amounts sufficient to alter the expression or activity of PPAR gamma in a cell. Also described are methods for suppressing the... Agent: Blank Rome LLP

20100216884 - Nitrated-fatty acids modulation of type ii diabetes: Nitro oleic acid and related metabolites are agonists of PPAR-γ. Surprisingly, nitro oleic acid is a more potent agonist of PPAR-γ, relative to nitro linoleic acid. Thus, nitro oleic acid and its metabolites, as well as their pharmaceutically acceptable salts and prodrug forms, are candidate therapeutics for the treatment of... Agent: Foley And Lardner LLP Suite 500

20100216885 - Orodispersible composition comprising polyunsaturated fatty acids without bad odor or taste: An orodispersible composition without bad odor, smell, or taste comprising polyunsaturated fatty acids (PUFA) and a disintegrant. The disintegrant is a solid dispersion comprising mannitol, xylitol, microcrystalline cellulose, crospovidone and dibasic calcium phosphate. A process of preparing the composition and its use as nutritional or dietary supplement for balancing the... Agent: Bayer Healthcare LLC Consumer Care Division

20100216886 - Polymorphs of n2-(1,1'-biphenyl-4-ylcarbonyl)-n1-[2-(4-fluorophenyl)-1,1-dimethylethyl]-l-alpha-glutamine: Disclosed are novel polymorphic forms of N2-(1,1′-biphenyl-4-ylcarbonyl)-N1-[2-(4-fluorophenyl)-1,1-dimethylethyl]-L-α-glutamine, methods of preparing the polymorphic forms, compositions containing the polymorphic forms, and methods of treatment using the polymorphic forms.... Agent: Wyeth LLC Patent Law Group

20100216887 - Intrathecal baclofen pharmaceutical dosage forms with fewer degradation products: The present invention relates generally to a sterile, particulate-free, stable intrathecal baclofen solution with less than 0.5% 4-(4-chlorophenyl)-2-pyrrolidone, a degradation product. These solutions are stable under a variety of storage conditions and for extended periods of time. Also disclosed are methods for preparing such compositions.... Agent: Global Patent Group - Cns

20100216888 - Liquid compositions containing solubilized benzoyl peroxide, means for applying same and methods of treatment using same: Liquid medicaments incorporate about 1.0-3.0% active benzoyl peroxide (BP) by weight in substantially fully solubilized form, while being substantially free of acetone and other harsh, dermatologically undesirable solvents. The novel compositions are produced by (a) creating an emulsion or slurry of BP in an emollient, topically acceptable ester, and (b)... Agent: Kirschstein, Israel, Schiffmiller & Pieroni, P.C.

20100216889 - Prolonged effect disinfectant cleanser: The present invention relates to cleanser compositions, and their uses, wherein the cleanser compositions comprise one or more cationic antiseptic agents, a film-forming cationic emulsifying agent, a dispersing auxiliary solvent, a solvent system, and optionally an alkanediol.... Agent: Baker Botts L.L.P.

20100216890 - Disinfectant: Disinfectant compositions, containing (a) at least one amine and/or quaternary salt of the general formula (Ia) or (Ib), respectively, and (b) at least one alkanolamine of the general formula (II), or a corresponding salt. The mass ratio of the components in the formulas (I):(II) is between 20:1 and 1:20. The... Agent: Fisher, Christen & Sabol

20100216891 - Aromatic antihypertensive agent, and method for lowering blood pressure in mammals: The antihypertensive agent of the present invention comprises citral and linalool, and has a mass ratio of citral to linalool of not less than 10:1 and not greater than 40:1. Since this antihypertensive agent has a superior antihypertensive action, it can be utilized as antihypertensive compositions for medical drugs, foods... Agent: Mcdermott Will & Emery LLP

20100216892 - Use of synergistically active 1,2-alkanediol mixtures as skin moisture-regulating compositions: Synergistically active mixtures of straight-chain 1,2-alkanediols having 5 to 10 C atoms and their use as skin moisture-regulating compositions are described. Binary and ternary mixtures of 1,2-pentanediol, 1,2-hexanediol and 1,2-octanediol have proved to be particularly active here. Cosmetic or pharmaceutical formulations and ready-to-use cosmetic or pharmaceutical products comprising particularly synergistically... Agent: Roylance, Abrams, Berdo & Goodman, L.L.P.

20100216893 - Long-term stable pharmaceutical preparation containing the active ingredient glycerol trinitrate: A pharmaceutical preparation containing the active substance glyceryl trinitrate having improved storage stability in a container. The improved storage stability is achieved by the addition of a proton-absorbing substance either as part of the preparation as placed into the container or applied to the surface of the preparation's storage container... Agent: K&l Gates LLP

20100216894 - Novel compounds prepared by adding an oxetane derivative to an alcohol: The invention relates to compositions obtained by the reaction of an alcohol having a variable nature and that can be modified beforehand by the addition of alkylene oxide, and of a substrate characterised by an oxetane pattern and at least one hydroxyl function.... Agent: Air Liquide Usa LLC Intellectual Property

20100216895 - Food grade colouring agent: The present invention relates to a method for the preparation of a food grade colouring agent by drying one or more coloured vegetable materials selected from the group consisting of red cabbage, beetroot, lemon, black currant, red currant, strawberry, blackberry, blueberry, and saffron under conditions resulting in a predetermined colour.... Agent: Alston & Bird LLP

  
08/19/2010 > patent applications in patent subcategories. inventions list

20100210504 - Enhanced transport using membrane disruptive agents: Compositions and methods for transport or release of therapeutic and diagnostic agents or metabolites or other analytes from cells, compartments within cells, or through cell layers or barriers are described. The compositions include a membrane barrier transport enhancing agent and are usually administered in combination with an enhancer and/or exposure... Agent: Christensen, O'connor, Johnson, Kindness, PLLC

20100210506 - Intranasal administration of rapid acting insulin: What is described are pharmaceutical compositions, formulations, and uses thereof, for medicaments for intranasal delivery of insulin to a patient, comprising an aqueous mixture of human insulin, a solubilizing agent, and a surface active agent, wherein the human insulin may be rapid actin insulin.... Agent: Eckman Basu LLP

20100210505 - Polymer conjugates of glp-1: Conjugates of a GLP-I moiety may be covalently attached to one or more water-soluble polymers. For instance, a GLP-I polymer conjugate may include a GLP-I moiety releasably attached at its N-terminus to a water-soluble polymer. The GLP-I polymer conjugate may include a GLP-I moiety covalently attached to a water-soluble polymer,... Agent: Nektar Therapeutics

20100210511 - Combination vegfr2 therapy with temozolomide: The present disclosure relates to improved methods of treating neoplastic disorders by combining VEGFR2 specific inhibitor treatment with temozolomide. In particular, methods for treating glioblastoma with a combination of a VEGFR2 inhibitor and temozolomide are provided.... Agent: Ropes & Gray LLP

20100210509 - Long acting hyaluronic acid - peptide conjugate: The invention relates to a novel bioconjugation protocol for peptide suitable for in vivo applications. Bioconjugation of the peptide to HA derivative increases its half life in circulation contributing for a high efficacy. More over, conjugate of HA derivative and peptide which is treated with hyaluronidase shows increased bioactivity. And... Agent: LexyoumeIPGroup, LLC

20100210508 - Method for the massive culture of cells producing recombinant human erythropoietin: The present invention relates, in general, to a method for the massive culture of recombinant mammalian cells for the production of recombinant human erythropoietin (EPO) in culture medium containing insulin. The present invention also refers to a method of producing EPO and to the EPO thus produced.... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20100210510 - Oral lactoferrin in the treatment of sepsis: The present invention relates to methods of treating prophylactically or therapeutically bacteremia, sepsis, septic shock or related conditions such as ARDS by administering orally a composition of lactoferrin alone or in combination with standard therapies or metal chelators to prevent or treat the consequences of bacterially induced systemic inflammatory response... Agent: Fulbright & Jaworski, LLP

20100210513 - Rnai inhibition of alpha-enac expression: The invention relates to compositions and methods for modulating the expression of alpha-ENaC, and more particularly to the downregulation of alpha-ENaC expression by chemically modified oligonucleotides.... Agent: Novartis Institutes For Biomedical Research, Inc.

20100210514 - Rnai inhibition of alpha-enac expression: The invention relates to compositions and methods for modulating the expression of alpha-ENaC, and more particularly to the downregulation of alpha-ENaC expression by chemically modified oligonucleotides.... Agent: Novartis Institutes For Biomedical Research, Inc.

20100210512 - Thyroid-stimulating hormone receptor polypeptide agonist glycoforms to treat metabolic syndrome: TSHR agonists that are substantially desialylated are described for treating metabolic syndrome and obesity and for inducing lipolysis. The TSHR polypeptide agonists are useful for treatment of hallmarks of metabolic syndrome: obesity, insulin resistance, hyperlipidemia, and liver steatosis, without producing a hyperthyroid state in treated individuals.... Agent: Seed Intellectual Property Law Group PLLC

20100210507 - Glycopegylated erythropoietin: The present invention provides conjugates between erythropoietin and PEG moieties. The conjugates are linked via an intact glycosyl linking group interposed between and covalently attached to the peptide and the modifying group. The conjugates are formed from glycosylated peptides by the action of a glycosyltransferase. The glycosyltransferase ligates a modified... Agent: Leydig Voit & Mayer, Ltd

20100210516 - Growth factor binding molecules: Growth factor binding molecules having a plurality of peptide loops attached to a non-peptide organic scaffold, preferably having pseudo-six amino acid peptide loops with four amino acid sidechains. The growth factor binding molecules specifically bind various growth factors and are suitable for treating a subject having tumors or restinosis. In... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20100210515 - Methods for preparing purified polypeptide compositions: The present invention relates to purified peptidomimetic macrocycles. The invention additionally provides methods of preparing and using such macrocycles, for example in therapeutic applications.... Agent: Wilson, Sonsini, Goodrich & Rosati

20100210517 - Cyclic receptor-associated protein (rap) peptides: The present invention relates generally to receptor-selective variants of the low-density lipoprotein receptor-associated protein (RAP) and compositions thereof, methods of generating such variants and methods of using such receptor-selective RAP variant compositions for therapeutic purposes.... Agent: Marshall, Gerstein & Borun LLP

20100210518 - Peg-lipid conjugates for increasing the solubility of drug compounds: Diacyl lipid-polymer conjugates are used to enhance the solubility of lipophilic drugs in aqueous solution. The conjugates comprise a backbone, two lipophilic acyl groups and a hydrophilic polymer.... Agent: Lee Pederson

20100210519 - Peptide slow-release formulations: A composition for the delayed delivery of a peptide active agent comprising; i) a salt of said peptide active agent comprising at least one positively charged peptide ion and at least one negatively charged counter-ion ii) a sustained-release delivery vehicle. Wherein said at least one negatively charged counter-ion is a... Agent: J.a. Lindeman & Co. PLLC

20100210531 - Agents with angiogenic and wound healing activity: The invention relates to the use of angiogenic crystallin proteins to promote angiogenesis, wound healing and/or endothelial cell migration. Alpha A crystallin and βB2 crystallin have particular application in these methods. The crystallins will usually be in monomeric form. Typically, truncated form(s) of βB2 crystallin protein are utilized as can... Agent: Edwards Angell Palmer & Dodge LLP

20100210543 - Aldehyde-tagged protein-based drug carriers and methods of use: The disclosure provides aldehyde-tagged protein carriers that can be covalently and site-specifically bound to drug to provide a drug-containing scaffold. The invention also encompasses methods of production of such drug-containing scaffolds and intermediates, as well as methods of use.... Agent: Bozicevic, Field & Francis LLP

20100210541 - Biomarkers for appetite regulation: The invention provides compositions and methods for characterizing appetite regulation in a subject. In one embodiment, the composition comprises a solid support comprising probes for measuring a biomarker panel comprising, for example, total ghrelin, obestatin, cholecystokinin, GLP-1(6-37)-NH2, NPY and α-MSH. The simultaneous use of multiple biomarkers with independent classification power... Agent: Morgan, Lewis & Bockius, LLP (sf)

20100210546 - Combination chemotherapy with chlorotoxin: This invention includes compositions and methods for combination chemotherapy, particularly involving at least one chemotherapeutic agent used in combination with chlorotoxin or a derivative thereof.... Agent: Choate, Hall & Stewart LLP

20100210525 - Combined preparation of a thiazide diuretic and a loop diuretic: The specific molecular basis of the interaction between talin and integrin β3 has been defined. This specific interaction provides a new therapeutic target; agents that can disrupt this specific interaction should be useful therapeutic agents for a number of significant diseases and conditions including inflammation, heart disease, including myocardial infarction,... Agent: Catalyst Law Group, Apc

20100210521 - Compositions and methods for modulating ampa receptor-mediated excitotoxicity: The present invention provides AMPAR excitotoxicity mediating polypeptides comprising the GluR2 NT1-3-2 (Y142-K172) amino acid sequence (SEQ ID NO:1) or the GAPDH(2-2-1-1) (I221-E250) amino acid sequence (SEQ ID NO:2). Also disclosed are nucleotide sequences encoding the polypeptides, methods of inhibiting GAPDH association with the GluR2 subunit or p53. Methods of... Agent: Dowell & Dowell P.C.

20100210528 - Compositions, methods and uses for inhibition and/or treatment of influenza infection: Embodiments of the present invention illustrate methods and compositions for treating medical disorders. In certain embodiments, compositions and methods relate to reducing or inhibiting a the onset or development of a viral disorder.... Agent: Faegre & Benson LLP Patent Docketing - Intellectual Property

20100210530 - Extracellular matrix compositions: The present invention is directed to a method of producing compositions including embryonic proteins. The method includes culturing cells under hypoxic conditions on a biocompatible three-dimensional surface in vitro. The culturing method produces both soluble and non-soluble fractions, which may be used separately or in combination to obtain physiologically acceptable... Agent: Dla Piper LLP (us)

20100210552 - Human glucagon-like peptide-1 mimics and their use in the treatment of diabetes and related conditions: The present invention provides novel human glucagon-like peptide-1 (GLP-1) peptide mimics that mimic the biological activity of the native GLP-1 peptide and thus are useful for the treatment or prevention of diseases or disorders associated with GLP activity. Further, the present invention provides novel, chemically modified peptides that not only... Agent: Louis J. Wille Bristol-myers Squibb Company

20100210522 - Method for determining presence of cancer in a sample by assaying for expression of dppa-2 nucleotide sequences: The invention relates to the discovery of known molecule “ESCA/DPPA-2” and a so-called “cancer-testis antigen.” ESCA/DPPA-2 is also a possible cancer stem cell marker. One can determine presence of cancer by assaying for the molecule, and also prevent or treat cancer via administration of the molecule.... Agent: Fulbright & Jaworski, LLP

20100210547 - Method for the production of conjugates of insulin-like growth factor-1 and poly(ethylene glycol): The present invention relates to a fusion protein comprising IGF-I or an IGF-I variant N-terminally linked to the C-terminus of a propeptide. The invention relates also to a method involving the use of the aforementioned fusion protein in the production of a lysine-PEGylated IGF-I or IGF-I variant. The method comprises... Agent: Hoffmann-la Roche Inc. Patent Law Department

20100210542 - Methods of treating disorders with group i mglur antagonists: mGluR5 antagonists are used for the treatment and prevention of disorders, including Fragile X, autism, mental retardation, schizophrenia and Down's Syndrome. The methods of the invention can be used to treat epilepsy and anxiety in a human having Fragile X syndrome, autism, mental retardation, schizophrenia and Down's Syndrome.... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20100210523 - Modulation of activity of proneurotrophins: The present invention provides agents for inhibiting binding of a pro-neurotrophin to a Vps10p-domain receptor, in particular the binding of a pro-NGF or a pro-BDNF to a Sortilin receptor. The invention thus provides agents for the manufacture of a medicament, for treating and/or preventing disease or disorders such as but... Agent: Lundbeck Research Usa, Inc. Attention: Stephen G. Kalinchak, Legal

20100210548 - Novel bacillus thuringiensis crystal polypeptides, polynucleotides, and compositions thereof: The present invention provides insecticidal polypeptides related to Bacillus Cry2 polypeptides. Nucleic acids encoding the polypeptides of the invention are also provided. Methods for using the polypeptides and nucleic acids of the invention to enhance resistance of plants to insect predation are encompassed.... Agent: Pioneer Hi-bred International, Inc.

20100210550 - Novel bacillus thuringiensis crystal polypeptides, polynucleotides, and compositions thereof: The present invention provides insecticidal polypeptides related to Bacillus Cry2 polypeptides. Nucleic acids encoding the polypeptides of the invention are also provided. Methods for using the polypeptides and nucleic acids of the invention to enhance resistance of plants to insect predation are encompassed.... Agent: Pioneer Hi-bred International, Inc.

20100210551 - Novel bacillus thuringiensis crystal polypeptides, polynucleotides, and compositions thereof: The present invention provides insecticidal polypeptides related to Bacillus Cry2 polypeptides. Nucleic acids encoding the polypeptides of the invention are also provided. Methods for using the polypeptides and nucleic acids of the invention to enhance resistance of plants to insect predation are encompassed.... Agent: Pioneer Hi-bred International, Inc.

20100210549 - Novel bacillus thuringiensis crystal polypetides, polynucleotides, and compositions thereof: The present invention provides insecticidal polypeptides related to Bacillus Cry2 polypeptides. Nucleic acids encoding the polypeptides of the invention are also provided. Methods for using the polypeptides and nucleic acids of the invention to enhance resistance of plants to insect predation are encompassed.... Agent: Pioneer Hi-bred International, Inc.

20100210524 - Novel estrogen receptor ligands: The invention provides a compound of formula (I) or a pharmaceutically acceptable ester, amide, solvate or salt thereof, including a salt of such an ester or amide, and a solvate of such an ester, amide or salt, wherein W, X, Y, Z, R1, R2, R7, R8, R9, R10, R11, R12,... Agent: Wiggin And Dana LLP Attention: Patent Docketing

20100210526 - Oral administration of a calcitonin: The invention is directed to a method of administering pharmaceutical compositions comprising peptide drugs such as a calcitonin in combination with one or more oral delivery agents, together with an amount of a liquid, and method of treatment of disorders responsive to the action of peptide drugs such as a... Agent: Novartis Corporate Intellectual Property

20100210529 - P53 peptide vaccine: The invention relates to a peptide derived from p53 that could be used as a vaccine against cancer.... Agent: Edwards Angell Palmer & Dodge LLP

20100210544 - Peptides and pharmaceucal compositions for treating connective tissue: Provided is a pharmaceutical composition for sequestering cells in connective tissue. The composition includes a biocompatible scaffolding to which one or more peptides or proteins are linked. The peptides or proteins have an amino acid sequence that is a subsequence of human ficolin and are capable of binding the cells... Agent: The Nath Law Group

20100210545 - Preventive/remedy for cancer: The present invention provides a preventive or remedy agent for cancer for a TRAIL signal activator sensitive patient, the agent comprising a TRAIL signal activator, wherein the patient is screened by using the fluctuation in the expression or activity of TRAIL signal activator sensitivity markers in a sample collected from... Agent: Edwards Angell Palmer & Dodge LLP

20100210527 - Pro- and anti-angiogenic treatments: The invention provides a method of selectively pro-oranti-angiogenic treatment of a mammalian subject, comprising site-specific control of alternative splicing during processing of VEGF pre-mRNA transcribed from the C terminal exon 8 of the VEGF gene using controlling agents for the splicing, wherein one or more controlling agent which favours proximal... Agent: Harness, Dickey, & Pierce, P.l.c

20100210520 - Regulation of function of angiopoietin: Pharmaceutical compositions that comprise a pharmaceutically acceptable carrier and either a therapeutically effective amount of an ECM-binding fragment of Ang-1 protein that comprises SEQ ID NO:1 and/or SEQ ID NO:2 or a homologous peptide thereof and pharmaceutical compositions that comprise a pharmaceutically acceptable carrier and a vector comprising a nucleic... Agent: Pepper Hamilton LLP

20100210535 - Therapeutic use of neuropeptide ei and acth 7-38 and compositions thereof: The present invention is directed to the use of the peptide compound Glu-Ile-Gly-Asp-Glu-Glu-Asn-Ser-Ala-Lys-Phe-Pro-Ile-NH2 as a therapeutic agent for the prophylaxis and/or treatment of cancer, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurodegenerative diseases, infectious diseases, lung diseases, heart and vascular diseases and metabolic diseases. Moreover the present invention relates to pharmaceutical... Agent: Winstead PC

20100210538 - Therapeutic uses of intermedin 47 and 53 peptides: The present invention is directed to the use of the peptide compound His-Ser-Gly-Pro-Arg-Arg-Thr-Gln-Ala-Gln-Leu-Leu-Arg-Val-Gly-Cys-Val-Leu-Gly-Thr-Cys-Gln-Val-Gln-Asn-Leu-Ser-His-Arg-Leu-Trp-Gln-Leu-Met-Gly-Pro-Ala-Gly-Arg-Gln-Asp-Ser-Ala-Pro-Val-Asp-Pro-Ser-Ser-Pro-His-Ser-Tyr-NH2 as a therapeutic agent for the prophylaxis and/or treatment of cancer, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurodegenerative diseases, infectious diseases, lung diseases, heart and vascular diseases and metabolic diseases. Moreover the present invention relates to pharmaceutical... Agent: Winstead PC

20100210537 - Use of a defensin peptide as a therapeutic agent: The present invention is directed to the use of the peptide compound Cys-Tyr-Cys-Arg-Ile-Pro-Ala-Cys-Ile-Ala-Gly-Glu-Arg-Arg-Tyr-Gly-Thr-Cys-Ile-Tyr-Gln-Gly-Arg-Leu-Trp-Ala-Phe-Cys-Cys-OH as a therapeutic agent for the prophylaxis and/or treatment of cancer, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurodegenerative diseases, infectious diseases, lung diseases, heart and vascular diseases and metabolic diseases. Moreover the present invention relates to pharmaceutical... Agent: Winstead PC

20100210534 - Use of a peptide as a therapeutic agent: The present invention is directed to the use of the peptide compound Ala-Ala-Val-Ala-Leu-Leu-Pro-Ala-Val-Leu-Leu-Ala-Leu-Leu-Ala-Pro-Val-Gln-Arg-Lys-Arg-Gln-Lys-Leu-Met-Pro-OH as a therapeutic agent for the prophylaxis and/or treatment of cancer, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurodegenerative diseases, infectious diseases, lung diseases, heart and vascular diseases and metabolic diseases. Moreover the present invention relates to pharmaceutical... Agent: Winstead PC

20100210536 - Use of leptin (22-56 ) as a therapeutic agent: The present invention is directed to the use of the peptide compound Val-Pro-Ile-Gln-Lys-Val-Gln-Asp-Asp-Thr-Lys-Thr-Leu-Ile-Lys-Thr-Ile-Val-Thr-Arg-Ile-Asn-Asp-Ile-Ser-His-Thr-Gln-Ser-Val-Ser-Ser-Lys-Gln-Lys-OH as a therapeutic agent for the prophylaxis and/or treatment of cancer, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurodegenerative diseases, infectious diseases, lung diseases, heart and vascular diseases and metabolic diseases. Moreover the present invention relates to pharmaceutical... Agent: Winstead PC

20100210532 - Use of neuropeptide sf, alone or in combination with glp-2, as a therapeutic agent: The present invention is directed to the use of the peptide compound Ser-Gln-Ala-Phe-Leu-Phe-Gln-Pro-Gln-Arg-Phe-NH2 as a therapeutic agent for the prophylaxis and/or treatment of cancer, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurodegenerative diseases, infectious diseases, lung diseases, heart and vascular diseases and metabolic diseases. Moreover the present invention relates to pharmaceutical... Agent: Winstead PC

20100210539 - Use of peptide ll-37 as a therapeutic agent: The present invention is directed to the use of the peptide compound Leu-Leu-Gly-Asp-Phe-Phe-Arg-Lys-Ser-Lys-Glu-Lys-Ile-Gly-Lys-Glu-Phe-Lys-Arg-Ile-Val-Gln-Arg-Ile-Lys-Asp-Phe-Leu-Arg-Asn-Leu-Val-Pro-Arg-Thr-Glu-Ser-NH2 as a therapeutic agent for the prophylaxis and/or treatment of cancer, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurodegenerative diseases, infectious diseases, lung diseases, heart and vascular diseases and metabolic diseases. Moreover the present invention relates to pharmaceutical... Agent: Winstead PC

20100210540 - Use of the peptide combination thymosin beta 4 and delta sleep inducing peptide as a therapeutic agent: The present invention is directed to the use of the combination of the peptide compounds Ac-Ser-Lys-Pro-Asp-Met-Ala-Glu-Ile-Glu-Lys-Phe-Asp-Lys-Ser-Lys-Leu-Lys-Lys-Thr-Glu-Thr-Gln-Glu-Lys-Asn-Pro-Leu-Pro-Ser-Lys-Glu-Thr-Ile-Glu-Gln-Glu-Lys-Gln-Ala-Gly-Glu-Ser-OH and Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu-OH as a therapeutic combination for prophylaxis and/or treatment of cancer, a heart and vascular disease, an infectious disease, a fibrotic disease, an inflammatory disease, a neurodegenerative disease, or an autoimmune disease.... Agent: Winstead PC

20100210533 - Use of urocortin and corticotropin-releasing factor as therapeutic agents: The present invention is directed to the use of the peptide compound Asp-Asn-Pro-Ser-Leu-Ser-Ile-Asp-Leu-Thr-Phe-His-Leu-Leu-Arg-Thr-Leu-Leu-Glu-Leu-Ala-Arg-Thr-Gln-Ser-Gln-Arg-Glu-Arg-Ala-Glu-Gln-Asn-Arg-Ile- Ile-Phe-Asp-Ser-Val-NH2 as a therapeutic agent for the prophylaxis and/or treatment of cancer, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurodegenerative diseases, infectious diseases, lung diseases, heart and vascular diseases and metabolic diseases. Moreover the present invention relates to... Agent: Winstead PC

20100210554 - Therapeutic uses of gastrin- 1 and g- pen-grgdspca: The present invention is directed to the use of the peptide compound Pyr-Gly-Pro-Trp-Leu-Glu-Glu-Glu-Glu-Glu-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2 as a therapeutic agent for the prophylaxis and/or treatment of cancer, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurodegenerative diseases, infectious diseases, lung diseases, heart and vascular diseases and metabolic diseases. Moreover the present invention relates to pharmaceutical... Agent: Winstead PC

20100210555 - Use of a laminin peptide as a therapeutic agent: The present invention is directed to the use of the peptide compound Cys-Ser-Arg-Ala-Arg-Lys-Gln-Ala-Ala-Ser-Ile-Lys-Val-Ala-Val-Ser-Ala-Asp-Arg-OH as a therapeutic agent for the prophylaxis and/or treatment of cancer, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurodegenerative diseases, infectious diseases, lung diseases, heart and vascular diseases and metabolic diseases. Moreover the present invention relates to pharmaceutical... Agent: Winstead PC

20100210556 - Use of a peptide as a therapeutic agent: The present invention is directed to the use of the peptide compound Ala-Ile-Phe-Ile-Phe-Ile-Arg-Trp-Leu-Leu-Lys-Leu-Gly-His-His-Gly-Arg-Ala-Pro-Pro-OH as a therapeutic agent for the prophylaxis and/or treatment of cancer, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurodegenerative diseases, infectious diseases, lung diseases, heart and vascular diseases and metabolic diseases. Moreover the present invention relates to pharmaceutical... Agent: Winstead PC

20100210553 - Use of the peptide asn-asp-asp-cys-glu- leu-cys-val-asn-val-ala-cys-thr-gly-cys-leu alone or in combination with the peptide thr-thr-ser-gln-val- arg-pro-arg as a therapeutic agent: The present invention is directed to the use of the peptide compound Asn-Asp-Asp-Cys-Glu-Leu-Cys-Val-Asn-Val-Ala-Cys-Thr-Gly-Cys-Leu-OH or its combination with the peptide Thr-Thr-Ser-Gln-Val-Arg-Pro-Arg-OH as a therapeutic agent for the prophylaxis and/or treatment of cancer, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurodegenerative diseases, infectious diseases, lung diseases, heart and vascular diseases and metabolic diseases.... Agent: Winstead PC

20100210558 - Minigastrin as a therapeutic agent: The present invention is directed to the use of the peptide compound Leu-Glu-Glu-Glu-Glu-Glu-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2 as a therapeutic agent for the prophylaxis and/or treatment of cancer, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurodegenerative diseases, infectious diseases, lung diseases, heart and vascular diseases and metabolic diseases. Moreover the present invention relates to pharmaceutical... Agent: Winstead PC

20100210560 - Neurotensin receptor agonists and opioid receptor agonists: This document provides methods and materials for treating pain. For example, this document provides methods that involve administering a neurotensin receptor (NTR) agonist and an opioid receptor agonist to a mammal (e.g., a human). Compositions containing an NTR agonist in combination with an opioid receptor agonist also are provided.... Agent: O''melveny & Myers LLP Ip&t Calendar Department La-13-a7

20100210559 - Trap-14 as a therapeutic agent: The present invention is directed to the use of the peptide compound Ser-Phe-Leu-Leu-Arg-Asn-Pro-Asn-Asp-Lys-Tyr-Glu-Pm-Phe-OH as a therapeutic agent for the prophylaxis and/or treatment of cancer, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurodegenerative diseases, infectious diseases, lung diseases, heart and vascular diseases and metabolic diseases. Moreover the present invention relates to pharmaceutical... Agent: Winstead PC

20100210557 - Use of rfrp, alone or in combination with neurokinin-b, as a therapeutic agent: The present invention is directed to the use of the peptide compound Met-Pro-His-Ser-Phe-Ala-Asn-Leu-Pro-Leu-Arg-Phe-NH2 as a therapeutic agent for the prophylaxis and/or treatment of cancer, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurodegenerative diseases, infectious diseases, lung diseases, heart and vascular diseases and metabolic diseases. Moreover the present invention relates to pharmaceutical... Agent: Winstead PC

20100210562 - Use of il-1 receptor peptide, alone or in combination with d-ala-gln-octadecyl ester, as a therapeutic agent: The present invention is directed to the use of the peptide compound Lys-lle-Cys-lle-Arg-lle-Gln-lle-Ser-OH as a therapeutic agent for the prophylaxis and/or treatment of cancer, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurodegenerative diseases, infectious diseases, lung diseases, heart and vascular diseases and metabolic diseases. Moreover the present invention relates to pharmaceutical... Agent: Winstead PC

20100210561 - Use of peptide as a therapeutic agent: The present invention is directed to the use of the peptide compound Tyr-D-Cys(tBu)-Gly-Phe-Leu-Thr(tBu)-OH as a therapeutic agent for the prophylaxis and/or treatment of cancer, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurodegenerative diseases, infectious diseases, lung diseases, heart and vascular diseases and metabolic diseases. Moreover the present invention relates to pharmaceutical... Agent: Winstead PC

20100210564 - Drug or food containing a peptide: A pharmaceutical or a foodstuff including as an active ingredient a peptide containing Tyr (Y), Phe (F), Trp (W), or His (H) and a hydrophobic amino acid adjacent thereto, or an analog thereof.... Agent: Leydig Voit & Mayer, Ltd

20100210565 - Methods and apparatus for the enhanced delivery of physiologic agents to tissue surfaces: Apparatus and methods deliver physiologically active agents in the presence of adjuvant gases. The adjuvant gases can enhance the effectiveness of the drug, lower the dosage of drug or concentration of drug necessary to achieve a therapeutic result, or both. Exemplary adjuvant gases include carbon dioxide, nitric oxide, nitrous oxide,... Agent: Howrey LLP-ca

20100210563 - Metastasis-specific peptides and their diagnostic and therapeutic applications: The present invention concerns peptide sequences that specifically recognize cells of human hepatic metastases. The invention comprises also the use of nucleic acids coding for such peptides, as well as conjugates and formulations of such peptides for diagnostic and therapeutic purposes.... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20100210566 - Azapeptides as cd36 binding compounds: An azapeptide derivative of growth hormone releasing peptide (GHRP) of Formula I: A-(Xaa)a-N(RA)—N(RB)—C(O)-(Xaa′)b-B which binds to CD 36.... Agent: Nixon & Vanderhye, PC

20100210568 - Thyrotropin releasing hormone for therapeutic applications: The present invention is directed to the use of the peptide compound Pyr-His-Pro-NH2 as a therapeutic agent for the prophylaxis and/or treatment of cancer, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurodegenerative diseases, infectious diseases, lung diseases, heart and vascular diseases and metabolic diseases. Moreover the present invention relates to pharmaceutical... Agent: Winstead PC

20100210567 - Use of a tuftsin as a therapeutic agent: The present invention is directed to the use of the peptide compound Thr-Lys-Pro-Arg-OH as a therapeutic agent for the prophylaxis and/or treatment of cancer, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurodegenerative diseases, infectious diseases, lung diseases, heart and vascular diseases and metabolic diseases. Moreover the present invention relates to pharmaceutical... Agent: Winstead PC

20100210569 - Mitochondria-targeting antioxidant therapeutics: The instant invention constitutes an unique subject matter as a whole which has four individual aspects: (1) a class of chiral, non-racemic, synthetic carnitinoid analog carrier molecules which constitute biocompatible transport compounds not found in nature; (2) a subsequently formed, mitochondria-targeting, coupled antioxidant-carrier complex comprising an antioxidant reversibly attached to... Agent: David Prashker, P.C.

20100210570 - Lincomycin derivatives and antimicrobial agents comprising the same as active ingredient: N-optionally substituted C1-6 alkyl-N-optionally substituted C1-6 alkylamino-C1-6 alkyl; R2 represents a hydrogen atom or optionally substituted C1-6 alkyl; R3 represents optionally substituted C1-6 alkyl or C3-6 cycloalkyl-C1-4 alkyl; m is 1 to 3; n is 0; and p is 0 to 2. The compounds are novel lincomycin derivatives that have... Agent: Wenderoth, Lind & Ponack, L.L.P.

20100210571 - Topical formulations for treatment of skin disorders: Topical compositions and methods of using same for treating skin disorders or conditions comprising a storage-stable mixture of a benzoyl peroxide dispersion, clindamycin or pharmaceutically acceptable salts or esters thereof, and a pharmaceutically acceptable carrier.... Agent: Glaxo Smith Kline C/o The Nath Law Group

20100210572 - Hydrolysate of crocin: The present invention relates to a composition derived from the hydrolysate of plant containing crocin or the derivatives thereof. The composition includes a significant amount of crocetin monoester. The present invention also provides a method to hydrolyze crocin existing in a plant extract, and further relates to the use.... Agent: Fulbright & Jaworski L.L.P. Attn: MnIPDocket

20100210573 - Compound and compositions for treatment of disease: The present invention relates to flavonoids and to flavonoid-containing compositions for use in the treatment of parasites.... Agent: Schwegman, Lundberg & Woessner, P.A.

20100210574 - Avermectin b1 and avermectin b1 monosaccharide derivatives having an alkoxymethyl substituent in the 4\"-or 4'-position: e

20100210576 - Polyene diester antibiotics: The present invention discloses a new polyene diester and its preparation. This polyene diester has a structure of Formula 1, which is used as prodrugs by introducing diester group to polyene antibiotics, and these prodrugs exhibit antifungal or antiviral activities through releasing parent polyenes by esterase in vivo. The new... Agent: Brian S. Boyer, Ph.d.

20100210575 - Structuring effect of cholesterol in peg-phospholipid micelles, drug delivery of amphotericin b, and combination antifungals: The disclosure herein relates to embodiments of compositions and methods in connection with polymeric micelles including PEG-phospholipids. Embodiments also relate to the controlled release of pharmaceutical agents in the context of drug delivery. Further disclosed are embodiments of PEG-DSPE/Cholesterol micelle formulations prepared with an antifungal agent, Amphotericin B, with capabilities... Agent: Greenlee Winner And Sullivan P C

20100210577 - Cyclic carboxylic acid rhodanine derivatives for the treatment and prevention of tuberculosis: Disclosed are methods for the prevention or treatment of tuberculosis in a subject infected with Mycobacterium tuberculosis by administering rhodanine derivatives of formula (I), as well as some novel such compounds. Other embodiments are also disclosed.... Agent: Nixon Peabody LLP - Patent Group

20100210578 - Prevention/treatment of ichthyosis vulgaris, atopy and other disorders: The present invention relates to the prevention/treatment of ichthyosis vulgaris (IV), atopy and potentially other disorders associated with loss-of-function mutations in the filaggrin gene sequence. The prevention/therapy is based on the use of agents which enable the host's translational machinery to read through a nonsense mutation found in a mutant... Agent: Baker Botts L.L.P.

20100210708 - Compound profiling method: The present invention provides a method for deriving an upstream or downstream component of a component necessary for phenotypic alteration of a living organism, the method comprising the steps of: specifying a pathway of interest related to the phenotypic alteration and a reference pathway different from the pathway of interest,... Agent: Seed Intellectual Property Law Group PLLC

20100210711 - Methods and compositions for the treatment of sterile inflammation: Described are methods and compositions that inhibit IL-1 signalling for the treatment of acute inflammatory response to cell necrosis, and the attendant collateral tissue damage.... Agent: Fish & Richardson PC

20100210709 - Methods of treatment of opioid tolerance, physical dependence, pain and addiction with inhibitors of certain growth factor receptors: Methods of preventing the development and reversing or partially reversing opioid tolerance in a subject are provided herein. Such methods include the step of administering to a subject in need thereof a therapeutically effective amount of a PDGFR modulator or EGFR modulator alone or together with an opiate analgesic. The... Agent: NielsenIPLaw LLC

20100210707 - Small activating rna molecules and methods of use: The present invention provides compositions, pharmaceutical preparations, kits and methods for increasing expression of a gene product in a cell by contacting the cell with a small activating RNA (saRNA) molecule comprising a ribonucleic strand that is complementary to a non-coding nucleic acid sequence of the gene.... Agent: Bozicevic, Field & Francis LLP

20100210710 - Therapeutic sirna molecules for reducing vegfr1 expression in vitro and in vivo: The invention relates to nucleic acid molecule compositions for use in modulating the expression and activity of VEGF pathway genes and decreasing unwanted neovascularization, including tumor angiogenesis, by RNA interference and methods and compositions comprising the nucleic acid molecules.... Agent: Ropes & Gray LLP

20100210715 - Biodegradable cationic polymers: Polymers comprising a polyethylenimine, a biodegradable group, and a relatively hydrophobic group are useful for the delivery of bioactive agents to cells.... Agent: Knobbe Martens Olson & Bear LLP

20100210714 - Her-2/neu dna vaccine having anti-cancer activity: The present invention relates to human Her-2/neu expressing plasmid constructs having anti-cancer activity and a DNA vaccine comprising same for preventing and/or treating cancer. The Her-2/neu DNA vaccines of the present invention can be effectively used as a therapeutic vaccine in reducing metastasis after tumor surgery or as a prophylactic... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20100210713 - Regeneration and survival of cardiac progenitors and cardiomyocytes with a stretch activated transcription factor: The present invention relates generally to the field of cardiovascular repair, and more particularly to methods and compositions for the survival of cells in response to mechanical stress and to the proliferation of postnatal cardiomyocytes. The present invention relates to a nuclear form of Creb312(N) polypeptide which when expressed in... Agent: David S. Resnick

20100210712 - Short rna antagonist compounds for the modulation of target mrna: The invention provides LNA gapmer oligomers of between 10-20 nucleobases in length, which have a total of 1-3 phosphodiester internucleoside linkages. Such oligomers have been found to have superior bioavailability and have also been found to selectively accumulate in kidney cells.... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20100210579 - Partial and full agonists of a1 adenosine receptors: e

20100210582 - Method and composition for treating patients with a high risk of developing neuro-immune disorders or developmental delays, identified through the utilization of low homocysteine or its precursors/metabolites, as the predictor of such risk: A method for predicting the likelihood of developing ASD and ASD-related diseases in a subject is disclosed. The method includes the steps of measuring the level of homocysteine, a homocysteine precursor or a homocysteine metabolite in the subject and evaluating the likelihood of developing ASD and ASD-related diseases based on... Agent: Andrews Kurth LLP

20100210583 - Novel antifolate combination therapies: A method of administering an antifolate to a mammal in need thereof, comprising administering an effective amount of said antifolate in combination with a methylmalonic acid lowering agent.... Agent: Eli Lilly & Company

20100210581 - Nucleoside derivatives as inhibitors of viral polymerases: A class of nucleoside derivatives of formula (I), as defined herein, that are useful as inhibitors of RNA-dependent RNA viral replication and in particular HCV replication, are provided. Also provided are processes for the synthesis and use of such compounds for treating or preventing HCV infection.... Agent: Merck

20100210580 - Vitamin b12 nasal spray and method of use: The present invention relates generally to vitamin B12 nasal spray compositions and methods of using the same in the treatment of vitamin B12 deficiency and various disorders that are related to such deficiency. In particular embodiments, the present invention is directed to treatment methods comprising intranasal administration of a cobalamin... Agent: Arent Fox LLP

20100210588 - Hyaluronic acid linked with a polymer of an alpha hydroxy acid: The invention concerns a product comprising hyaluronic acid or a salt thereof, wherein the hyaluronic acid has been partially or fully linked or crosslinked with a polymer of an alpha hydroxy acid. The invention also concerns manufacture of the product, uses of the product of the invention in the field... Agent: Novozymes North America, Inc.

20100210584 - Liquid or paste compositions intended to provide elements essential for the synthesis and formation of proteoglycans, in particular, for the treatment of cartilage degradation: The invention relates to the field of pharmaceuticals, dietary supplements and food and, more specifically, to the field of dietary supplements intended for the treatment of degradation of cartilage of any origin. The invention relates to liquid or paste compositions based on glucosamin and chondroitin sulphate, intended to provide elements... Agent: Jerome D. Jackson (jackson Patent Law Office)

20100210586 - Pomegranate extracts, nutritional products containing them and their uses: The present invention relates to new pomegranate extracts, combined or not with soluble fiber, compositions free of any kind of organic solvent, soluble in cold water in high concentration, with very low sugar content and specially standardized to punicalagins, and its addition to foods to provide nutritional products and beverages... Agent: Hess Patent Law Firm, P.C.

20100210587 - Swellable crosslinked hyaluronan powder and method for producing the same: The present invention is provides a crosslinked hyaluronan powder excellent in swellability in water and a method for simply producing the same. A method for producing the swellable crosslinked hyaluronan powder is characterized by comprising mixing a crosslinking agent with a hyaluronan powder in a state dispersed in a liquid... Agent: Rankin, Hill & Clark LLP

20100210585 - Use of hyaluronic acid for the preparation of compositions intended for improving in particular the protective function of the skin, the eye and the mucous: The present invention relates to the use of hyaluronic acid for the preparation of compositions intended for improving the protective function of the skin, the eye and the mucous membranes, in particular of the upper and lower airways and the intestinal mucosa.... Agent: Young & Thompson

20100210589 - Method for improving hepatic function: An object of the present invention is to provide a means for improving hepatic function of mammals including humans to normal condition. The present invention achieves the above object by providing a hepatic function-improving agent comprising α-glucosyl-hesperidin as an effective ingredient.... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20100210592 - Amines or amino alcohols as glyt1 inhibitors:

20100210591 - Bis(trimethylsilyl)phenyl compound or salt thereof, and use thereof:

20100210590 - Compositions and treatments for seizure-related disorders: The present invention relates to therapeutic and/or prophylactic uses of pyridazine compounds and to pharmaceutical compositions containing one or more of these compounds as an active component for treating a disorder characterized by conduction disturbances, electroconvulsions and/or seizures, in particular epilepsy, more particularly pediatric epilepsy. In an aspect of the... Agent: Millen, White, Zelano & Branigan, P.C.

20100210593 - Pyridine- and pyrimidinecarboxamides as cxcr2 modulators: There is disclosed pyridine- and pyrimidinecarboxamide compounds useful as pharmaceutical agents, synthesis processes, and pharmaceutical compositions which include pyridine- and pyrimidinecarboxamides compounds. More specifically, there is disclosed a genus of CXCR2 inhibitor compounds that are useful for treating a variety of inflammatory and neoplastic disorders.... Agent: Syntrix Biosystems, Inc.

20100210594 - Substituted arylsulfonylaminomethylphosphonic acid derivatives, their preparation and their use in the treatment of type i and ii diabetes mellitus: wherein R, X, Y and Z are defined as in claim 1, the tautomers, enantiomers, diastereomers, mixtures thereof and salts thereof which have valuable pharmacological properties, particularly the suppression of the interaction of glycogen phosphorylase a with the GL subunit of glycogen-associated protein phosphatase 1 (PP1), and their use as... Agent: Michael P. Morris Boehringer Ingelheim Usa Corporation

20100210595 - Substituted arylsulfonylaminomethylphosphonic acid derivatives, their preparation and their use in the treatment of type i and ii diabetes mellitus: wherein R, X, Y and Z are defined as in claim 1, the tautomers, enantiomers, diastereomers, mixtures thereof and salts thereof which have valuable pharmacological properties, particularly the suppression of the interaction of glycogen phosphorylase a with the GL subunit of glycogen-associated protein phosphatase 1 (PP1), and their use as... Agent: Michael P. Morris Boehringer Ingelheim Usa Corporation

20100210597 - C21-deoxy ansamycin derivatives as antitumor agents: According to the invention there are provided derivatives of a C21-deoxy ansamycin or salt thereof which contain a 1-hydroxyphenyl moiety bearing at position 3 an aminocarboxy substituent, in which position 5 and the aminocarboxy substituent at position 3 are connected by an aliphatic chain of varying length characterised in that... Agent: Dann, Dorfman, Herrell & Skillman

20100210599 - Prodrugs of piperazine and substituted piperidine antiviral agents: c

20100210598 - Toll-like receptor modulators and treatment of diseases: Provided herein are small molecule conjugates that are agonists or antagonists of one or more toll-like receptors.... Agent: Schwegman, Lundberg & Woessner, P.A.

20100210596 - Use of aminopyrimidine compounds in the treatment of immune disorders: The present invention provides methods of treating immune disorders. The present invention provides methods of treating an autoimmune disorder; methods of reducing the risk of transplant rejection; methods of increasing transplant survival; and methods of treating graft-versus host disease. The methods generally involve administering to an individual in need thereof... Agent: Bozicevic, Field & Francis LLP

20100210600 - Methods and compositions for treating urogenital disorders: Glycerophosphate salts have been found to drastically improve the treatment of urogenital disorders such as urethral strictures and vaginal atrophy. Methods, devices and kits are described for treating urogenital disorders using a composition comprising an effective amount of a glycerophosphate salt.... Agent: Panitch Schwarze Belisario & Nadel LLP

20100210601 - Flea control method: This invention relates to a method of controlling or preventing maturation of fleas on an animal or its environment comprising applying to a warm blooded animal or its environment a composition comprising an developmentally disruptive amount of a compound of Formula 1 or an N-oxide, or a salt thereof.... Agent: E I Du Pont De Nemours And Company Legal Patent Records Center

20100210602 - Phou (perf), a persistence switch involved in persister formation and tolerance to multiple antibiotics and stresses as a drug target for persister bacteria: The PhoU protein is a widely expressed protein in bacteria, but not in eukaryotes. The PhoU protein is required for persister formation in bacteria. The invention includes compositions to reduce persister formation and their use as therapeutic agents. The invention further includes methods for identification of compounds to reduce persister... Agent: Edwards Angell Palmer & Dodge LLP

20100210603 - Novel sulfonamide inhibitors of aspartyl protease: The present invention relates to a novel class of sulfonamides which are aspartyl protease inhibitors. In one embodiment, this invention relates to a novel class of HIV aspartyl protease inhibitors characterized by specific structural and physicochemical features. This invention also relates to pharmaceutical compositions comprising these compounds. The compounds and... Agent: Ropes & Gray LLP

20100210604 - Zwitterion solution for low-volume therapeutic delivery: A formulation is provided that includes a volume of an aqueous multivalent physiological ion solution compatible with cerebrospinal fluid containing at least one divalent cation of magnesium or calcium, and at least one anion of carbonate or phosphate, and having a pH between 6.5 and 8.0. A zwitterionic therapeutic agent... Agent: Gifford, Krass, Sprinkle,anderson & Citkowski, P.c

20100210605 - Compositions comprising 5-amino-2-hydroxybenzoic acid and a reducing sugar: Compositions comprising 5-amino-2-hydroxybenzoic acid (5-amino salicylic acid, mesalamine) and a reducing sugar, e.g., lactose, undergo the Maillard and other chemical reactions and produce, in the case of lactose, a degradant 5-[2-formyl-5-(hydroxymethyl)-1H-pyrrol-1-yl]-2-hydroxybenzoic acid. Inventors have developed means to contain and/or reduce the formation of degradants of 5-amino-2-hydroxybenzoic acid.... Agent: Fitzpatrick Cella Harper & Scinto

20100210606 - Methods and reagents for the treatment of inflammatory disorders: The invention features a method for treating an immunoinflammatory administering a compound of formula (I), e.g., ibudilast or KC-764, alone or in combination with a corticosteroid, tetra-substituted pyrimidopyrimidine, or other compound. The invention also features pharmaceutical compositions including the combination above for the treatment or prevention of an immunoinflammatory disorder.... Agent: Clark & Elbing LLP

20100210607 - Hydrogen sulfide derivatives of non-steroidal anti-inflammatory drugs: The present invention relates to derivatives of non-steroidal anti-inflammatory drugs (NSAIDs) having improved anti-inflammatory properties useful in the treatment of inflammation, pain and fever. More particularly, NSAIDs are derivatized with a hydrogen sulfide (H2S) releasing moiety to produce novel anti-inflammatory compounds having reduced side effects.... Agent: Bennett Jones LLP C/o Ms Roseann Caldwell

20100210608 - Therapeutic treatment: The invention describes the use of betaine for treating and preventing arterites. The invention also describes an orally administered composition for treating arterites and, in particular, intermittent claudication, said composition containing, as an active ingredient, an active therapeutic quantity of betaine glycine by single dose. The invention particularly describes a... Agent: Hovey Williams LLP

20100210609 - Compositions and methods for enhancing corticosteroid delivery: The present invention comprises a composition, method of enhancing potency and method of delivering corticosteroids in a vehicle comprising at least two penetration enhancers, and solvents and emulsifiers. The propylene glycol and penetration enhancers are present in ratio to the total of the propylene glycol, penetration enhancers, and solvents and... Agent: Reed Smith LLP

20100210611 - Combination therapy: The present invention provides inhalation compositions comprising montelukast acid and a second active agent selected from a PDE4 inhibitor and an inhaled corticosteroid. Also provided is a method for the treatment of respiratory disorders such as asthma using such compositions.... Agent: Merck

20100210610 - Organic compounds: There are provided according to the invention compounds of formula (I), in free or salt form, wherein R1, R2, R3, R4, R5, R6, Q, W, X, m, n and p are as described in the specification, process for preparing them, and their use as pharmaceuticals.... Agent: Novartis Institutes For Biomedical Research, Inc.

20100210612 - Detection of esr1 amplification in endometrium cancer and ovary cancer: The present invention relates to an in-vitro method of identifying a tumor resulting from a proliferative disease of the endometrium or ovary as responsive to anti-estrogen treatment. Further, the invention relates to an in-vitro method of identifying a candidate patient with a proliferative disease of the endometrium or ovary as... Agent: Marshall, Gerstein & Borun LLP

20100210613 - Transdermally absorbable preparation: A transdermally absorbable preparation comprises a natural type sex hormone, a polyoxyethylene oleyl ether having a molar number of ethylene oxide units added of 20, at least two kinds of oily ingredients selected from the group consisting of diisopropyl adipate, cetyl alcohol, benzyl alcohol, and propylene glycol dicaprate, a polyhydric... Agent: Rankin, Hill & Clark LLP

20100210614 - Compositions and methods for enhancing corticosteroid delivery: The present invention comprises a composition, method of enhancing potency and method of delivering corticosteroids in a vehicle comprising at least two penetration enhancers, and solvents and emulsifiers. The propylene glycol and penetration enhancers are present in ratio to the total of the propylene glycol, penetration enhancers, and solvents and... Agent: Reed Smith LLP

20100210615 - Compositions and methods for enhancing corticosteroid delivery: The present invention comprises a composition, method of enhancing potency and method of delivering corticosteroids in a vehicle comprising at least two penetration enhancers, and solvents and emulsifiers. The propylene glycol and penetration enhancers are present in ratio to the total of the propylene glycol, penetration enhancers, and solvents and... Agent: Reed Smith LLP

20100210616 - Metal complexes incorporated within biodegradable nanoparticles and their use: Compounds for antimicrobial applications, and for treating bacterial and fungal infection are set forth. The compounds may include a metal complex incorporated into a biodegradable polymeric nanoparticle. Also, a method of treating bacterial and fungal infections in a mammal includes the steps of administering an effective amount of a silver(I)... Agent: Hahn Loeser & Parks, LLP

20100210619 - 6-amino-pyrimidine-4-carboxamide derivatives and related compounds which bind to the sphingosine 1-phosphate (s1p) receptor for the treatment of multiple sclerosis: m

20100210621 - Crystalline polymorphic form 631: A new polymorphic form of 3-{[5-(azetidin-1-ylcarbonyl)pyrazin-2-yl]oxy}-5-{[(1S)-1-methyl-2-(methyloxy)ethyl]oxy}-N-(5-methylpyrazin-2-yl)benzamide, processes for making it and its use as an activator of glucokinase are described.... Agent: Morgan Lewis & Bockius LLP

20100210618 - Piperidine/piperazine derivatives: The invention relates to a DGAT inhibitor of formula (I), including any stereochemically isomeric form thereof, wherein A represents CH or N; the dotted line represents an optional bond in case A represents a carbon atom; X represents —O—C(═O)—; —C(═O)—C(═O)—; —NRX—C(═O)—; —Z—C(═O)—; —Z—NRX—C(═O)—; —C(═O)—Z—; —NRX—C(═O)—Z—; —C(═S)—; —NRX—C(═S)—; —Z—C(═S)—; —Z—NRX—C(═S)—; —C(═S)—Z—;... Agent: Philip S. Johnson Johnson & Johnson

20100210620 - Substituted aryl sulfone derivatives as calcium channel blockers: A series of substituted aryl sulfone derivatives represented by Formula I, or pharmaceutically acceptable salts thereof. Pharmaceutical compositions comprise an effective amount of the instant compounds, either alone, or in combination with one or more other therapeutically active compounds, and a pharmaceutically acceptable carrier. Methods of treating conditions associated with,... Agent: Merck

20100210617 - Aryl-alkylamines and heteroaryl-alkylamines as protein kinase inhibitors: The invention provides a compound of the formula (II): or a salt, solvate, tautomer or N-oxide thereof; wherein n is 0 or 1; one of Y1 and Y2 is CH and the other is selected from CH, CR8 and N; q is 0, 1 or 2 provided that q is... Agent: Heslin Rothenberg Farley & Mesiti PC

20100210622 - Heterocyclic compounds and methods of use: in which the variable X1a, X1b, X1c, X1d, Q, A, R1, B, L, E, and the subscripts m and n have the meanings as described herein. In another aspect, the present invention provides for pharmaceutical compositions comprising compounds of Formula I as well as methods for using compounds of Formula... Agent: Jones Day

20100210623 - Therapeutic compounds: The present invention relates to pyrazine substituted pyrrolopyridines which are inhibitors of JAK kinases (JAK1, JAK2, JAK3 and/or TYK2) and/or PDK1 and are thus useful for the treatment of myeloproliferative disorders or cancer.... Agent: Merck

20100210624 - Aryloxy- and heteroaryloxy-substituted tetrahydrobenzazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin: The aryloxy- and heteroaryloxy-substituted tetrahydrobenzazepine derivative compounds of the present invention are represented by formulae (I) (A-E) having the following structure where the carbon atom designated * is in the R or S configuration and the substituents X and R1-R9 are as defined herein.... Agent: Nixon Peabody LLP - Patent Group

20100210625 - Novel1,4-diaza-bicyclo[3.2.2]nonyl heteroaryl derivatives useful as nicotinic acetylcholine receptor ligands: Due to their pharmacological profile the compounds of the invention may be useful for the treatment of diseases or disorders as diverse as those related to the cholinergic system of the central nervous system (CNS), the peripheral nervous system (PNS), diseases or disorders related to smooth muscle contraction, endocrine diseases... Agent: Birch Stewart Kolasch & Birch

20100210626 - Pharmaceutical composition comprising a monoamine neurotransmitter re-uptake inhibitor and an acetylcholinesterase inhibitor: The invention relates to a pharmaceutical composition comprising a monoamine neurotransmitter re-uptake inhibitor comprising a 2,3-disubstituted tropane moiety, or a tautomer, a pharmaceutically acceptable salt, solvate, or physiologically functional derivative thereof (1), and at least one acetylcholinesterase inhibitor or a pharmaceutically acceptable salt, solvate, or physiologically functional derivative thereof (2),... Agent: Birch Stewart Kolasch & Birch

20100210628 - Novel seh inhibitors and their use: wherein R1, R2, R3, R5a, R6a A, B, Y, x, and m are defined below, and to pharmaceutically-acceptable salts thereof. The compounds of the invention are sEH inhibitors and can be used in the treatment of diseases mediated by the sEH enzyme, such as hypertension. Accordingly, the invention is further... Agent: Glaxosmithkline Global Patents -us, Uw2220

20100210627 - Pyrazine compounds, their use and methods of preparation: their use and methods for preparation wherein A, X, Y, R1, R2 and R3 are defined herein. The compounds of the invention inhibit specific serine/threonine kinases involved in inflammatory processes and aberrant cell proliferation, and are thus useful for treating associated diseases and pathological conditions such as Pim kinase-mediated diseases... Agent: Michael P. Morris Boehringer Ingelheim Usa Corporation

20100210629 - 1,6-dihydro-1,3,5,6-tetraaza-as-indacene based tricyclic compounds and pharmaceutical compositions comprising same: e

20100210630 - Diamine derivatives as inhibitors of leukotriene a4 hydrolase: where r, q, R, R2, R3, R4, R5a, R5b, R5c, R6a, R6b, R6c, R7, R8, and R9 are described herein, as single stereoisomers or as mixtures of stereoisomers, or pharmaceutically acceptable salts, solvates, clathrates, polymorphs, ammonium ions, N-oxides or prodrugs thereof; which are leukotriene A4 hydrolase inhibitors and therefore useful... Agent: Jacqueline S Larson

20100210631 - Substituted 2-[2-(phenyl) ethylamino] alkaneamide derivatives and their use as sodium and/or calcium channel modulators: Substituted 2-[2-(phenyl)ethylamino]alkaneamide derivatives, pharmaceutically acceptable salts thereof, and pharmaceutical compositions containing them are useful as sodium and/or calcium channel modulators for preventing, alleviating and curing pathologies wherein the above mechanisms play a pathological role. The compounds may be particularly used for the prevention, alleviation, and curing of, for example, neurological,... Agent: Dechert LLP

20100210632 - Novel pyrrolinone derivative and pharmaceutical composition comprising the same: b

20100210633 - Carboxamide compounds and their use: Chemokine receptor antagonists, in particular, compounds of Formula (I) that act as antagonists of the chemokine CCR2 receptor, including pharmaceutical compositions and uses thereof to treat or prevent diseases associated with monocyte accumulation, lymphocyte accumulation or leukocyte accumulation are described herein.... Agent: Goodwin Procter LLP Patent Administrator

20100210634 - Certain chemical entities, compositions and methods: Certain substituted urea derivatives selectively modulate the cardiac sarcomere, for example by potentiating cardiac myosin, and are useful in the treatment of systolic heart failure including congestive heart failure.... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20100210636 - Benzoxazinone derivative: r

20100210635 - Renin inhibitors: Compounds, pharmaceutical compositions, kits and methods are provided for use with Renin that comprise a compound selected from the group consisting of: wherein the variables are as defined herein.... Agent: Takeda San Diego, Inc.

20100210637 - Heteroaryloxy nitrogenous saturated heterocyclic derivative: m

20100210638 - Modulators of atp-binding cassette transporters: Compounds of the present invention, and pharmaceutically acceptable compositions thereof, are useful as modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator (“CFTR”). The present invention also relates to methods of treating ABC transporter mediated diseases using compounds of the present invention.... Agent: Vertex Pharmaceuticals Inc.

20100210639 - 9h-pyrimido[4,5-b]indoles, 9h-pyrido[4',3':4,5]pyrrolo[2,3-d]pyridines, and 9h 1,3,6,9 tetraaza-fluorenes as chk1 kinase function inhibitors: The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain tricyclic compounds (referred to herein as TC compounds), and especially certain 9H-pyrimido[4,5-b]indole, 9H-pyrido[4′,3′:4,5]pyrrolo[2,3-d]pyridine, and 9H-1,3,6,9-tetraaza-fluorene compounds, which, inter alia, inhibit Checkpoint Kinase 1 (CHK1) kinase function. The present invention also pertains to pharmaceutical compositions... Agent: Swanson & Bratschun, L.L.C.

20100210642 - Acetylenyl-pyrazolo-pyrimidine derivatives: e

20100210640 - Benzamide derivatives, their preparation and uses in medicine thereof: The present invention discloses novel benzamide derivatives represented by general formula (I), their preparation, pharmaceutical compositions containing the derivatives and their use as medicament, especially as a 5-HT4 stimulator, wherein the definition of each substituent of the general formula (I) is the same as defined in the description.... Agent: Workman Nydegger 1000 Eagle Gate Tower

20100210641 - Organic compounds: Compounds of formula I: in free or salt or solvate form, where R1, R2, R3 and R20 have the meanings as indicated in the specification, are useful for treating diseases mediated by the ALK-5 and/or ALK-4 receptor. Pharmaceutical compositions that contain the compounds and processes for preparing the compounds are... Agent: Novartis Institutes For Biomedical Research, Inc.

20100210645 - Certain chemical entities, compositions and methods: Provided are certain chemical entities, and methods of use to modulate skeletal myosin, skeletal actin, skeletal tropomyosin, skeletal troponin C, skeletal troponin I, skeletal troponin T, and skeletal muscle, including fragments and isoforms thereof, as well as the skeletal sarcomere, and methods of use in the treatment of obesity, sarcopenia,... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20100210644 - Chemical compounds: The present invention encompasses compounds of general formula (1) wherein the groups R1 to R5 are defined as in claim 1, which are suitable for treating diseases characterised by excessive or abnormal cell proliferation, and their use for preparing a medicament having the above-mentioned properties.... Agent: Michael P. Morris Boehringer Ingelheim Usa Corporation

20100210643 - Sgc stimulators, sgc activators and combinations for the treatment of urological disorders: The invention provides pharmacological compositions comprising a stimulator or activator of the soluble guanylate cyclase alone (sGC) or in combination with a PDE5 inhibitor for the treatment of urological disorders comprising of Benign Prostate Syndrome (BPS), Benign Prostate Hyperplasia (BPH), Benign Prostate Enlargement (BPE), Bladder Outlet Obstruction (BOO), Lower Urinary... Agent: Barbara A. Shimei Director, Patents & Licensing

20100210646 - 2-morpholin-4-yl-pyrimidines as pi3k inhibitors: wherein R1 and R2 have any of the values defined herein; or a pharmaceutically acceptable salt thereof. These compounds are inhibitors of PI3K and may thus be used to treat diseases and disorders arising from abnormal cell growth, function or behaviour associated with PI3 kinase such as cancer, immune disorders,... Agent: Viksnins Harris & Padys Pllp

20100210647 - Indole compounds as an inhibitor of cellular necrosis: The present invention relates to new indole compounds, pharmaceutically acceptable salts or isomers thereof which are useful for the prevention or treatment of cellular necrosis and necrosis-associated diseases. The present invention also relates to a method and a composition for the prevention or treatment of cellular necrosis and necrosis-associated diseases,... Agent: Birch Stewart Kolasch & Birch

20100210648 - Pyrazolylaminopyrimidine derivatives useful as tyrosine kinase inhibitors: e

20100210649 - Pyridazinones and furan-containing compounds: The present invention is directed to pyridazinone compounds of formula (I) and furan compounds of formula (II), pharmaceutical compositions of compounds of formula (I) and (II), kits containing these compounds, methods of syntheses, and a method of treatment of a proliferative disease in a subject by administration of a therapeutically... Agent: Choate, Hall & Stewart LLP/mskcc Sloan-kettering Institute For Cancer Research

20100210650 - Isoxazole compound for the treatment of cancer: The use of 5-(2,4-Dihydroxy-5-isopropyl-phenyl)-4-(4-morpholin-4-ylmethyl-phenyl)-isoxazole-3-carboxylic acid ethylamide or a tautomer thereof or a pharmaceutically acceptable salt or a hydrate or a solvate for the treatment of cancer of the bladder, the colon, the liver, the lung, the breast, the vagina, the ovaries, the pancreas, the kidney, the stomach, the gastrointestinal tract,... Agent: Novartis Corporate Intellectual Property

20100210651 - Isoxazole-isoxazoles and isoxazole-isothiazoles: The present invention is concerned with isoxazole-isoxazoles and isoxazole-isothiazoles of formula I, having affinity and selectivity for GABA A α5 receptor, their manufacture, pharmaceutical compositions containing them and their use as cognitive enhancers or for the therapeutic and/or prophylactic treatment of cognitive disorders like Alzheimer's disease.... Agent: Hoffmann-la Roche Inc. Patent Law Department

20100210652 - Method for controlling fungal pests: e

20100210653 - Novel compounds, their preparations and use: Novel compounds of the general formula (I), the use of these compounds as pharmaceutical compositions, pharmaceutical compositions comprising the compounds and methods of treatment employing these compounds and compositions. The present compounds may be useful in the treatment and/or prevention of conditions mediated by Peroxisome proliferator-activated receptors (PPAR), in particular... Agent: High Point Pharmaceuticals, LLC

20100210654 - Novel p2y12 receptor antagonists: The present invention relates to novel P2Y12 receptor antagonists useful for treating, alleviating and/or preventing diseases and disorders related to P2Y12 receptor function as well as pharmaceutical compositions comprising such compounds and methods for preparing such compounds. The present invention is further directed to the use of these compounds, alone... Agent: Techlaw LLP

20100210655 - Novel seh inhibitors and their use: wherein R1, R2, R5a, R6a, A, B, Y, I, and m are defined below, and to pharmaceutically-acceptable salts thereof. The compounds of the invention are sEH inhibitors and can be used in the treatment of diseases mediated by the sEH enzyme, such as hypertension. Accordingly, the invention is further directed... Agent: Glaxosmithkline Global Patents -us, Uw2220

20100210656 - Novel seh inhibitors and their use: wherein R1, R2, R4, R5, R6, A, B, Y, Z, n, and m are defined below, and to pharmaceutically-acceptable salts thereof. The compounds of the invention are sEH inhibitors and can be used in the treatment of diseases mediated by the sEH enzyme, such as hypertension. Accordingly, the invention is... Agent: Glaxosmithkline Global Patents -us, Uw2220

20100210657 - Bicyclic benzamides of 3-or 4-substituted 4-(aminomethyl)-piperidine derivatives: e

20100210658 - Novel tetracyclic heteroatom containing derivatives useful as sex steroid hormone receptor modulators: The present invention is directed to novel tetracyclic heteroatom containing derivatives, pharmaceutical compositions containing them, their use in the treatment of disorders mediated by one or more sex steroid hormone receptors and processes for their preparation.... Agent: Philip S. Johnson Johnson & Johnson

20100210659 - Pyrrolidine derivatives as nk3 receptor antagonists: wherein A, Ar, R, R2, R3, R4, p, and o are as defined in the specification and claims or to a pharmaceutically active salt thereof. The present compounds are high potential NK-3 receptor antagonists for the treatment of depression, pain, psychosis, Parkinson's disease, schizophrenia, bipolar disorders, anxiety and attention deficit... Agent: Hoffmann-la Roche Inc. Patent Law Department

20100210660 - Heterocyclic fxr binding compounds: The present invention relates to compounds which bind to the NRI H4 receptor (FXR) and act as agonists or partial agonists of the NR1 H4 receptor (FXR). The invention further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions... Agent: Kilyk & Bowersox, P.l.l.c.

20100210661 - Stat3/5 activation inhibitor: e

20100210662 - Indol-2-one derivatives disubstituted in the 3-position, preparation thereof and therapeutic use thereof: The present invention relates to 3-disubstituted indol-2-one derivatives, to their preparation and to their therapeutic application.... Agent: Andrea Q. Ryan Sanofi-aventis U.s. LLC

20100210663 - Hybrid 2-aminotetralin and aryl-substituted piperazine compounds and their use in altering cns activity: Hybrid compounds containing an aminotetralin moiety or a heterocyclic and/or open chain analog thereof linked through an alkylene group to an aryl ring system-substituted piperidiene moiety exhibit high levels of CNS activity, in some cases exhibiting especially high relative binding efficiencies between D3 and D2 dopaminergic receptor subtypes.... Agent: Brooks Kushman P.C.

20100210664 - Benzenesulfonamide compounds suitable for treating disorders that respond to modulation of the dopamine d3 receptor: The invention relates to compounds of the formula R1 is selected from the group consisting of hydrogen, linear C1-C3 alkyl and fluorinated linear C1-C3 alkyl; R2 is hydrogen or methyl; R3 is selected from the group consisting of hydrogen, halogen, C1-C2-alkyl, fluorinated C1-C2-alkyl, C1-C2-alkoxy and fluorinated C1-C2-alkoxy, R4 is C1-C2-alkyl... Agent: Abbott Laboratories C/o Polsinelli Shughart PC

20100210665 - Diarylhydantoin compounds: The present invention relates to diarylhydantoin compounds, including diarylthiohydantoins, and methods for synthesizing them and using them in the treatment of hormone refractory prostate cancer.... Agent: Venable LLP

20100210666 - Methods of using a g protein-coupled receptor to identify peptide yy (pyy) secretagogues and compounds useful in the treatment of conditions modulated by pyy: The present invention relates to methods of using GPR119 receptor to identify peptide YY (PYY) secretagogues and compounds useful in the treatment of conditions modulated by PYY, such as conditions modulated by stimulation of NPY Y2 receptor (Y2R). Agonists of GPR119 receptor are useful as therapeutic agents for treating or... Agent: Fish & Richardson P.C.

20100210667 - Imidazo [1, 2-c] pyrimidin-2-ylmethylpiperidines as orexin receptor antagonists: e

20100210668 - Composition and method for treatment or prevention of benign prostatic hyperplasia and lower urinary tract symptoms: The present invention relates to a composition and a method for treating or preventing benign prostatic hyperplasia (BPH) and lower urinary tract symptoms (LUTS) without showing the side effect, by dramatically relaxing the smooth muscle in prostate and bladder.... Agent: Lerner, David, Littenberg, Krumholz & Mentlik

20100210669 - Crystalline form of entecavir, its preparation and the pharmaceutical composition and uses thereof: The present invention relates to a crystalline form of entecavir and its process for preparation, and provides a pharmaceutical composition comprising a therapeutically effective amount of the crystalline form of entecavir. Furthermore, the present invention also provides a use of the crystalline form of entecavir in preparation for a medicament... Agent: Emerson, Thomson & Bennett, LLC

20100210670 - Methods and compostions utiliziing quinazolinones: Quinazolinones of formulae (a, b, c and d) are disclosed. They are useful for treating cellular proliferative diseases and disorders associated with KSP kinesin activity.... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20100210671 - Quinazolinone t-type calcium channel antagonists: The present invention is directed to quinazolinone compounds which are antagonists of T-type calcium channels, and which are useful in the treatment or prevention of disorders and diseases in which T-type calcium channels are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of... Agent: Merck

20100210672 - Azabicyclo [3. 1. o] hexyl derivatives as modulators of dopamine d3 receptors: R1 is a 5-membered heteroaryl group, optionally fused with a 6-membered hetero or carbocycle; such 5 or 11-membered system, may be optionally substituted by 1, 2, 3 or 4 substituents selected from the group consisting of: halogen, cyano, C1-4alkyl, haloC1-4alkyl, C1-4alkoxy, C1-4alkanoyl, haloC1-4alkoxy and SF5; and n is 1 or... Agent: Glaxosmithkline Global Patents -us, Uw2220

20100210673 - Pyrimidylaminobenzamide derivatives for systemic mastocytosis: The present invention relates to the use of pyrimidylaminobenzamide derivatives for the preparation of a drug for the treatment of systemic mastocytosis.... Agent: Novartis Corporate Intellectual Property

20100210674 - Spiroindolinone derivatives: e

20100210676 - Chemically modified small molecules: Methods of modifying the rate of systemic absorption of a drug administered to a subject by a pulmonary route, the method comprising covalently conjugating a hydrophilic polymer to a drug, wherein the drug has a half-life of elimination from the lung of less than about 180 minutes, to form a... Agent: Jones Day

20100210675 - Solvent-free crystalline form of naltrexone: Solvent-free crystalline polymorphic form of naltrexone, characterized in that it has the XRD data listed in Table 1, and a method for the preparation of this polymorphic form; and a method for converting this polymorphic form of naltrexone into a known polymorphic form of naltrexone.... Agent: Hoffmann & Baron, LLP

20100210677 - Novel compound, corresponding compositions, preparation and/or treatment methods: Disclosed is a novel crystalline form of topotecan monohydrochloride pentahydrate, which is a pentahydrate of 10-[(dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-1H-pyrano[3′,4′:6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)dione monohydrochloride, corresponding pharmaceutical compositions, methods preparation and/or use thereof to treat anti-viral and/or cancer-related diseases.... Agent: Glaxosmithkline Corporate Intellectual Property - Uw2220

20100210678 - Tricyclic androgen receptor modulator compounds and methods: Provided are non-steroidal tricyclic compounds that are modulators of androgen receptors and methods for making and using such compounds.... Agent: K&l Gates LLP

20100210679 - Preventive and therapeutic medicament for gastroesophageal reflux disease: wherein R1 and R2 independently represent a hydrogen atom or a lower alkyl group; A represents a group selected from the group consisting of 1-azabicyclo[3.2.2]nonyl group, 1-azabicyclo[2.2.2]octyl group, or an N-oxide thereof, or a pharmaceutically acceptable salt thereof or a hydrate thereof has both improving effect on enterokinetic functions and... Agent: Wenderoth, Lind & Ponack, L.L.P.

20100210680 - Tricyclic heterocyclic derivatives: The present invention relates to a tricyclic heterocyclic derivative of Formula (I) wherein the variables are as defined in the specification. The present invention further relates to pharmaceutical compositions comprising these compounds and to their use in therapy, in particular for the treatment of serotonin-mediated disorders such as obesity, schizophrenia... Agent: Organon Usa, Inc. C/o Merck

20100210681 - Aqueous pharmaceutical composition: The present invention relates to an aqueous pharmaceutical composition comprising 1-(2-dimethylaminoethyl)-3-((2R,4aS,5R,10bS)-5-phenyl-9-trifluoromethyl-3,4,4a,5,6,10b-hexahydro-2H-pyrano[3,2-c]quinolin-2-ylmethyl)urea as active compound, to a liquid pharmaceutical composition which is suitable for the preparation of the aqueous pharmaceutical composition, and to a process for the preparation of the compositions.... Agent: Millen, White, Zelano & Branigan, P.C.

20100210682 - Repeated dosing of trpv1 antagonists: Disclosed herein are methods for increasing analgesic potency of TRPV1 antagonists, said methods comprise of repeated administration of the TRPV1 antagonists in a subject. Methods for treating or preventing pain by repeated administration of a TRPV1 antagonist are also discussed.... Agent: Paul D. Yasger Abbott Laboratories

20100210683 - Imidate compound and use thereof for pest control: wherein Z represents an optionally substituted carbocyclic group or an optionally substituted heterocyclic group; G represents a -A1-R1 group, etc.; X0 represents a -A2-R4 group, etc.; X represents a -A2-R4 group, etc.; X0 represents a -A3-R6 group, etc.; or X and X0 are optionally taken together to form a -A2-T0-A3-... Agent: Sughrue Mion, PLLC

20100210684 - Amine salt of carbostyril derivative: The invention provides an amine salt of a carbostyril derivative formed from a carbostyril derivative represented by the formula (1) [wherein R is a halogen atom; the substituted position of the side chain is 3- or 4-position in the carbostyril skeleton; and the bonding between 3- and 4-positions of the... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20100210685 - Novel substituted indoles: The present invention relates to substituted indoles of formula (I), useful as pharmaceutical compounds for treating respiratory disorders.... Agent: Fish & Richardson P.C.

20100210686 - Therapeutic agents useful for treating pain: e

20100210687 - Compounds which have activity at m1 receptor and their uses in medicine:

20100210688 - Novel benzothiazolone derivatives: The present invention provides compounds of formula (I) wherein e, R1, R2, R3, R4, R5, R4, R5, R6, R7, R7a, R7b, A, D, m and n are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.... Agent: Fish & Richardson P.C.

20100210689 - Therapeutic substituted chlorocyclopentanols: e

20100210691 - Compositions for the control of plant pests: The present invention provides a composition comprising imidacloprid and metalaxyl. The compositions of the present invention find use as pesticides.... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20100210690 - N-(pyrazole-3-yl)-benzamide derivatives as glucokinase activators: e

20100210692 - Methods of treatment using sirt modulators and compositions containing sirt1 modulators: Methods of treatment using SIR1 modulators and compositions containing SIRT1 modulators are described. Combinations of a SIRT1 modulator and a second agent, and uses of such combinations, are also described.... Agent: Lando & Anastasi, LLP E2023

20100210693 - Benzylether and benzylamino beta-secretase inhibitors for the treatment of alzheimer's disease: The present invention is directed to compounds which are inhibitors of the beta-secretase enzyme and that are useful in the treatment of diseases in which the beta-secretase enzyme is involved, such as Alzheimer's disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these... Agent: Merck

20100210694 - New no-donor aspirin derivatives: The present invention refers to new NO-donors aspirin derivatives, a process for their preparation and pharmaceutical compositions containing them.... Agent: Arent Fox LLP

20100210695 - Compositions and methods for treating skin disorders: The present invention is directed to pharmaceutical compositions formulated for topical administration comprising an inhibitor of carnitine palmitoyl transferase (CPT1) and methods for treating skin disorders, such as psoriasis, by administration of a CPT1 inhibitor. In particular embodiments, the invention provides a pharmaceutical composition formulated for topical administration comprising the... Agent: Myers Bigel Sibley & Sajovec

20100210696 - 5-membered heterocyclic compound: e

20100210697 - Pharmaceutical composition for treatment of cataract:

20100210698 - Pesticidal composition and method for controlling pests: A pesticidal composition comprising [2,5-dioxo-3-(2-propynyl)-1-imidazolidinyl]methyl 3-(2-methyl-1-propenyl)-2,2-dimethylcyclopropanecarboxylate and 4-methoxymethyl-2,3,5,6-tetrafluorobenzyl 3-(2-cyano-1-propenyl)-2,2-dimethylcyclopropanecarboxylate as active ingredients, and a pests-controlling method characterized by applying an effective amount of said pesticidal composition to the pests or a locus where the pests inhabit, have an excellent controlling effect on the pests.... Agent: Birch Stewart Kolasch & Birch

20100210699 - Imidazolidine derivatives, uses therefor, preparation thereof and compositions comprising such: p

20100210700 - Methods of treatment using intravenous formulations comprising temozolomide: This invention relates to methods and drug products for treating proliferative disorders using intravenous formulations comprising temozolomide over a specific infusion time. These methods and drug products are particularly well-suited for patients who cannot swallow oral formulations. These methods and drug products also afford an added convenience to patients who... Agent: Merck Patent Department (k-6-1, 1990)

20100210701 - Novel forms of bendamustine free base: Novel polymorphic forms of bendamustine free base are described, including amorphous bendamustine free base, six anhydrous crystalline forms, four hydrate forms, and five solvate forms, with methods of their preparation and use also being described.... Agent: Ross J. Oehler Cephalon, Inc.

20100210702 - Anti-fungal formulation: Provided herein are compositions and formulations comprising an antifungal agent. Pharmaceutical compositions comprising luliconazole in an amount effective for the treatment of onychomycosis are provided. Also provided are methods for treating dermatomycoses and onychomycosis using the compositions and formulations.... Agent: Morrison & Foerster LLP

20100210703 - Anti-fungal formulation: Provided herein are compositions and formulations comprising an antifungal agent. Pharmaceutical compositions comprising luliconazole in an amount effective for the treatment of onychomycosis are provided. Also provided are methods for treating dermatomycoses and onychomycosis using the compositions and formulations.... Agent: Morrison & Foerster LLP

20100210704 - 3-alkoxy-1-phenylpyrazole derivatives and pesticides: wherein, for example, R1 is a C1-C10 alkyl group or the like, R2 is a hydrogen atom or the like, R3 is a hydrogen atom or the like, and each of R4, R5, R6 and R8 which are independent of one another, is a hydrogen atom or the like, and... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, L.L.P.

20100210705 - Pyrrole and isoindole carboxamide derivatives as p2x7 modulators: The compounds or salts modulate P2X7 receptor function and are capable of antagonizing the effects of ATP at the P2X7 receptor. The invention also provides the use of such compounds or salts, or pharmaceutical compositions thereof, in the treatment of disorders mediated by the P2X7 receptor, for example pain, inflammation... Agent: Glaxosmithkline Global Patents -us, Uw2220

20100210706 - Pyrrolidinone anilines as progesterone receptor modulators: e

20100210716 - Process for preparing an alpha-lipoic acid/cyclodextrin complex and product prepared: The invention relates to a process for the preparation of a cyclodextrin/alpha-lipoic acid complex, wherein in a first step, an alpha-lipoic acid and a cyclodextrin are dissolved in an aqueous alkaline solution having a pH above pH 7, and in a second step an acid is added to lower the... Agent: Brooks Kushman P.C.

20100210717 - Pharmaceutical compositions comprising mycophenolic acid or mycophenolate salt: The invention provides a solid dosage form, e.g. a tablet, comprising mycophenolic acid or mycophenolate salt and a process for its production.... Agent: Novartis Corporate Intellectual Property

20100210718 - Synergistic anti-oxidant treatment for lipotoxicity and other metabolically related phenomena: A method for ameliorating, reducing, and/or preventing lipotoxicity-induced metabolic dysfunction in at least one cell is disclosed, said method comprising a step of contacting said at least one cell with a therapeutically effective amount of a synergistic anti-lipotoxicity cocktail, said cocktail comprising N-acetylcysteine, ascorbic acid, and resveratrol. Also disclosed is... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20100210719 - O-desmethylvenlafaxine: Processes for preparing desvenlafaxine and stable amorphous O-desmethylvenlafaxine succinate solid dispersions with one or more pharmaceutically acceptable carriers.... Agent: Dr. Reddy''s Laboratories, Inc.

20100210720 - Preservative-free prostaglandin-based ophthalmic solution: The present invention provides an ophthalmic solution without an antimicrobial preservative. The solution includes as an active substance at least one prostaglandin and as a solubilizing agent, a surfactant, where the solubilizing agent is polyoxyl-15-hydroxystearate.... Agent: Darby & Darby P.C.

20100210721 - Polyenylcyclopropanecarboxylic esters with high insecticidal activity: Described are new insecticide compounds that are derived from 2,2-dimethyl-3-(2-methylpropenyl)cyclopropanecarboxylic acid, also known as chrysanthemic acid, insecticidal compositions that contain the compounds, methods of synthesizing the compounds and methods of eliminating harmful insects from a substrate including bringing the substrate into contact with an effective amount of one or more... Agent: Knobbe Martens Olson & Bear LLP

20100210722 - Composition for preventing or treating lipid metabolic disorders comprising fucoxanthin or marine plant extract containing same: The present invention relates to a composition for the prevention or treatment lipid metabolic disorders comprising fucoxanthin or marine plant extract comtaining the same as an effective indredients. Fucoxanthin or a marine plant extract comprising the same is effective in reducing weight increase and reducing triglyceride and cholesterol level in... Agent: Edwards Angell Palmer & Dodge LLP

20100210723 - Lipase inhibitor: An object of the present invention is to provide a fat-soluble lipase inhibitor which can contribute to prevention or treatment of obesity due to excessive fat intake or diseases caused by obesity, can be added to fats and oils of all types, and can mildly inhibit hydrolysis by lipase. The... Agent: Wenderoth, Lind & Ponack, L.L.P.

20100210725 - Copolymer-grafted polyolefin substrate having antimicrobial properties and method for grafting: (ii) from 20 to 50% by volume, related to the total volume of the reaction medium, of an antimicrobial agent having an average molecular weight of at least 200 g·mol−1, to thereby form a copolymer-grafted polyolefin substrate. Copolymer-grafted polyolefin substrates obtained by this method and a packaging material including copolymer-grafted... Agent: Young & Thompson

20100210724 - Method for modifying the properties of an aqueous suspension: A method for modifying the properties of a suspension of solid or liquid particles in an aqueous medium, includes the step of adding to the suspension or to the aqueous medium a polymer prepared by inverse emulsion polymerization of monomers Ab, comprising a betaine group, and of nonionic monomers Ba... Agent: Rhodia, Inc.

20100210726 - Composition for promoting ketone body production: Provided is a composition for promoting ketone body production that comprises a water insoluble polymer of a β-hydroxy short-medium chain fatty acid such as homopolymer of β-hydroxybutyric acid or a copolymer of β-hydroxybutyric acid and β-hydroxyvaleric acid. The composition is useful for the treatment or prevention of a disease or... Agent: Wenderoth, Lind & Ponack, L.L.P.

20100210727 - Hepoxilin analog enantiomers: The present invention relates to enantiomeric forms of hepoxilin analogs of Formula I-VIII, pharmaceutical compositions thereof, a method for the separation of said enantiomeric forms of hepoxilin analogs comprising applying said hepoxilin to a chiral phase HPLC column and eluting said hepoxilin with an alkane and alcohol solvent mixture. Said... Agent: M. Carmen & Associates, PLLC

20100210728 - Composition for treating a dermal anomaly: An improved composition for treatment of ulcer-type skin conditions. The composition is primarily characterized by a combination of nitroglycerin and arginine. Other embodiments comprise emollient cream, mineral oil, tumeric powder, folic acid, vitamin B12, and zinc citrate. The composition is particularly effective in improving blood flow in the underlying capillary... Agent: Patton Boggs LLP

20100210729 - Methods of inducing terminal differentiation: The present invention provides methods of selectively inducing terminal differentiation, cell growth arrest and/or apoptosis of neoplastic cells, and/or inhibiting histone deacetylase (HDAC) by administration of pharmaceutical compositions comprising potent HDAC inhibitors. The oral bioavailability of the active compounds in the pharmaceutical compositions of the present invention is surprisingly high.... Agent: Mintz Levin Cohn Ferris Glovsky & Popeo

20100210730 - N-halogenated amino acid formulations with anti-inflammatory compounds: The present invention relates to a formulation having antimicrobial activity comprising a N-halogenated amino acid and a anti-inflammatory compound. This specification also describes methods for treating a tissue infection comprising contacting the infected tissue with a pharmaceutically effective amount of a formulation comprising a N-halogenated amino acid and a anti-inflammatory... Agent: Alcon

20100210731 - Modafinil compositions: Polymorphs and solvates of racemic, enantiomerically pure, and enantiomerically mixed modafinil are formed and discussed. In addition, said forms are described as useful for the treatment of many conditions including, but not limited to, narcolepsy.... Agent: Ross J. Oehler Cephalon, Inc.

20100210732 - Methods of preventing the serotonin syndrome and compositions for use therefor: The present invention is directed to pharmaceutical compositions and the use thereof for preventing or minimizing the intensity of the serotonin syndrome. The present invention is directed at a method of preventing or minimizing the intensity of the serotonin syndrome in humans which comprises administering proserotonergic agents and serotonin surge... Agent: Najib Babul

20100210733 - Composition for prevention or treatment of bone metabolism disorder comprising d-pinitol as an active ingredient: The present invention provides a composition for inhibiting osteoclastogenesis and a pharmaceutical composition for preventing or treating a bone metabolism disorder, which comprise D-pinitol as an active ingredient. The present compositions have an inhibitory activity on the differentiation of osteoclast and are useful in the prevention or treatment of a... Agent: Clark & Elbing LLP

20100210734 - Method of using calcitriol for treating intraocular diseases associated with angiogenesis: The present invention provides a method of treating pathologies resulting from neovascular growth in the eye such as those manifested as retinopathy of prematurity, diabetic retinopathy and macular degeneration. The invention comprises the administration of an effective amount of calcitriol that is administered at doses less than toxicity and results... Agent: Kening Li Pinsent Masons LLP

20100210735 - Modulating the activity of nuclear receptors in order to treat hypoxia-related disorders: The subject invention provides methods for treating hypoxia-related conditions by modulating the activity of certain nuclear receptors. Specifically exemplified herein are materials and methods for treating cancer and other pathological conditions involving hypoxia and/or abnormal or excessive neovascularization.... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20100210736 - Method for stabilizing calcium phosphates fine particles, method for manufacturing calcium phosphates fine particles by using the method, and use thereof: It is possible to stabilize the fine particles of calcium phosphates by stopping the growth of the fine particles formed in an aqueous solution supersaturated with respect to calcium phosphates. More specifically, the fine particles of calcium phosphates were stabilized by lowering the inorganic ion concentration of a fine-particle-forming solution... Agent: Nixon & Vanderhye, PC

20100210737 - Synthetically derived illuminating and heating paraffin oil: The invention provides synthetically derived distillate kerosene produced by catalytic conversion of Fisher-Tropsch derived light olefins to distillates (COD) and hydrotreating thereof. The kerosene boils in the range of about 170 to 250° C. and includes less than 10% n-paraffins, more than 75% iso-paraffins and less than 1% aromatics.... Agent: Knobbe Martens Olson & Bear LLP

20100210738 - Prognostic biomarkers to predict overall survival and metastatic disease in patients with triple negative breast cancer: The present invention relates to a method for prognosing cancer in a subject with triple negative (TN) breast cancer, whose tumors lack expression of the estrogen receptor (ER), the progesterone receptor (PR) and normal (not amplified) levels of the human epidermal growth factor receptor 2 (HER2). Methods and biomarkers are... Agent: Benoit & Cote, S.e.n.c.

  
08/12/2010 > patent applications in patent subcategories. inventions list

20100204086 - Bone morphogenic proteins (bmp), bmp receptors and bmp binding proteins and their use in the diagnosis and treatment of glaucoma: The present invention provides methods and kits for diagnosing and treating glaucoma.... Agent: Alcon

20100204085 - Structure-based design of peptide inhibitors of amyloid fibrillation: The invention provides methods for designing peptides that inhibit aggregation in target polypeptides. The candidate inhibitory peptidic compounds have an oligomeric sequence that forms energetically-favorable interactions with the amino acid sequence of the steric zipper region of the target protein, and also possess a zipper-disrupting feature that disrupt the peptide... Agent: Venable LLP

20100204087 - Tribonectins: The invention features a tribonectin and a method of tribosupplementation carried out by administering tribonectins directly to an injured or arthritic joint.... Agent: Clark & Elbing LLP

20100204088 - Cyclic peptide antitumor agents: Cyclic peptide compounds and derivatives thereof having antitumor activity as shown by treatment of human melanoma, pancreatic, breast, prostate cancer cells.... Agent: Reinhart Boerner Van Deuren S.c. Attn: Linda Kasulke, Docket Coordinator

20100204089 - Phosphorylated pyrone analogs and methods: The invention relates to phosphorylated polyphenols, phosphorylated flavonoids, and phosphorylated pyrone analogs. Methods and compositions for the modulation of side effects of substances using such phosphorylated compounds are described. Methods and compositions are described for the modulation of blood-tissue barrier (BTB) transporter activity to increase the efflux of drugs and... Agent: Wilson, Sonsini, Goodrich & Rosati

20100204090 - Use of a peptide as a therapeutic agent: The present invention is directed to the use of the peptide compound Cyclo(-Gly-Ile-Cys-Arg-Cys-Ile-Cys-Gly-Arg-Gly-Ile-Cys-Arg-Cys-Ile-Cys-Gly-Arg) as a therapeutic agent for the prophylaxis and/or treatment of cancer, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurodegenerative diseases, infectious diseases, lung diseases, heart and vascular diseases and metabolic diseases. Moreover the present invention relates to pharmaceutical... Agent: Winstead PC

20100204119 - 4-amino-5-oxo-7,8-dihydropyrimido[5,4-f][1,4]oxazepin-6(5h)-yl phenyl derivatives: e

20100204092 - Activin-actrii antagonists and uses for increasing red blood cell levels: In certain aspects, the present invention provides compositions and methods for increasing red blood cell and/or hemoglobin levels in vertebrates, including rodents and primates, and particularly in humans.... Agent: Ropes & Gray LLP

20100204111 - Astressin and beta- endorphin for use as therapeutic agents: The present invention is directed to the use of the peptide compound D-Phe-His-Leu-Leu-Arg-Glu-Val-Leu-Glu-Nle-Ala-Arg-Ala-Glu-Gln-Leu-Ala-Gln-cycloC-Glu-Ala-His-Lys)-Asn-Arg-Lys-Leu-Nle-Glu-Ile-Ile-NH2 as a therapeutic agent for the prophylaxis and/or treatment of cancer, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurodegenerative diseases, infectious diseases, lung diseases, heart and vascular diseases and metabolic diseases. Moreover the present invention relates to pharmaceutical... Agent: Winstead PC

20100204100 - Biological agents active in central nervous system: Cell-permeant fusion peptides Tat-PDZ can dose-dependently reduce the threshold for anesthesia. PDZ domain-mediated protein interactions at synapses in the central nervous system play an important role in the molecular mechanisms of anesthesia. Moreover, Tat-PDZ cell-permeant fusion peptides are delivered intracellularly into neurons in the central nervous system subsequent to intraperitoneally... Agent: Banner & Witcoff, Ltd.

20100204117 - Cgrp as a therapeutic agent: The present invention is directed to the use of the peptide compound Ala-Cys-Asn-Thr-Ala-Thr-Cys-Val-Thr-His-Arg-Leu-Ala-Gly-Leu-Leu-Ser-Arg-Ser-Gly-Gly-Met-Val-Lys-Ser-Asn-Phe-Val-Pro-Thr-Asn-Val-Gly-Ser-Lys-Ala-Phe-NH2 as a therapeutic agent for the prophylaxis and/or treatment of cancer, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurodegenerative diseases, infectious diseases, lung diseases, heart and vascular diseases and metabolic diseases. Moreover the present invention relates to pharmaceutical... Agent: Winstead PC

20100204124 - Compositions and methods for minimally-invasive systemic delivery of proteins including tgf-beta superfamily members: The present invention is directed to methods and compositions for systemic delivery of minimally-soluble bioactive agents such as, but not limited to, proteins of the TGF-β superfamily. According to the invention, an exemplary bioactive agent is BMP-7 The invention further provides for minimally-invasive systemic treatment of skeletal disorders such as... Agent: K&l Gates LLP

20100204121 - Dietary supplements containing terpenoid acids of maslinic acid or oleanolic acid and process for enhancing muscle mass in mammals: A process for increasing lean body mass in a mammalian subject is provided that includes administering to the subject a purified quantity of maslinic acid, oleanolic acid, or a combination thereof. The administration can be orally and benefits from ingestion of an amino acid source such as dietary protein, oligopeptides,... Agent: Gifford, Krass, Sprinkle,anderson & Citkowski, P.c

20100204094 - Diuretic and natriuretic polypeptides: This document provides diuretic and natriuretic polypeptides. For example, this document provides polypeptides having diuretic and/or natriuretic activities. In some cases, a polypeptide provided herein can have diuretic and natriuretic activities, while lacking the ability to lower blood pressure. This document also provides methods and materials for inducing diuretic and/or... Agent: Fish & Richardson P.C.

20100204104 - Fusion proteins containing two tgf-beta binding domains of tgf-beta type ii receptor: The disclosure provides fusion proteins that contain two TGF-β binding domains of TGF-β type II receptor joined to each other by a linker. For example, the C terminus of the first TGF-β binding domain is joined by a short peptide linker (e.g., a 9-glycine linker) to the N terminus of... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20100204125 - Genetic alterations associated with cancer: The present invention provides new probes for the detection of chromosomal alterations associated with cancer, particularly ovarian cancer. The probes bind selectively with target nucleic acid sequences at 3q26.... Agent: Townsend And Townsend And Crew, LLP

20100204095 - Genetically modified tfpi and method of making the same: The present invention provides long half life genetically modified TFPI sequences (LTFPI) for anticoagulation. On the genetically modified TFPI sequence, the lysine at the carboxy-terminal sites 241, 254, 260 and 261 are replaced by alanin and the amino acid asparagine at glycosylation sites 117, 167, 228 and the amino acids... Agent: Yuan Qing Jiang

20100204105 - Glucagon analogues: The invention provides materials and methods for promoting weight loss or preventing weight gain in a subject. In particular, the invention provides novel glucagon analogue peptides effective in such methods and in the treatment of obesity, eating disorders, metabolic syndrome, and non-alcoholic liver steatosis. The peptides may mediate their effect... Agent: Clark & Elbing LLP

20100204103 - Helical synthetic peptides that stimulate cellular cholesterol efflux: The present invention provides peptides comprising at least one amphipathic alpha helix and having a cholesterol mediating activity and an ABCA stabilization activity. The invention further provides methods of using such peptides.... Agent: Townsend And Townsend And Crew, LLP

20100204102 - Hybrid gel comprising chemically crosslinked hyaluronic acid derivative and pharmaceutical composition comprising the same: The present invention provides a composition comprising a hyaluronic acid derivative having a crosslinking group(s) and a hydrophilic polysaccharide derivative having a hydrophobic group(s), wherein the hyaluronic acid derivative having a crosslinking group(s) is prepared by crosslinkage formation reaction in hyaluronic acid or a derivative thereof having a crosslinkable group(s)... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20100204101 - Method and product for treatment and/or prevention of complications of prematurity: The present invention relates to a composition comprising Insulin Growth Factor I (IGF-I) or an analog thereof in combination with Insulin Growth Factor Binding Protein (IGFBP) or an analog thereof, said combination having a molar ratio of IGF-I to IGFBP being lower than equimolar, preferably in the range from 1:20... Agent: Fish & Richardson P.C.

20100204098 - Peptides with antifungal activity: The present invention relates to antifungal and/or antibacterial peptides, especially antifungal peptides obtained from insect species, particularly lepidopterans. The present invention also provides methods of using these antifungal peptides to treat or prevent fungal growth for a variety of purposes such as; protecting plants from fungal infections, treating fungal infections... Agent: Cooper & Dunham, LLP

20100204123 - Peripheral administration of proteins including tgf-beta superfamily members for treatment of systemic disorders and disease: The present invention is directed to methods and compositions for accomplishing systemic delivery of minimally-soluble bioactive agents such as, but not limited to, proteins of the TGF-β superfamily via a peripheral mode of administration. According to the invention, an exemplary bioactive agent is BMP-7. The invention further provides for minimally-invasive... Agent: K&l Gates LLP

20100204091 - Siva ubiquitination and/or degradation-related activity and modulators thereof: The present invention relates to the ubiquitination and/or degradation-related activity of a SIVA polypeptide and to agents capable of modulating said activity.... Agent: David S. Resnick

20100204097 - Therapeutic methods using a thymus peptide: A method for treating or preventing a disease involving a cell having a T1/ST2 receptor, including administering to subject in need thereof a therapeutically effective amount of a thymic peptide, is provided. Also provided is a method for inhibiting the pathological effects of activated monocytes in a subject in need... Agent: The Nath Law Group

20100204126 - Therapy for melanin related afflictions: Methods for treating melanin related afflictions by local administration of a Clostridial toxin, such as a botulinum toxin, to a patient with a melanin related affliction.... Agent: Allergan, Inc.

20100204096 - Treatment of inflammation, demyelination and neuronal/axonal loss: The invention relates to compositions and methods for treating or preventing inflammation in a mammal comprising mucosal administration of an effective amount of an E-selectin polypeptide. Such compositions and methods are useful for treating or preventing a variety of conditions and diseases, including, for example, stroke, vascular dementia and autoimmune... Agent: Klarquist Sparkman, LLP (ott-nih)

20100204122 - Treatment of osteoporosis in peri- and post- menopausal women with hepcidin: The present invention is directed to a method of treating, preventing, or reducing the risk of bone deterioration or osteoporosis in a peri- or post-menopausal female subject. The method involves selecting a peri- or post-menopausal female subject in need of treating, preventing, or reducing the risk of bone deterioration or... Agent: Nixon Peabody LLP - Patent Group

20100204099 - Treatment of type 2 diabetes, metabolic syndrome, myocardial injury and neurodegeneration with humanin and analogs thereof: Provided are methods of using humanin and humanin analogs to treat a mammal exhibiting or at risk for insulin resistance, increase insulin sensitivity in a mammal exhibiting or at risk for insulin resistance, treat type-2 diabetes mellitus, metabolic syndrome, and neurodegeneration, treat and prevent myocardial injury, and determine longevity.... Agent: Amster, Rothstein & Ebenstein LLP

20100204120 - Trimeric hiv fusion inhibitors for treating or preventing hiv infection: Disclosed herein are trimeric polypeptide pharmaceutical compositions comprising three monomers, each monomer comprising a polypeptide having the amino acid sequence of the N-terminal heptad repeat (NHR or HR1) or C-terminal heptad repeat (CHR or HR2) of the transmembrane glycoprotein of human immunodeficiency virus (HIV) and a trimerization motif.... Agent: K&l Gates LLP

20100204127 - Use of a botulinum neurotoxin to alleviate various disorders: Methods for treating obsessions and compulsions by local administration of a Clostridial toxin. The obsessions or compulsions can be eye poking, body rocking, finger biting, counting, checking and related disorders treated by low dose, intramuscular administration of a botulinum toxin.... Agent: Allergan, Inc.

20100204114 - Use of a galanin peptide as a therapeutic agent: The present invention is directed to the use of the peptide compound Gly-Trp-Thr-Leu-Asn-Ser-Ala-Gly-Tyr-Leu-Leu-Gly-Pro-His-Ala-Val-Gly-Asn-His-Arg-Ser-Phe-Ser-Asp-Lys-Asn-Gly-Leu-Thr-Ser-OH as a therapeutic agent for the prophylaxis and/or treatment of cancer, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurodegenerative diseases, infectious diseases, lung diseases, heart and vascular diseases and metabolic diseases. Moreover the present invention relates to pharmaceutical... Agent: Winstead PC

20100204110 - Use of a peptide as a therapeutic agent: The present invention is directed to the use of the peptide compound Pyr-Pro-Leu-Pro-Asp-Cys-Cys-Arg-Gln-Lys-Thr-Cys-Ser-Cys-Arg-Leu-Tyr-Glu-Leu-Leu-His-Gly-Ala-Gly-Asn-His-Ala-Ala-Gly-lle-Leu-Thr-Leu-NH2 as a therapeutic agent for the prophylaxis and/or treatment of cancer, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurodegenerative diseases, infectious diseases, lung diseases, heart and vascular diseases and metabolic diseases. Moreover the present invention relates to pharmaceutical... Agent: Winstead PC

20100204115 - Use of acetyl- (ala10, 11)-rantes (1-14) and/or calcitonin as anti-angiogenic agents: The present invention is directed to the use of the peptide compound Ac-Ser-Pro-Tyr-Ser-Ser-Asp-Thr-Thr-Pro-Ala-Ala-Phe-Ala-Tyr-NH2 as a therapeutic agent for the prophylaxis and/or treatment of cancer, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurodegenerative diseases, infectious diseases, lung diseases, heart and vascular diseases and metabolic diseases. Moreover the present invention relates to pharmaceutical... Agent: Winstead PC

20100204109 - Use of c-type natriuretic peptide, alone or in combination with neuropeptide af, as a therapeutic agent: The present invention is directed to the use of the peptide compound Asp-Leu-Arg-Val-Asp-Thr-Lys-Ser-Arg-Ala-Ala-Trp-Ala-Arg-Leu-Leu-Gln-Glu- His-Pro-Asn-Ala-Arg-Lys-Tyr-Lys-Gly-Ala-Asn-Lys-Lys-Gly-Leu-Ser-Lys-Gly-Cys-Phe-Gly-Leu-Lys-Leu-Asp-Arg-Ile-Gly-Ser-Met-Ser-Gly-Leu-Gly-Cys-OH as a therapeutic agent for the prophylaxis and/or treatment of cancer, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurodegenerative diseases, infectious diseases, lung diseases, heart and vascular diseases and metabolic diseases. Moreover the present invention relates to... Agent: Winstead PC

20100204116 - Use of calcitonin as anti-angiogenic agent: The present invention is directed to the use of the peptide compound Cys-Gly-Asn-Leu-Ser-Thr-Cys-Met-Leu-Gly-Thr-Tyr-Thr-Gln-Asp-Phe-Asn-Lys-Phe-His-Thr-Phe-Pro-Gln-Thr-Ala-Ile-Gly-Val-Gly-Ala-Pro-Nh2 as a therapeutic agent for the prophylaxis and/or treatment of cancer, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurodegenerative diseases, infectious diseases, lung diseases, heart and vascular diseases and metabolic diseases. Moreover the present invention relates to pharmaceutical... Agent: Winstead PC

20100204106 - Use of gip for the treatment of disorders associated with dysfunctional synaptic transmission: The present invention relates to a peptide comprising at least 12 amino acid residues from the N-terminal end of gastric inhibitory polypeptide, or an analogue thereof, which are useful to prophylactically prevent, improve, or reverse the diminished cognitive function associated with these types of disorders, by increasing (or sustaining) the... Agent: Licata & Tyrrell P.C.

20100204118 - Use of grf-1 (1-29 ) and corticotropin-releasing factor as therapeutic agents: The present invention is directed to the use of the combination of the Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-NH2 and Ser-Glu-Glu-Pro-Pro-Ile-Ser-Leu- Asp-Leu-Thr-Phe-His-Leu-Leu-Arg-Glu-Val-Leu-Glu-Met-Ala-Arg-Ala-Glu-Gln-Leu-Ala-Gln-Gln-Ala-His-Ser-Asn-Arg-Lys-Leu-Met-Glu-Ile-Ile-NH2 as a therapeutic combination for prophylaxis and/or treatment of cancer, a heart and vascular disease, an infectious disease, a fibrotic disease, an inflammatory disease, a neurodegenerative disease, or an autoimmune disease.... Agent: Winstead PC

20100204093 - Use of heat shock activators for tissue regeneration: The present invention generally provides therapeutic compositions and methods for treating a disease, disorder, or injury characterized by a deficiency in cell number. The method involves inducing a heat shock response in tissue or organ effected by disease and recruiting stem cells to repair or regenerate the disease-effected tissue.... Agent: Edwards Angell Palmer & Dodge LLP

20100204108 - Use of neurotrophic factor for retinal cholinergic neurons (nfrcn) and chorionic gonadotropin-beta (109-145) as therapeutic agents: The present invention is directed to the use of the peptide compound Tyr-Leu-Leu-Pro-Ala-Gln-Val-Asn-Ile-Asp-OH as a therapeutic agent for the prophylaxis and/or treatment of cancer, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurodegenerative diseases, infectious diseases, lung diseases, heart and vascular diseases and metabolic diseases. Moreover the present invention relates to pharmaceutical... Agent: Winstead PC

20100204113 - Use of stresscopin-related peptide as a therapeutic agent: The present invention is directed to the use of the peptide compound His-Pro-Gly-Ser-Arg-Ile-Val-Leu-Ser-Leu-Asp-Val-Pro-Ile-Gly-Leu-Leu-Gln-Ile-Leu-Leu-Glu-Gln-Ala-Arg-Ala-Arg-Ala-Ala-Arg-Glu-Gln-Ala-Thr-Thr-Asn-Ala-Arg-Ile-Lu-Ala-Arg-Val-NH2 as a therapeutic agent for the prophylaxis and/or treatment of cancer, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurodegenerative diseases, infectious diseases, lung diseases, heart and vascular diseases and metabolic diseases. Moreover the present invention relates to pharmaceutical... Agent: Winstead PC

20100204112 - Use of tyr-w-mif-1 and urocortin 2 as therapeutic agents: The present invention is directed to the use of the peptide compound Tyr-Pro-Trp-Gly-NH2 as a therapeutic agent for the prophylaxis and/or treatment of cancer, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurodegenerative diseases, infectious diseases, lung diseases, heart and vascular diseases and metabolic diseases. Moreover the present invention relates to pharmaceutical... Agent: Winstead PC

20100204107 - Use of urodilatin as a therapeutic agent: The present invention is directed to the use of the peptide compound Thr-Ala-Pro-Arg-Ser-Leu-Arg-Arg-Ser-Ser-Cys-Phe-Gly-Gly-Arg-Met-Asp-Arg-Ile-Gly-Ala-Gln-Ser-Gly-Leu-Gly-Cys-Asn-Ser-Phe-Arg-Tyr-OH as a therapeutic agent for the prophylaxis and/or treatment of cancer, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurodegenerative diseases, infectious diseases, lung diseases, heart and vascular diseases and metabolic diseases. Moreover the present invention relates to pharmaceutical... Agent: Winstead PC

20100204128 - Novel peptides: The present invention relates to novel peptides and mixtures thereof which have been shown anti-tumor activity. Further, the invention relates to methods for identifying such compounds as well as to methods for their production. DNA encoding said peptides, vectors, host organisms, pharmaceutical preparations and antibodies that specifically bind with said... Agent: Volpe And Koenig, P.C.

20100204132 - Therapeutic uses of peptides ysaypdsvpmms and wmnstgftkvcgappc: The present invention is directed to the use of the peptide compound Tyr-Ser-Ala-Tyr-Pro-Asp-Ser-Val-Pro-Met-Met-Ser-OH as a therapeutic agent for the prophylaxis and/or treatment of cancer, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurodegenerative diseases, infectious diseases, lung diseases, heart and vascular diseases and metabolic diseases. Moreover the present invention relates to pharmaceutical... Agent: Winstead PC

20100204129 - Use of a peptide as a therapeutic agent: e

20100204131 - Use of a peptide as a therapeutic agent: The present invention is directed to the use of the peptide compound Ser-Tyr-Ser-Met-Glu-His-Phe-Arg-Trp-Gly-Lys-Pro-Val-Gly-Lys-Lys-Arg-Arg-Pro-Val-Lys-Val-Tyr-Pro-OH as a therapeutic agent for the prophylaxis and/or treatment of cancer, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurodegenerative diseases, infectious diseases, lung diseases, heart and vascular diseases and metabolic diseases. Moreover the present invention relates to pharmaceutical... Agent: Winstead PC

20100204130 - Use of human neuropeptide as a therapeutic agent: The present invention is directed to the use of the peptide compound Ala-Gly-Glu-Gly-Leu-Asn-Ser-Gln-Phe-Trp-Ser-Leu-Ala-Ala-Pro-Gln-Arg-Phe-NH2 as a therapeutic agent for the prophylaxis and/or treatment of cancer, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurodegenerative diseases, infectious diseases, lung diseases, heart and vascular diseases and metabolic diseases. Moreover the present invention relates to pharmaceutical... Agent: Winstead PC

20100204133 - Irreversibly-inactivated pepsinogen fragment and pharmaceutical compositions comprising the same for detecting, preventing and treating hiv: An isolated antiviral peptide is characterized by the amino acid sequence GDEPLENYLDTEYF and a significant in vitro binding affinity for HIV-1 gp 120 and gp 41 and human CD4 cells. The peptide exhibits anti-retroviral activity in vivo, particularly anti-HIV-1 activity.... Agent: Cislo & Thomas LLP

20100204137 - The use of substances for the treatment of loss of eyesight in humans with glaucoma and other degenerative eye diseases: Methods for the prevention and treatment of ocular disorders, in particular glaucoma, through blocking the toxic effects of β-amyloid (Aβ) derivatives, and pharmaceutical compositions for effecting such prevention and treatment thereof.... Agent: The Firm Of Hueschen And Sage

20100204136 - Use of a peptide as a therapeutic agent: The present invention is directed to the use of the peptide compound Ac-Ser-Tyr-Ser-Met-Glu-His-Phe-Arg-Trp-Gly-Lys-Pro-Val-NH2 as a therapeutic agent for the prophylaxis and/or treatment of cancer, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurodegenerative diseases, infectious diseases, lung diseases, heart and vascular diseases and metabolic diseases. Moreover the present invention relates to pharmaceutical... Agent: Winstead PC

20100204135 - Use of lvv-hemorphin-6 and optionally af12198 as therapeutic agent(s): The present invention is directed to the use of the peptide compound Leu-Val-Val-Tyr-Pro-Trp-Thr-Gln-Arg-OH as a therapeutic agent for the prophylaxis and/or treatment of cancer, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurodegenerative diseases, infectious diseases, lung diseases, heart and vascular diseases and metabolic diseases. Moreover the present invention relates to pharmaceutical... Agent: Winstead PC

20100204134 - Use of the peptide his-ser-leu-gly-lys-trp-leu-gly-his-pro-asp-lys-phe alone or in combination with the peptide gly-ard-gly-asp-asn-pro-oh as a therapeutic agent: The present invention is directed to the use of the peptide compound His-Ser-Leu-Gly-Lys-Trp-Leu-Gly-His-Pro-Asp-Lys-Phe as a therapeutic agent for the prophylaxis and/or treatment of cancer, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurodegenerative diseases, infectious diseases, lung diseases, heart and vascular diseases and metabolic diseases. Moreover the present invention relates to pharmaceutical... Agent: Winstead PC

20100204143 - Gamma 1 msh alone or in combination with pentagastrin as a therapeutic agent: The present invention is directed to the use of the peptide compound Tyr-Val-Met-Gly-His-Phe-Arg-Trp-Asp-Arg-Phe-NH2 as a therapeutic agent for the prophylaxis and/or treatment of cancer, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurodegenerative diseases, infectious diseases, lung diseases, heart and vascular diseases and metabolic diseases. Moreover the present invention relates to pharmaceutical... Agent: Winstead PC

20100204146 - Treatment of oestrogen dependant conditions in pre-menopausal women: The present invention relates to a method for treating and/or preventing ovarian cycle disturbance, prolonged un-opposed secretion of estrogens, and/or ovarian follicular cyst formation in pre-menopausal women with functional ovaries when treated with steroid sulfatase inhibitors (STS-I) for an estrogen-dependant condition.... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20100204140 - Use of a peptide as a therapeutic agent: The present invention is directed to the use of the peptide compound Asp-Met-His-Asp-Phe-Phe-Val-Gly-Leu-Met-NH2 as a therapeutic agent for the prophylaxis and/or treatment of cancer, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurodegenerative diseases, infectious diseases, lung diseases, heart and vascular diseases and metabolic diseases. Moreover the present invention relates to pharmaceutical... Agent: Winstead PC

20100204145 - Use of a peptide as a therapeutic agent: The present invention is directed to the use of the peptide compound Pyr-His-Trp-Ser-Tyr-D-Ser(tBu)-Leu-Arg-Pro-NHEt as a therapeutic agent for the prophylaxis and/or treatment of cancer, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurodegenerative diseases, infectious diseases, lung diseases, heart and vascular diseases and metabolic diseases. Moreover the present invention relates to pharmaceutical... Agent: Winstead PC

20100204141 - Use of bpp-b as a therapeutic agent: The present invention is directed to the use of the peptide compound Pyr-Gly-Leu-Pro-Pro-Arg-Pro-Lys-Ile-Pro-Pro-OH as a therapeutic agent for the prophylaxis and/or treatment of cancer, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurodegenerative diseases, infectious diseases, lung diseases, heart and vascular diseases and metabolic diseases. Moreover the present invention relates to pharmaceutical... Agent: Winstead PC

20100204139 - Use of gonadorelin as a therapeutic agent: The present invention is directed to the use of the peptide compound Pyr-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH2 as a therapeutic agent for the prophylaxis and/or treatment of cancer, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurodegenerative diseases, infectious diseases, lung diseases, heart and vascular diseases and metabolic diseases. Moreover the present invention relates to pharmaceutical... Agent: Winstead PC

20100204142 - Use of the peptide phpfhlfvy (renin inhibitor) as a therapeutic agent: The present invention is directed to the use of the peptide compound Pro-His-Pro-Phe-His-Leu-Phe-Val-Tyr-OH as a therapeutic agent for the prophylaxis and/or treatment of cancer, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurodegenerative diseases, infectious diseases, lung diseases, heart and vascular diseases and metabolic diseases. Moreover the present invention relates to pharmaceutical... Agent: Winstead PC

20100204144 - Use of the peptides maippkknqdk (cow kappa casein 106-116) and/or ygfqna (serorphin) as therapeutic agents: The present invention is directed to the use of the peptide compound Met-Ala-Ile-Pro-Pro-Lys-Lys-Asn-Gln-Asp-Lys-OH as a therapeutic agent for the prophylaxis and/or treatment of cancer, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurodegenerative diseases, infectious diseases, lung diseases, heart and vascular diseases and metabolic diseases. Moreover the present invention relates to pharmaceutical... Agent: Winstead PC

20100204138 - Use of trp6-triptorelin and d-leu6-leuprolide as therapeutic agents: The present invention is directed to the use of the peptide compound Pyr-His-Trp-Ser-Tyr-Trp-Leu-Arg-Pro-Gly-NH2 as a therapeutic agent for the prophylaxis and/or treatment of cancer, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurodegenerative diseases, infectious diseases, lung diseases, heart and vascular diseases and metabolic diseases. Moreover the present invention relates to pharmaceutical... Agent: Winstead PC

20100204148 - (d-leu7 ) -histrelin as a therapeutic agent: The present invention is directed to the use of the peptide compound Pyr-His-Trp-Ser-Tyr-D-His(Bzl)-D-Leu-Arg-Pro-NHEt as a therapeutic agent for the prophylaxis and/or treatment of cancer, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurodegenerative diseases, infectious diseases, lung diseases, heart and vascular diseases and metabolic diseases. Moreover the present invention relates to pharmaceutical... Agent: Winstead PC

20100204147 - Methods for delivering thymosin beta 4, analogues, isoforms and other derivatives: A composition and method utilizes a substantially purified composition including an adhesive and a polypeptide containing amino acid sequence LKKTET or a conservative variant thereof.... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20100204150 - Use of a peptide as a therapeutic agent: The present invention is directed to the use of the peptide compound His-Pro-Phe-His-Leu-D-Leu-Val-Tyr-OH as a therapeutic agent for the prophylaxis and/or treatment of cancer, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurodegenerative diseases, infectious diseases, lung diseases, heart and vascular diseases and metabolic diseases. Moreover the present invention relates to pharmaceutical... Agent: Winstead PC

20100204151 - Use of a peptide as a therapeutic agent: The present invention is directed to the use of the peptide compound Ac-His-Trp-Ala-VaI-GIy-HiS-LeU-NH2 as a therapeutic agent for the prophylaxis and/or treatment of cancer, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurodegenerative diseases, infectious diseases, lung diseases, heart and vascular diseases and metabolic diseases. Moreover the present invention relates to pharmaceutical... Agent: Winstead PC

20100204152 - Use of gluten exorphin c : as a therapeutic agent: The present invention is directed to the use of the peptide compound Ala-Val-Pro-Tyr-Pro-Gln-Arg-OH as a therapeutic agent for the prophylaxis and/or treatment of cancer, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurodegenerative diseases, infectious diseases, lung diseases, heart and vascular diseases and metabolic diseases. Moreover the present invention relates to pharmaceutical... Agent: Winstead PC

20100204149 - Use of octreotide as a therapeutic agent: The present invention is directed to the use of the peptide compound H-D-Phe-Cys-Phe-D-Trp-Lys-Thr-Cys-L-threoninol as a therapeutic agent for the prophylaxis and/or treatment of cancer, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurodegenerative diseases, infectious diseases, lung diseases, heart and vascular diseases and metabolic diseases. Moreover the present invention relates to pharmaceutical... Agent: Winstead PC

20100204158 - Combination of splenopentin and thymopentin and the use thereof in medicine: The present invention is directed to the use of the combination of the peptide compounds Arg-Lys-Glu-Val-Tyr-OH and Arg-Lys-Asp-Val-Tyr-OH as a therapeutic combination for prophylaxis and/or treatment of cancer, a heart and vascular disease, an infectious disease, a fibrotic disease, an inflammatory disease, a neurodegenerative disease, or an autoimmune disease.... Agent: Winstead PC

20100204157 - Use of a peptide as a therapeutic agent: The present invention is directed to the use of the peptide compound Phe-Phe-Val-Ala-Pro as a therapeutic agent for the prophylaxis and/or treatment of cancer, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurodegenerative diseases, infectious diseases, lung diseases, heart and vascular diseases and metabolic diseases. Moreover the present invention relates to pharmaceutical... Agent: Winstead PC

20100204153 - Use of band 3 protein (824-829) and/or melanocyte-stimulating hormone release-inhibiting factor as a therapeutic agent in the treatment of pseudomonas aeruginosa infection: The present invention is directed to the use of the peptide compound Tyr-Val-Lys-Arg-Val-Lys-OH as a therapeutic agent for the prophylaxis and/or treatment of cancer, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurodegenerative diseases, infectious diseases, lung diseases, heart and vascular diseases and metabolic diseases. Moreover the present invention relates to pharmaceutical... Agent: Winstead PC

20100204154 - Use of the peptide rfmwmr as a therapeutic agent: The present invention is directed to the use of the peptide compound Ac-Arg-Phe-Met-Trp-Met-Arg-NH2 as a therapeutic agent for the prophylaxis and/or treatment of cancer, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurodegenerative diseases, infectious diseases, lung diseases, heart and vascular diseases and metabolic diseases. Moreover the present invention relates to pharmaceutical... Agent: Winstead PC

20100204155 - Use of the peptide sfllr-oh and muramyl dipeptide as therapeutic agents: The present invention is directed to the use of the peptide compound Ser-Phe-Leu-Leu-Arg-OH as a therapeutic agent for the prophylaxis and/or treatment of cancer, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurodegenerative diseases, infectious diseases, lung diseases, heart and vascular diseases and metabolic diseases. Moreover the present invention relates to pharmaceutical... Agent: Winstead PC

20100204156 - Use of thymopentin as a therapeutic agent: The present invention is directed to the use of the peptide compound Arg-Lys-Asp-Val-Tyr-OH as a therapeutic agent for the prophylaxis and/or treatment of cancer, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurodegenerative diseases, infectious diseases, lung diseases, heart and vascular diseases and metabolic diseases. Moreover the present invention relates to pharmaceutical... Agent: Winstead PC

20100204159 - Organic compounds and their uses: The present application describes organic compounds that are useful for the treatment, prevention and/or amelioration of human diseases.... Agent: Novartis Institutes For Biomedical Research, Inc.

20100204160 - Substituted 1,2-ethylenediamines, methods for preparing them and uses thereof: e

20100204161 - Substances and pharmaceutical compositions for the inhibition of glyoxalases and their use against bacteria: The present invention pertains to substances of the formula (I) wherein X is O or S; and R1-R4 are defined in the claims as inhibitors of glyoxalase I and/or II, pharmaceutical compositions comprising one or more compounds according to formula (I) and the use of one or more compounds according... Agent: Gudrun E. Huckett Draudt

20100204162 - Substrate reduction therapy: The present invention provides a compound which is an inhibitor of sphingolipid biosynthesis for use in the treatment of a disease which has a secondary Niemann-Pick type C disease like cellular phenotype.... Agent: Klarquist Sparkman, LLP

20100204163 - Metabolites and derivatives of ambrisentan: The invention relates to derivatives and metabolites of ambrisentan, including compounds of general Formula (I) or salts, hydrates, solvates, racemates, or optical isomers thereof, wherein R1 is —H or —OCH3; R2 is —H, lower alkyl (e.g. C1-C4 alkyl) or glycosidyl; and R3 and R4 are independently —CH3, —C(O)H or —CH2OR6,... Agent: Harness, Dickey, & Pierce, P.l.c

20100204164 - Pesticidal compositions: The invention disclosed in this document is related to the field of pesticides and their use in controlling pests. A compound having the following structure is disclosed.... Agent: Dow Agrosciences LLC

20100204165 - Pesticidal compositions: The invention disclosed in this document is related to the field of pesticides and their use in controlling pests. A compound having the following structure is disclosed.... Agent: Dow Agrosciences LLC

20100204166 - Polyacetylenic compounds for stimulating insulin gene exression, production and secretion: in which R1 is H, C1-C10 alkyl, C2-C10 alkenyl, C2-C10 alkynyl, C3-C20 cycloalkyl, C3-C20 cycloalkenyl, C1-C20 heterocycloalkyl, C1-C20 heterocycloalkenyl, aryl, or heteroaryl; R2 is H or a monosaccharide residue; R3 is H or C1-C10 alkyl; m is 2, 3, or 4; n is 0, 1, 2, or 3; o is... Agent: Ipc Intellectual Property Connections, Inc.

20100204167 - Active compound combinations having insecticidal and acaricidal properties: The novel active compound combinations comprising a compound of the formula (I-1) or (I-2) and the active compounds (1) to (26) listed in the description have very good insecticidal and acaricidal properties.... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20100204168 - Stable needle-shaped crystals of natamycin: The present invention describes natamycin comprising needle shaped crystals.... Agent: Nixon & Vanderhye, PC

20100204169 - Composition comprising xanthoceras sorbifolia extracts, compounds isolated from same, methods for preparing same and uses thereof: This invention provides compositions, methods and process of producing extracts and pure compounds from Xanthoceras sorbifolia. The extract comprises saponins and other constituents including alkaloids, coumarins, saccharides, proteins, polysaccharides, glycosides, tannins, acid, flavonoids and others. The composition can be used for treating cancer and other conditions, such as arthritis, rheumatism,... Agent: Law Offices Of Albert Wai-kit Chan, PLLC

20100204170 - Heterobifunctional pan-selectin inhibitors: Compounds and methods are provided for modulating in vitro and in vivo processes mediated by selectin binding. More specifically, selectin modulators and their use are described, wherein the selectin modulators that modulate (e.g., inhibit or enhance) a selectin-mediated function comprise particular glycomimetics alone or linked to a member of a... Agent: Seed Intellectual Property Law Group PLLC

20100204171 - Materials and methods for treating diseases caused by genetic disorders using aminoglycosides and derivatives thereof which exhibit low nephrotoxicity: Various aspects related to the preparation of congeners of the aminoglycosides gentamicin such as the congener C2 and using this compound or derivatives thereof and pharmaceutically active salts to treat diseases that involve genetic mutations which introduce a missense or premature stop codon into a gene. Still other aspects include... Agent: Bose Mckinney & Evans LLP

20100204300 - Anti-viral methods and compositions: The instant disclosure relates to methods and compositions for silencing poxvirus gene expression and replication using RNA interference. In certain embodiments, the disclosure relates to methods of treating a subject with a poxvirus infection.... Agent: Mueting, Raasch & Gebhardt, P.A.

20100204299 - C-cbl and antagonists thereof for the treatment and diagnosis of cancer: The present invention relates to the treatment of cancer. More specifically, the present invention relates to the use of c-cbl as a marker for the diagnosis and/or prognosis of cancer, and to the use of a c-cbl antagonist for the treatment of a cancer associated with resistance to apoptosis.... Agent: Michael Best & Friedrich LLP

20100204307 - Compositions and methods for inhibiting expression of the hamp gene: The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of the HAMP gene (HAMP gene), comprising an antisense strand having a nucleotide sequence which is less that 30 nucleotides in length, generally 19-25 nucleotides in length, and which is substantially complementary to at least a part... Agent: Alnylam/fenwick

20100204297 - Influenza therapeutic: The present invention provides compositions comprising an RNAi-inducing entity targeted to an influenza virus transcript and any of a variety of delivery agents. The invention further includes methods of use of the compositions for inhibiting a biological activity of an influenza virus and/or for treatment or prevention of influenza. The... Agent: Choate, Hall & Stewart LLP

20100204306 - Method of treating neurodegenerative disease: Aspects featured in the invention relate to compositions and methods for inhibiting alpha-synuclein (SNCA) gene expression, such as for the treatment of neurodegenerative disorders. An anti-SNCA agent featured herein that targets the SNCA gene can have been modified to alter distribution in favor of neural cells.... Agent: Alnylam/fenwick

20100204304 - Nogo receptor binding protein: The invention provides Sp35 polypeptides and fusion proteins thereof, Sp35 antibodies and antigen-binding fragments thereof and nucleic acids encoding the same. The invention also provides compositions comprising, and methods for making and using, such Sp35 antibodies, antigen-binding fragments thereof, Sp35 polypeptides and fusion proteins thereof.... Agent: Sterne, Kessler, Goldstein & Fox, P.l.l.c.

20100204303 - Pharmaceutical compositions for administering oligonucleotides: The invention relates to pharmaceutical compositions useful for administering an oligonucleotide to an animal in need thereof. The pharmaceutical compositions include nano-particles or micro-particles of (i) a protonated oligonucleotide and (ii) a pharmaceutically acceptable organic base or include nano-particles or micro-particles of (i) an oligonucleotide and (ii) a divalent metal... Agent: Townsend And Townsend And Crew, LLP

20100204301 - Reducible polymers for nonviral gene delivery: Provided herein are biodegradable copolymers and nanoplex delivery systems comprising the same and a cargo molecule, such as a nucleic acid, a polynucleotide or other biomolecule. The biodegradable copolymers may comprise a reducible polymer linearly modified with lysine, such as a linear lysine-modified N,N′-cystamine bisacrylamide. The biodegradable copolymers also may... Agent: Benjamin Aaron Adler Adler & Associates

20100204302 - Sidna against hepatitis c virus (hcv): Silencing of HCV RNA can be achieved by siDNA. These are oligodeoxynucleotides consisting of an antisense strand homologous to the viral RNA and a second strand, partially complementary to the antisense-strand. The two strands are preferentially linked by a linker (eg 4 thymidines). Triple-helix formation is a preferred effect. The... Agent: Joyce Von Natzmer Pequignot + Myers LLC

20100204305 - Small interfering rna molecules against ribonucleotide reductase and uses thereof: Small interfering RNA (siRNA) molecules that target a mammalian ribonucleotide reductase gene, and which are capable of inhibiting the expression of their target gene are provided. The siRNA molecules of the invention are capable of attenuating neoplastic cell growth and/or proliferation in vitro and in vivo and, therefore, can be... Agent: Sheridan Ross PC

20100204298 - Use of antisense oligonucleotides against cpla2 in the treatment of cancer: Inhibitors of cPLA2α expression are used in the preparation of pharmaceutical compositions for the inhibition of cancer cell proliferation and for the treatment of cancer; the inhibitors are selected from cPLA2α-specific ribozymes, RNA sequences usable for RNA-interference of the cPLA2α gene, and antisense oligonucleotides directed against cPLA2α.... Agent: Cooper & Dunham, LLP

20100204308 - Cell proliferation inhibitory proteins and polynucleotides, antisense polynucleotides to the polynucleotides, cell proliferation inhibitors using the foregoing, cancer diagnostic agents, cancer therapeutic agents and compositions for gene therapy: The genes the expression of which is reduced or disappeared in immortal cells including cancer cells are isolated, their DNA sequences are determined, the genes are expressed to produce cell proliferation inhibitory proteins, and the genes and the proteins are utilized as agents for diagnosis or treatment, including the genetic... Agent: Fitch, Even, Tabin & Flannery

20100204310 - New modalities for treatment of drug-resistant tuberculosis and other diseases: The invention provides antibacterial compounds comprising an oligonucleotide having a sequence complementary to a translation initiation region of an mRNA encoding a mycolyl transferase of Mycobacterum tuberculosis selected from protein 30, 32A and 32B, and further having 5′ and 3′ palindromic hairpin-forming sequences, said compound being covalently linked to a... Agent: Preti, Flaherty, Beliveau & Pachios, LLP

20100204311 - Normal-tension glaucoma model and method for evaluation of test substances by using same: It is intended to provide a simple normal-tension glaucoma model capable of spontaneously, age-dependently and surly developing conditions similar to symptoms of normal-tension glaucoma which occurs more frequently in elder people, and a method of evaluating therapeutic effect on normal-tension glaucoma whereby a drug useful in treating and diagnosing can... Agent: Oliff & Berridge, PLC

20100204309 - Oligonucleotide compositions for the treatment of alzheimer's disease: The invention relates to the identification of microRNAs whose expression is diminished in neurodegenerative disorders. In particular, the identified microRNAs can be used for the downregulation of the beta-secretase (BACE1) in mammalian brain and hence for the treatment of Alzheimer's disease.... Agent: Traskbritt, P.C.

20100204172 - Inactivators of o6-alkylguanine-dna alkyltransferase: Disclosed are compounds that are AGT inactivators that include a folate residue, e.g., a compound of formula (I), wherein X1, X2, R1, and R2 are as described herein. Also disclosed is a pharmaceutical composition comprising a compound of the invention and a pharmaceutically acceptable carrier. Also disclosed are methods of... Agent: Leydig, Voit & Mayer, Ltd.

20100204173 - Methods of treating hepatic encephalopathy: The application describes treatment of hepatic encephalopathy using gastrointestinal specific antibiotics. One example of a gastrointestinal specific antibiotic is rifaximin.... Agent: Edwards Angell Palmer & Dodge LLP

20100204174 - Novel active ingredient in cicatrization and use thereof: The present invention relates to the use of a known compound as an agent for promoting and/or accelerating fibroblast proliferation and/or differentiation and, consequently, cicatrization. This compound is a copolymer of a 2-methyl-2-[(1-oxo-2-propenyl)amino]-1-propanesulphonic acid salt and of propenoic acid 2-hydroxyethyl ester. It may be used alone or in combination with... Agent: Hamre, Schumann, Mueller & Larson, P.C.

20100204176 - Advanced glycation end products as active ingredients: Cosmetic composition comprising at least one compound from advanced glycation end products (‘AGEs’) and/or precursors thereof as an agent for skin treatment, especially for protection and/or care of the skin. The present invention further provides a cosmetic composition comprising at least one compound from the group of the AGEs and/or... Agent: Henkel Corporation

20100204175 - Use of conjugates of hyaluronic acid in the local treatment of hyperproliferative skin diseases: The use is described of a conjugate between hyaluronic acid or a derivative thereof and antitumoral drugs for the preparation of pharmaceutical compositions for the topical treatment of hyperproliferative skin diseases.... Agent: Birch Stewart Kolasch & Birch

20100204177 - Process for preparing thermosensitive (poly(ethylene oxide) poly(propylene oxide)) derivates that can be used to functionalize chitosan: The invention relates to a thermosensitive (poly(ethylene oxide) poly(propylene oxide))-acetal derivative, which can be used to functionalize chitosan, and to the process for the preparation thereof. The invention therefore also relates to a process for functionalizing chitosan by grafting this thermosensitive copolymer and optionally another thermosensitive polymer, poly(ethylene oxide). A... Agent: Thorp Reed & Armstrong, LLP

20100204178 - Novel parenteral carbamazepine formulation: The present invention is directed to a carbamazepine-cyclodextrin inclusion complex useful for the parenteral administration of carbamazepine. The carbamazepine-cyclodextrin inclusion complex is prepared by the admixture of a modified cyclodextrin and carbamazepine in a physiologically acceptable fluid. Modified cyclodextrins include 2-hydroxypropyl-beta-cyclodextrin and sulfoalkyl cyclodextrins. More particularly, the sulfoalkyl cyclodextrins are... Agent: Edward P. Gamson Suite 2200

20100204179 - Resveratrol complex and process for the preperation: The present invention provides products having resveratrol with high water solubility and nutraceutical and/or phytotherapic compositions having said substances. The processes for obtaining them include the solubility increase of the polyphenol corresponding to a resveratrol compound, preferably trans-resveratrol in water, by its complexation with cyclodextrin under specific conditions that favor... Agent: Smith, Gambrell & Russell

20100204180 - Proteasome inhibitors: The present invention provides novel compounds useful as proteasome inhibitors. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various diseases.... Agent: Millennium Pharmaceuticals, Inc.

20100204181 - N-halogenated amino acid formulations comprising phosphine or amine oxides: The present invention relates to methods for treating an infected tissue comprising treating the infected tissue with a formulation comprising a N-halogenated amino acid and a phosphine oxide or amine oxide. This specification also discloses methods for improving the antimicrobial activity of a formulation comprising a N-halogenated amino acid, the... Agent: Alcon

20100204182 - Ectonucleotidase inhibitors: The present invention provides ectonucleotidase inhibitors represented by the following formula, including ecto-nucleotide triphosphate diphosphohydrolase (NTPDase) inhibitors and ecto-5′-nucleotidase (ecto-5′-NT) inhibitors, namely nucleotide mimetics as selective NTPDase or ecto-5′-NT inhibitors. It also provides methods for preparations of said compounds. Furthermore provided are pharmaceutical and diagnostic compositions comprising said compounds, and... Agent: Ballard Spahr LLP

20100204183 - Substituted phosphonates and their use in decreasing amyloid aggregates: The invention relates to novel and known substituted phosphonates for use in ameliorating amyloid aggregates, particularly for use in the treatment of Alzheimer's disease.... Agent: Pepper Hamilton LLP

20100204184 - Phosphonates useful as modulators of t-gamma-9-delta-2 activity: The invention concerns novel phosphonate derivatives, preparation method, use thereof as ligands modulating T γ9δ2 lymphocyte activity and pharmaceutical compositions comprising them.... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20100204185 - Phenazopyridine compounds: The present invention is directed to substituted phenazopyridines represented by Formula I. The present invention also relates to the discovery that compounds of Formula I have increased bioavailability as compared to unconjugated phenazopyridine.... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20100204186 - Aromatic a-ring derivatives of tetracycline compounds: Aromatized A-ring derivatives of tetracycline compounds are described.... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.c

20100204187 - Purine derivatives: Purine derivatives of Formula (I), wherein the meanings for the various substituents are as disclosed in the description. These compounds are useful as JAK3 kinase inhibitors.... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20100204188 - Method of synergistically enhancing the therapeutic efficacy and safety of medications through a combination therapy: The present invention provides combinations, for treatment of subjects suffering from or at high risk of developing diseases and disorders involving expression of peroxisome proliferator-activated receptors (PPAR). The combinations include abscisic acid and one other bioactive agent, which together provide synergistic effects toward treatment or blocking of development of the... Agent: Blank Rome LLP

20100204189 - Methods and compounds for vitamin d therapy: Methods and compositions comprising 1,25-dihydroxyvitamin D2 are disclosed. A method for lowering or maintaining lowered serum parathyroid hormone in human patients including administering to said patients an effective amount of 1,25-dihydroxyvitamin D2 to lower or maintain lowered serum parathyroid hormone levels is disclosed. Dosage forms and dosing regimens are also... Agent: Marshall, Gerstein & Borun LLP

20100204190 - New combinations: The present invention relates to a combination of organic compounds, a pharmaceutical composition and a kit of parts comprising said combination of organic compounds and to a method of treatment or prevention of certain conditions or diseases.... Agent: Novartis Corporate Intellectual Property

20100204192 - Agents, compositions and methods for enhancing neurological function: Neuro-enhancing agents, compositions and methods are disclosed herein. Preferred neuro-enhancing agents of the present invention include progesterone and metabolites of progesterone, such as 3α-hydroxy-5α-pregnan-20-one (THP). These agents yield neuro-enhancing effects on neural cells that include neural progenitor and/or stem cells, whereby the agents stimulate mitosis of neural progenitor cells, stimulate... Agent: Pabst Patent Group LLP

20100204191 - Function-selective vitamin d receptor agonist: The present invention provides a VDR ligand which does not induce hypercalcemia that is an adverse reaction of a vitamin D3 preparation; and a composition which comprises lithocholic acid propionate, a salt thereof, a solvate thereof, or a prodrug thereof.... Agent: Hogan Lovells US LLP

20100204193 - Metal complexes incorporated within biodegradable nanoparticles and their use: The invention is directed to providing a compound for treating cancer, the compound comprising a metal complex having predetermined characteristics, and which may be incorporated into a polymeric nanoparticle or other delivery system for delivering the metal complex for action on tumor cells. The metal complex for treating cancer wherein... Agent: Hahn Loeser & Parks, LLP

20100204194 - Superoxide dismutase mimics for the treatment of ocular disorders and diseases: The use of SOD mimics particularly pentaazacycle Mn(II) complex SOD mimics, for the treatment of AMD, DR, and retinal edema is disclosed.... Agent: Alcon

20100204195 - Pharmaceutical compositions and process for making them: Amorphous HMG CoA reductase inhibitors, especially amorphous atorvastatin, are described. Also described are pharmaceutical combinations comprising amorphous HMG CoA reductase inhibitors in combination with cholesterol absorption inhibitors or fibrates. A method of manufacturing the compositions using a hot melt extrusion process are also described.... Agent: Conley Rose, P.C.

20100204197 - Pyrrolopyrimidines: The present invention relates to compounds or pharmaceutically-acceptable salts thereof, processes for preparing them, pharmaceutical compositions containing them and their use in therapy. The invention particularly relates to compounds that are polo-like kinase (PLKs) inhibitors useful for the treatment of disease states mediated by PLK, especially PLK4, in particular such... Agent: Philip S. Johnson Johnson & Johnson

20100204199 - Cyclic 11-beta hydroxysteroid dehydrogenase type i inhibitors: e

20100204198 - Hydrogenated benzo (c) thiophene derivatives as immunomodulators: The invention relates to novel thiophene derivatives, their preparation and their use as pharmaceutically active compounds. Said compounds particularly act as immunosuppressive agents.... Agent: Hoxie & Associates LLC

20100204200 - Inhibitors of cathepsin s: e

20100204196 - 2-[2--1h-pyrrolo[2,3-d]pyrimidin-4-yl)amino] benzamide derivatives as igf-1r inhibitors for the treatment of cancer:

20100204201 - Hiv integrase inhibitors: wherein bond a, ring A, R1, R2 and R3 are defined herein. The compounds are useful for the prophylaxis or treatment of infection by HIV and the prophylaxis, treatment, or delay in the onset of AIDS. The compounds are employed against HIV infection and AIDS as compounds per se or... Agent: Merck

20100204202 - Drug for alleviating motor complications or psychiatric symptoms of parkinson's disease: or a pharmacologically acceptable salt thereof or their hydrates, which alleviates motor complications associated with a treatment with levodopa for Parkinson's disease, delays the onset of motor complications associated with a treatment with levodopa, and inhibiting or delaying the advance of symptoms of Parkinson's disease is provided. The compound having... Agent: Drinker Biddle & Reath (dc)

20100204203 - Chemical compounds 637: pyridopyrimidinediones as pde4 inhibitors: The present invention provides a compound of a formula (I), wherein the variables are defined herein; to a process for preparing such a compound; and to the use of such a compound in the treatment of a PDE4 mediated disease state.... Agent: Fish & Richardson P.C.

20100204204 - Nutraceutical co-crystal compositions: Co-crystals comprising at least one nutraceutical compound and at least one co-crystal former with or without impurities. These co-crystals may be included in compositions (optionally also including other components such as pharmaceutically acceptable excipients, other nutritional supplements, etc.) having utility as pharmaceuticals, nutraceuticals, nutritional supplements, and foodstuffs.... Agent: Bryan Cave LLP

20100204206 - Di(hetero)arylcyclohexane derivatives, their preparation, their use and pharmaceutical compositions comprising them: in which Ar1, Ar2, R1 and R2 have the meanings indicated in the claims. The compounds of the formula I are valuable pharmaceutical active compounds which inhibit ATP-sensitive potassium channels in the heart muscle and are suitable, for example, for the treatment of disorders of the cardiovascular system such as... Agent: Andrea Q. Ryan Sanofi-aventis U.s. LLC

20100204205 - Tolerability of mirtazapine and a second active agent by using them in combination: A reduction in the side effects of treating with an agent having combined 5HT2/5HT3 and alpha-2 antagonistic activity is obtained by administering an agent having histamine H1 receptor agonist activity. A combined dosage form comprising an agent having 5HT2/5HT3 and alpha-2 antagonistic activity and an agent having histamine H1 receptor... Agent: Martin D. Moynihan D/b/a Prtsi, Inc.

20100204207 - Compounds and methods for treating dyslipidemia: Compounds of Formula (I): wherein n, m, p, q, Y, R1, R2, R3a, R3b, R4, R5, and R6 are as defined herein and their pharmaceutical compositions and methods of use are disclosed.... Agent: Eli Lilly & Company

20100204208 - Protein kinase c inhibitors and uses thereof: This disclosure concerns compounds which are useful as inhibitors of protein kinase C (PKC) and are thus useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of PKC. This disclosure also relates to pharmaceutical compositions comprising these compounds, methods of using these... Agent: Rigel Pharmaceuticals, Inc. Bozicevic, Field & Francis LLP

20100204209 - Ccr2 receptor antagonists and uses thereof: The present invention relates to novel antagonists for CCR2 (CC chemokine receptor 2) and their use for providing medicaments for treating conditions and diseases, especially pulmonary diseases like asthma and COPD.... Agent: Michael P. Morris Boehringer Ingelheim Usa Corporation

20100204210 - Method for treating pulmonary diseases using rho kinase inhibitor compounds: This invention relates to methods of treating pulmonary diseases in patients that beta adrenergic receptor agonist therapy is not effective. The method comprises the steps of: identifying a patient who suffers from a pulmonary disease and has reduced responsiveness to treatment with one or more beta adrenergic receptor agonists, and... Agent: Howery LLP

20100204213 - Arylsulfonamide derivatives for use as ccr3 antagonists in the treatment of inflammatory and immunological disorders: The present invention relates to a sulfonamide derivative which is useful as an active ingredient of pharmaceutical preparations. The sulfonamide derivatives of the present invention have CCR3 (CC type chemokine receptor) antagonistic activity, and can be used for the prophylaxis and treatment of diseases associated with CCR3 activity, in particular... Agent: Jones Day

20100204212 - Fused heterocyclic compounds useful as kinase modulators: e

20100204211 - Medicaments for the treatment or prevention of fibrotic diseases:

20100204214 - Histamine h3 inverse agonists and antagonists and methods of use thereof: Provided herein are fused imidazolyl compounds, methods of synthesis, and methods of use thereof. The compounds provided herein are useful for the treatment, prevention, and/or management of various disorders, such as neurological disorders and metabolic disorders. Compounds provided herein inhibit the activity of histamine H3 receptors and modulate the release... Agent: Jones Day

20100204215 - Novel diaminophenothiazine compounds, a method for preparing same and uses thereof: Novel 2,8-diaminophenothiazine compounds, a method for preparing the same, and uses of the novel 2,8-diaminophenothiazine compounds in the field of treating liquid or gaseous fluids, especially influents and industrial or domestic effluents.... Agent: Young & Thompson

20100204216 - Pharmaceutical composition for inhibiting amyloid-beta protein accumulation: The present invention provides: a pharmaceutical composition for inhibiting amyloid-β protein accumulation comprising a compound represented by the formulas including (I) or a pharmaceutically acceptable salt thereof; a method for inhibiting amyloid-β protein accumulation, comprising a step of administering an effective amount of the compound represented by the formulas including... Agent: Birch Stewart Kolasch & Birch

20100204217 - Treatment for leukemia and idiopathic aplastic anemia: A process for treating a patient with leukemia or an aplastic anemia having cells with inclusions that stain with anti-E. canis antibodies or antibodies to other Ehrlichia or Anaplasma is disclosed. That process comprises administering to the patient (i) an antibacterial amount of a rifamycin, (ii) an antibacterial amount of... Agent: Husch Blackwell Sanders, LLP Husch Blackwell Sanders LLP Welsh & Katz

20100204218 - Fused bicyclic compound: p

20100204219 - Aromatic 1,4-di-carboxylamides and their use: The invention relates to novel compounds of formula (I) wherein X, Y, Z represent independently from one another C or N, n stands for 1, 2, 3, m is 0 or 1, p stands for 0 or an integer from 1 to 6, R1, R2 represent independently from one another... Agent: Ratnerprestia

20100204220 - Heterocyclic modulators of cannabinoid receptors: Heterocyclic compounds which modulate cannabinoid receptors are presented. Pharmaceutical compositions containing these compounds, methods of using these compounds as modulators of cannabinoid receptors and processes for synthesizing these compounds are also described herein.... Agent: NielsenIPLaw LLC

20100204223 - 2-substituted phenyl-5,7-dihydrocarbyl-3,7-dihydropyrrolo[2,3-d] pyrimidin-4-one derivatives, the preparation and the pharmaceutical use thereof: The invention relates to the compounds of formula I, their preparation and the pharmaceutical compositions containing the compounds. The invention also relates to the use of the compounds of formula I in preparing medicines, which can treat sexual dysfunction of animals including human (male and female), especially erectile dysfunction of... Agent: Kaplan Gilman & Pergament LLP

20100204222 - Pyridopyrimidine derivatives as p13 kinase inhibitors: Invented is a method of inhibiting the activity/function of PI3 kinases using pyridopyrimidine derivatives. Also invented is a method of treating one or more disease states selected from: autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, allergy, asthma, pancreatitis, multiorgan failure, kidney diseases, platelet aggregation, cancer, sperm motility, transplantation rejection,... Agent: Glaxosmithkline Global Patents -us, Uw2220

20100204221 - Pyrrolopyrimidinyl axl kinase inhibitors: v

20100204224 - Azacyclic compounds as inhibitors of sensory neurone specific sodium channels: Compounds of the formula (I), and pharmaceutically acceptable salts thereof, are found to be antagonists of SNS sodium channels. They are therefore useful as analgesic and neuroprotective agents; wherein (1) represents (A), (B) or (C); R1 represents: (a) -L-A or L′-A′ wherein L represents a bond or a C1-C6 alkyl,... Agent: Banner & Witcoff, Ltd.

20100204225 - Organic compounds: There are provided according to the invention compounds of formula (I), in free or salt form, wherein R1, R2, R3, R4, R5, R6, Q, W, X, m, n and p are as described in the specification, process for preparing them, and their use as pharmaceuticals.... Agent: Novartis Institutes For Biomedical Research, Inc.

20100204226 - Quinazolinones as prolyl hydroxylase inhibitors: e

20100204227 - Isoindoline compounds and methods of their use: Provided herein are isoindoline compounds, pharmaceutical compositions comprising one or more of such compounds, and methods of their use for treating, preventing, or managing various diseases.... Agent: Jones Day

20100204228 - Aryl sulfonamides useful for modulation of the progesterone receptor: In one embodiment, compounds of the following structure are described, wherein R1 to R7 are described herein. Also provided are methods for preparing these compounds and methods of contraception; treating or preventing fibroids; treating or preventing uterine leiomyomata; treating or preventing endometriosis, dysfunctional bleeding, and polycystic ovary syndrome; treating or... Agent: Howson & Howson LLP / Wyeth LLC

20100204231 - Amino-thiazolyl-pyrimidine derivatives and their use for the treatment of cancer: The present invention relates to compounds of Formula (I): and to their pharmaceutical compositions, and to their methods of use. These compounds provide a treatment for myeloproliferative disorders and cancer.... Agent: Astrazeneca R&d Boston

20100204229 - Fungicide heterocyclyl-pyrimidinyl-amino derivatives: heterocyclyl-pyrimidinyl-amino derivatives of formula (I) wherein Het, Y, p, Ra, Rb, Rc, X, n, L1 and L2 represent various substituents, their process of preparation, preparation intermediate compounds, their use as fungicide active agents, particularly in the form of fungicide compositions, and methods for the control of phytopathogenic fungi, notably of... Agent: Ostrolenk Faber Gerb & Soffen

20100204233 - Imidazole derivatives: t

20100204230 - Piperazine derivatives for treatment of ad and related conditions: Compounds of formula (I) selectively inhibit production of Aβ(1-42) and hence find use in treatment of Alzheimer's disease and other conditions associated with deposition of A(β) in the brain.... Agent: Merck

20100204232 - Xinafoate salt of n4-(2,2-difluoro-4h-benz0 [1,4] oxazin-3-one) -6-yl] -5-fluoro-n2- [3-(methylaminocar bonylmethyleneoxy) phenyl] 2,4-pyrimidinediamine: The present invention relates to the xinafoate salt of N4-[(2,2-difluoro-4H-benzo[1,4]oxazin-3-one)-6-yl]-5-fluoro-N2-[3-(methylaminocarbonylmethyleneoxy)phenyl]-2,4-pyrimidinediamine. This compound is a suitable drug substance and is useful in the treatment of conditions including asthma.... Agent: Pfizer Inc. Patent Department

20100204234 - 17beta-hydroxysteroid dehydrogenase type 1 inhibitors for the treatment of hormone-related diseases: The invention relates to the use of non-steroidal 17beta-hydroxysteroid dehydrogenase type 1 inhibitors for the treatment and prophylaxis of hormone-dependent, particularly estrogen-dependent, diseases. The invention further relates to suitable inhibitors and to a method for the production thereof.... Agent: Briscoe, Kurt G. Norris Mclaughlin & Marcus, Pa

20100204235 - Organic compounds: e

20100204238 - Bicyclic nitrogen-containing heterocyclic compounds for use as stearoyl coa desaturase inhibitors: The present invention discloses bicyclic nitrogen-containing heterocyclic compounds for use as inhibitors of stearoyl-CoA desaturase. The compounds are useful in treating and/or preventing various human diseases, mediated by stearoyl-CoA desaturase (SCD) enzymes, especially diseases related to abnormal lipid levels, cardiovascular disease, diabetes, obesity, oily skin conditions, metabolic syndrome, and the... Agent: Cv Therapeutics, Inc. Gilead Palo Alto, Inc.

20100204237 - Hydroxypyrimidinone derivatives having inhibitory activity against hiv integrase: (wherein, C ring is nitrogen-containing aromatic heterocyclic ring in which at least one atom in atoms neighboring the atom bound to the pyrimidine ring is unsubstituted nitrogen atom; R10 is hydrogen or lower alkyl; D ring is aryl or heteroaryl) Z1 and Z3 each is independently a single bond, O,... Agent: Wenderoth, Lind & Ponack, L.L.P.

20100204236 - Substituted imidazoles as bombesin receptor subtype-3 modulators: Certain novel substituted imidazoles are ligands of the human bombesin receptor and, in particular, are selective ligands of the human bombesin receptor subtype-3 (BRS-3). They are therefore useful for the treatment, control, or prevention of diseases and disorders responsive to the modulation of BRS-3, such as obesity, and diabetes.... Agent: Merck

20100204239 - Novel tetracyclic heteroatom containing derivatives useful as sex steroid hormone receptor modulators: The present invention is directed to novel tetracyclic heteroatom containing derivatives, pharmaceutical compositions containing them, their use in the treatment of disorders mediated by one or more sex steroid hormone receptors and processes for their preparation.... Agent: Philip S. Johnson Johnson & Johnson

20100204240 - Pyridin-2-yl-amino-1, 2, 4-thiadiazole derivatives as glucokinase activators for the treatment of diabetes mellitus: Provided are compounds of Formula (I): wherein R2, R3, R13, L and D2 are as defined in the specification, which are useful in the treatment and/or prevention of diseases or disorders mediated by deficient levels of glucokinase activity or which can be treated by activating glucokinase including, but not limited... Agent: Amgen Inc.

20100204241 - New pyridazin-3(2h)-one derivatives: o

20100204242 - Piperazine derivative having affinity for the histamine h3 receptor:

20100204243 - Process for the preparation of poly dl-lactide-co-glycolide nanoparticles having antitubercular drugs encapsulated therein: A process for the preparation of Poly DL-lactide-co-glycolide nanoparticles having antitubercular drugs encapsulated therein comprising: (i) preparation of an aqueous solution of stable water soluble drugs in DW/NS/PBS (ii) preparation of unstable drugs in DW/NS/PBS (iii) preparation of a polymer and hydrophobic drug solution in an organic solvent, (iv) mixing... Agent: The Webb Law Firm, P.C.

20100204244 - Agents for treatment of diabetic retinopathy and drusen formation in macular degeneration: Agents that stimulate nuclear translocation of Nrf2 protein and the subsequent increases in gene products that detoxify and eliminate cytotoxic metabolites are provided in a method for treating diabetic retinopathy or drusen formation in age-related macular degeneration. The structurally diverse agents that act on the Nrf2/ARE pathway induce the expression... Agent: Alcon

20100204245 - Amino-pyridines as inhibitors of beta-secretase: e

20100204246 - 5-aminopyrazol-3-yl-3h-imidazo (4,5-b) pyridine derivatives and their use for the treatment of cancer: The present invention relates to compounds of Formula (I) and to their pharmaceutical compositions, and to their methods of use. These novel compounds provide a treatment for myeloproliferative disorders and cancer.... Agent: Astrazeneca R&d Boston

20100204247 - N-substituted oxindoline derivatives as calcium channel blockers: A series of N-substituted oxindole derivatives represented by Formula I, or pharmaceutically acceptable salts thereof. Pharmaceutical compositions comprise an effective amount of the instant compounds, either alone, or in combination with one or more other therapeutically active compounds, and a pharmaceutically acceptable carrier. Methods of treating conditions associated with, or... Agent: Merck

20100204249 - Secretory phospholipase a2 (spla2) inhibitor and niacin drug compositions and methods for treating cardiovascular disease and dyslipidemia: Niacin drugs are frequently utilized as a therapeutic to treat CVD, increase HDL levels, and/or decrease TG levels. As disclosed herein, it has been found that administration of one or more sPLA2 inhibitors in combination with one or more niacin drugs unexpectedly results in a synergistic increase in HDL levels... Agent: Perkins Coie LLP

20100204250 - Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions: a

20100204248 - Medicaments and methods for inhibition of non-ocular scarring: Provided is the use of an agonist of a member of the nuclear hormone receptor NR4A subgroup in the manufacture of a medicament for the prevention, reduction or inhibition of scarring in a non-ocular tissue. Also provided is a method of preventing, reducing or inhibiting scarring in a non-ocular tissue,... Agent: Foley And Lardner LLP Suite 500

20100204251 - Molecular target of neurotoxicity: The present invention relates to the fields of biology, genetics and medicine. In particular it concerns new methods for the detection, characterisation and/or treatment (or management) of neurodegenerative diseases, particularly amyotrophic lateral sclerosis. The invention equally concerns methods for identifying or screening compounds active in these diseases. The invention further... Agent: Nixon & Vanderhye, PC

20100204252 - Methods of treating hypertension with at least one angiotensin ii receptor blocker and chlorthalidone: The present invention relates to a method of treating hypertension in a subject or patient needing treatment thereof by administering to said subject or patient at least one angiotensin II receptor blocker in combination with chlorthalidone.... Agent: Lisa Mueller C/o Polsinelli Shughart PC

20100204253 - Ribosome structure and protein synthesis inhibitors: The invention provides methods for producing high resolution crystals of ribosomes and ribosomal subunits as well as crystals produced by such methods. The invention also provides high resolution structures of ribosomal subunits either alone or in combination with protein synthesis inhibitors. The invention provides methods for identifying ribosome-related ligands and... Agent: Goodwin Procter LLP Patent Administrator

20100204255 - Bicyclic derivatives as modulators of ion channels: The present invention relates to bicyclic compounds useful as inhibitors of ion channels. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders.... Agent: Vertex Pharmaceuticals Inc.

20100204254 - Use of statins in the prevention and treatment of radiation injury and other disorders associated with reduced endothelial thrombomodulin: The present invention discloses statins (3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors) consistently and significantly increased endothelial cell thrombomodulin protein and functional activity. Statins also abrogated the downregulation of thrombomodulin that occurs in response to radiation injury. These results indicate that preserving or restoring endothelial thrombomodulin expression and function by statins may... Agent: Benjamin Aaron Adler, Ph.d., J.d.

20100204256 - 1-phenyl-2-pyridinyl alkyl alcohol compounds as phosphodiesterase inhibitors: 1-Phenyl-2-pyridinyl alkyl alcohol compounds are effective as inhibitors of the phosphodiesterase 4 (PDE4) enzyme and may be used to prevent and/or treat certain diseases or conditions.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, L.L.P.

20100204257 - Spiroindolinone pyridine derivatives: P

20100204258 - Methods and compositions for modulating insulin secretion and glucose metabolism: The present invention relates to methods and compositions for treating or ameliorating the effects of diabetes. In addition, the present invention relates to methods and compositions for treating or preventing hyperglycemia, as well as modulating monoamine levels, islet β-cell insulin secretion, insulin and/or glucagon levels in a patient. In certain... Agent: Bryan Cave LLP

20100204259 - Immediate release composition resistant to abuse by intake of alcohol: The present invention provides immediate release pharmaceutical compositions for oral administration that are resistant to abuse by intake of alcohol.... Agent: Stoel Rives LLP - Slc

20100204261 - Multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin for treatment of breast, colorectal, pancreatic, ovarian and lung cancers: e

20100204260 - Multi-substituted imidazolines and method of use thereof: A new class of imidazolines as 4-position acids or esters with very potent anti-inflammatory as well as antimicrobial activity is described. The synthesis of these imidazolines includes a multicomponent reaction applicable to a combinatorial synthetic approach. The combination of these two key characteristics provides an effective therapeutic drug in the... Agent: Medlen & Carroll, LLP

20100204262 - Cationic pharmaceutically active ingredient containing composition, and methods for manufacturing and using: A cationic pharmaceutically active ingredient containing composition is provided. The composition includes a cationic pharmaceutically active ingredient, a hydrophobic polymer/hydrophilic polymer adduct comprising a poly(vinylpyrrolidone/alkylene) polymer and a polymer comprising carboxylic acid groups, hydroxyl groups, or a mixture of carboxylic acid groups and hydroxyl groups, a compatibilizing amount of a... Agent: Merchant & Gould PC

20100204263 - Method of treating multidrug resistant cancers: A method of treating multidrug resistant cancers in a patient, comprising administering to said patient a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof. The values and preferred values for variables R1 and R2 are defined herein.... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20100204264 - Polymorphic form of granisetron base, methods for obtaining it and formulation containing it: Relates to a new polymorphic form of Granisetron base, Form I, to methods for obtaining thereof, to the method for obtaining Granisetron.HCl and its use for preparing pharmaceutical formulations. The Form I is characterized by the X-ray powder diffractogram shown in FIG. 1. Included in summarised form are the methods... Agent: Barnes & Thornburg LLP

20100204265 - Certain nitrogen containing bicyclic chemical entities for treating viral infections: Provided are certain chemical entities, pharmaceutical compositions, and methods of treatment of a member of the flaviviradae family of viruses such as hepacivirus (Hepatitis C or HCV).... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B482

20100204266 - Compositions for use in identification of mixed populations of bioagents: The present invention provides oligonucleotide primers, compositions, and kits containing the same for rapid identification of bacterial bioagents and populations of bioagents which are members of the Staphylococcus bacterial genus by amplification of a segment of bioagent nucleic acid followed by molecular mass analysis.... Agent: Casimir Jones, S.c.

20100204267 - Preventive and therapeutic medicament for gastroesophageal reflux disease: wherein R1 and R2 independently represent a hydrogen atom or a lower alkyl group; A represents a group selected from the group consisting of 1-azabicyclo[3.2.2]nonyl group, 1-azabicyclo[2.2.2]octyl group, or an N-oxide thereof, or a pharmaceutically acceptable salt thereof or a hydrate thereof has both improving effect on enterokinetic functions and... Agent: Wenderoth, Lind & Ponack, L.L.P.

20100204268 - Processes for preparing different forms of (s)-(+)-clopidogrel bisulfate: The invention provides improved processes for the preparation of hydrated form of (S)-(+)-Clopidogrel bisulfate as well as improved processes for the preparation of form-I and form-II of (S)-(+)-Clopidogrel bisulfate.... Agent: Nixon & Vanderhye, PC

20100204269 - Compounds and methods for treatment of chemotherapy-induced anemia: The invention relates to methods and compounds for treating chemotherapy-induced anemia. In particular, methods for treating chemotherapy-induced anemia in subjects refractory to treatment with recombinant human erythropoietin are encompassed herein.... Agent: Fibrogen, Inc.

20100204272 - Compounds which have activity at m1 receptor and their uses in medicine: e

20100204270 - Quinoline derivatives as antibacterial agents: Use of a compound for the manufacture of a medicament for the treatment of a bacterial infection provided that the bacterial infection is other than a Mycobacterial infection, said compound being a compound of formula (Ia) or (Ib) a pharmaceutically acceptable acid or base addition salt thereof, a stereochemically isomeric... Agent: Philip S. Johnson Johnson & Johnson

20100204271 - Stable crystal of 4-oxoquinoline compound: Provision of a stabilized crystal of 6-(3-chloro-2-fluorobenzyl)-1-[(S)-1-hydroxymethyl-2-methylpropyl]-7-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid (compound A). A crystal of compound A, which shows a particular X-ray powder diffraction pattern of a characteristic diffraction peaks at diffraction angles 2θ(°) as measured by X-ray powder diffractometry.... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20100204273 - Quinoline and quinazoline derivatives having affinity for 5ht1-type receptors: o

20100204275 - N-piperidin-4-ylmethyl-amide derivatives and their use as monoamine neurotransmitter re-uptake inhibitors:

20100204274 - Piperidinyl derivatives as modulators of chemokine receptor activity: The present application describes modulators of MIP-1α of formula (I) or stereoisomers or prodrugs or pharmaceutically acceptable salts thereof, wherein m, Q, T, W, Z, R1, R3, R4, R5, R5a and R5b, are as defined herein. In addition, methods of treating and preventing inflammatory diseases such as asthma and allergic... Agent: Louis J. Wille Bristol-myers Squibb Company

20100204276 - Indole compounds, a process for their preparation and pharmaceutical compositions containing them: e

20100204277 - Compositions and methods for controlling infestation: The present invention is directed to methods of treating pest infestation by inhibiting metabolic processes of the pest such as for example, processes involved in invertebrate remodelling.... Agent: Mcandrews Held & Malloy, Ltd

20100204278 - Niacin receptor agonists, compositions containing such compounds and methods of treatment: The present invention encompasses compounds of Formula (I) as well as pharmaceutically acceptable salts and hydrates thereof, that are useful for treating atherosclerosis, dyslipidemias and the like. Pharmaceutical compositions and methods of use are also included.... Agent: Merck

20100204279 - Therapeutic salt compositions and methods: Therapeutic salt compositions and methods are disclosed herein.... Agent: Goodwin Procter LLP Patent Administrator

20100204280 - Cinnamoyl inhibitors of transglutaminase: A compound of Formula, (I) or Formula: (II)... Agent: Woodcock Washburn LLP

20100204281 - Ectoparasite control method: c

20100204284 - Hetero-substituted acetanilide derivatives as analgesic agents: Hetero-substituted acetanilide derivatives are disclosed as analgesic agents. The compounds of the invention are useful in methods for treating a disease or condition in a mammal characterized by pain and/or fever.... Agent: Philip S. Johnson Johnson & Johnson

20100204283 - Pesticide composition potentiated in efficacy and method for potentiating efficacy of pesticidal active ingredients: (wherein, BO represents an ethyleneoxy group, PO represents a propyleneoxy group, R represents an alkyl or alkenyl group having 8 to 20 carbons, w represents on average an integer in the range of 1 to 25, x represents on average an integer in the range of 1 to 25, y... Agent: Kenyon & Kenyon LLP

20100204282 - Reverse indoles as 5-lipoxygenase-activating protein (flap) inhibitors: Described herein are compounds and pharmaceutical compositions containing such compounds, which modulate the activity of 5-lipoxygenase-activating protein (FLAP). Also described herein are methods of using such FLAP modulators, alone and in combination with other compounds, for treating respiratory, cardiovascular, and other leukotriene-dependent or leukotriene mediated conditions or diseases.... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B482

20100204287 - Heterocyclic amide derivatives useful as microbiocides: where Het is a 5- or 6-membered heterocyclic ring containing one to three heteroatoms, each independently selected from oxygen, nitrogen and sulphur, the ring being substituted by the groups R6, R7 and R8; R1 is hydrogen, C1-4 alkyl, C1-4 haloalkyl, C1-4 alkoxy, C1-4 haloalkoxy, CH2C≡CR9, CH2CR10═CHR11, CH═C═CH2 or COR12; R2... Agent: Syngenta Crop Protection , Inc. Patent And Trademark Department

20100204286 - Method for reducing gastrointestinal adverse effects of cytotoxic agents: A method for moderating a gastrointestinal adverse effect induced by at least one cytotoxic agent, for example ionizing radiation and/or at least one chemotherapeutic agent, in a subject comprises administering to the subject a therapeutically effective amount of an ACE2 inhibitor or a compound selected from (S,S)-2-[1-carboxy-2-[3-(3,5-dichlorobenzyl)-3H-imidazol-4-yl]-ethylaminol-4-methylpentanoic acid (ORE1001), pharmaceutically... Agent: Harness, Dickey, & Pierce, P.l.c

20100204285 - Trans-3-aza-bicyclo[3.1.0]hexane derivatives: The invention relates to novel trans-3-aza-bicyclo[3.1.0]hexane derivatives of formula (I), wherein A, B, n and R1 are as described in the description, and to the use of such compounds, or of pharmaceutically acceptable salts of such compounds, as medicaments, especially as orexin receptor antagonists.... Agent: Hoxie & Associates LLC

20100204288 - Heteroaryl-ureas and their use as glucokinase activators: e

20100204289 - viscose fiber with modified property and a process for making therefor: A viscose fiber having property modifying constituents such as thermoregulatory activity, antimicrobial activity, and perfumed and a method of making thereof is disclosed. Micro-reservoirs are formed in the fibers having thermoregulatory activity, antimicrobial constituents, and perfumed constituents.... Agent: Lucas & Mercanti, LLP

20100204291 - Method for facilitating extinction training using d-cycloserine: Methods are disclosed for improving treatment of various medical conditions via administration of D-cycloserine to facilitate learning. Specifically, by administering D-cycloserine on a post-training pre-sleep basis, subsequent to extinction training during the day, the methods can improve upon the known ability of D-cycloserine to facilitate extinction learning.... Agent: Jason P. Mcdevitt

20100204290 - Procedure for operating a particle filter arranged in an exhaust fume area of a brennkraftmaschine and device to execute the procedure: A method of increasing the survival of animals and aquatic species susceptible to birnavirus infection by treating them before, during and/or after bimavirus exposure, with a chemical compound capable of inhibiting viral replication. A method of treating aquatic species to increase their survival in the presence of a virus, particularly... Agent: Merchant & Gould PC

20100204292 - Pharmaceutical compositions comprising intra-and extra-granular fractions: A pharmaceutical composition comprising i) an intra-granular fraction containing a pharmaceutically acceptable active component and a first excipient and ii) an extra-granular fraction containing a second excipient. The pharmaceutical composition is characterized by being substantially surfactant-free and by exhibiting a rapid-dissolution profile.... Agent: Stikeman Elliott LLP

20100204293 - Pharmaceutical composition: Disclosed is an antifungal agent for external use, which is characterized by containing a compound represented by the general formula (1) below, 50-95% by mass of an alcohol, and 0.1-35% by mass of water and/or an anionic surfactant.... Agent: Knobbe Martens Olson & Bear LLP

20100204294 - Methods for assessing, improving, or maintaining urogenital health in postmenopausal woman: This invention relates to methods and kits useful for improving or maintaining urogenital health using an estrogen agonist/antagonist. The methods of treatment are effective for improving or maintaining urogenital health while substantially reducing the concomitant liability of adverse effects associated with estrogen administration. This invention also relates to methods of... Agent: Pfizer Inc. Patent Department

20100204295 - Treatment of allergic disease with immunomodulator compounds: A method of treatment for treating, preventing, inhibiting or reducing allergic disease or its effects in a subject, comprises administering to the subject an effective amount of an immunomodulator compound, which composes an aromatic or heterocyclic amino acid residue or a derivative thereof. Preferably, the immunomodulatory compound is a dipeptide... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20100204296 - Novel polymorphs of darifenacin free base and its hydrobromide salt: The present invention provides a novel and stable amorphous form of darifenacin free base, process for preparation, pharmaceutical compositions, and method of treating thereof. The present invention further provides a novel and stable polymorphic form of darifenacin hydrobromide, process for preparation, pharmaceutical compositions, and method of treating thereof.... Agent: Cantor Colburn, LLP

20100204312 - Methods and compositions for treating cancer: This disclosure provides compositions and method useful for treating cell proliferative disorders including cancer. The disclosure provides cannabidiol derivatives and compositions thereof either alone or in combination with THC or a derivative thereof.... Agent: Joseph R. Baker, Apc Gavrilovich, Dodd & Lindsey LLP

20100204313 - Modulation of nerve pain activity by resiniferatoxin and uses thereof: The present invention is directed to the treatment of chronic pain that occurs in chronic disease such as chronic pancreatitis by the application, of the drug, resiniferatoxin, to a visceral organ, such as the stomach, which then reduces the pain present in a second visceral organ, such as the pancreas.... Agent: Benjamin Aaron Adler Adler & Associates

20100204314 - Drug for treatment of influenza: e

20100204315 - Agents for preventing attachment of barnacle consisting of organic solvent extracts of red alga laurencia sp. and compounds isolated therefrom:

20100204316 - Pseudopolymorphic forms of a hiv protease inhibitor: New pseudopolymorphic forms of (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl (1S,2R)-3-[[(4-aminophenyl)sulfonyl](isobutyl)amino]-1-benzyl-2-hydroxypropylcarbamate and processes for producing them are disclosed.... Agent: Philip S. Johnson Johnson & Johnson

20100204317 - Methods of treating dermatological disorders or conditions: This invention is directed to the use of TOFA in the treatment of acne and other dermatological disorders. This invention is also directed to pharmaceutical compositions comprising TOFA and a pharmaceutically acceptable excipient for dermatological or oral administration.... Agent: Seed Intellectual Property Law Group PLLC

20100204318 - Treatment of virally induced lesions: The present invention relates generally to the treatment of cutaneous lesions containing cells infected by a virus, as well as compositions for the treatment of such lesions. More specifically, the invention relates to the use of ingenol compounds, particularly ingenol angelates, in treating lesions caused by infection with a papilloma... Agent: Scully, Scott, Murphy & Presser, P.C.

20100204319 - Treatment for benign prostatic hyperplasia: A method and composition for the treatment for bladder outlet obstruction, particularly benign prostatic hyperplasia (BPH), which includes administering to the mammal a therapeutically effective amount of a synergistic combination of Capsicum plants and aqueous extract from cruciferous vegetables.... Agent: J. Rodman Steele Novak Druce & Quigg LLP

20100204320 - Pharmaceuticals for xerosis: A method for preventing or treating xerosis by applying a prostaglandin D receptor selective agonist to a mammal.... Agent: Sughrue Mion, PLLC

20100204321 - Antitussive and bronchodilator uses for enaminone ester: The antitussive and bronchodilator use for an enaminone ester relates to the use of ethyl 4-[(4-chlorophenyl)amino]-6-methyl-2-oxocyclohex-3-en-1-oate (also referred to as “enaminone E121”) for treatment of respiratory conditions, and particularly to use of the ester as the active ingredient in a cough suppressant for nonproductive cough. The ester may be used... Agent: Litman Law Offices, Ltd.

20100204322 - Method of treating autoimmune diseases: A method of treating an autoimmune disease (for example, Systemic Lupus Erythematosus) comprises administering to the subject a treatment effective amount of a histone hyperacetylating agent, or a pharmaceutically acceptable salt thereof. Methods of screening compounds useful for the treatment of autoimmune disease are also disclosed.... Agent: Myers Bigel Sibley & Sajovec

20100204323 - Antimicrobial compositions comprising organic acid esters and methods for reducing virus and bacterial populations using such compositions: Antimicrobial compositions comprising organic acid esters and methods for reducing virus and/or bacteria populations using such compositions are provided. In one embodiment, an antimicrobial composition comprises a virucidally effective amount of an organic acid ester, the organic acid ester having a pKa1 value in the range of from about 3... Agent: The Dial Corporation

20100204324 - Optically active n-(alpha-mercaptopropionyl)glycine: An optically active N-(α-mercaptopropionyl)glycine, i.e., R-(−)-N-(α-mercaptopropionyl)glycine or S-(−)-N-(α-mercaptopropionyl)glycine, a preparation method thereof, a pharmaceutical preparation containing the compound or a pharmaceutically acceptable salt or ester thereof, and use of the same in preparation of detoxification medicament for improving metabolism, are provided.... Agent: The Webb Law Firm, P.C.

20100204325 - Valproic acid drug delivery systems and intraocular therapeutic uses thereof: Biocompatible, bioerodible, sustained release drug delivery system formulated as implants, microspheres and high viscosity hyaluronic acid solutions comprise valproic acid as therapeutic agent and a biodegradable polymer, the system being effective, when placed intraocular (such as into the subtenon space or into the vitreous) to treat a retinal disease or... Agent: Allergan, Inc.

20100204326 - Novel agents for treatment of ailments and dysfunctions: The present invention is related to the use of novel agents effective for differential killing of abnormal cells such as cancer cells without damaging or being toxic to normal cells. Further these agents may be used for treating a host of ailments including various types of cancers, skin diseases, prevention... Agent: Cook Alex Ltd

20100204327 - Methods for making retinoids and uses thereof: Described herein are methods for making retinoids. Also described herein are retinoids and methods of use thereof.... Agent: Ballard Spahr LLP

20100204329 - Method of using and establishing an absorption rate level and a neuron firing level: A method for modulating the homeostatic relationship between various amino acid neurotransmitters in the body. The method includes modulating the rate of neuron firing and modulating the rate of cellular absorption.... Agent: Knoble, Yoshida & Dunleavy

20100204328 - Solution and method to reduce, treat and/or prevent oxidative stress and cell activation: The present invention concerns a solution and methods to reduce, treat and/or prevent oxidative stress and cell activation. According to the invention the solution gives rise to the following concentrations of constituents within a blood flow of 0.1-18 mM N-acetyl-cysteine, optionally of 0.01-0.21 mM vitamin C, optionally of 2-26 mM... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20100204330 - Diclofenac formulations and methods of use: Methods and formulations are provided for treating migraine and other acute pain episodes using diclofenac, and formulations of diclofenac that provide both rapid and sustained relief from acute pain. Methods and formulations are also provided for treating symptoms that often accompany migraine and acute pain such as photophobia, phonophobia, nausea... Agent: Patent Correspondence Arnall Golden Gregory LLP

20100204332 - Method for treating a disease or condition responsive to opening of c1c-2 channel: Disclosed is a method for prophylactic or therapeutic treatment of a condition or disease responsive to opening of ClC-2 channel, which comprises the step of administrating an effective amount of a ClC-2 channel opener to a subject in need of said treatment. According to the invention, a tissue or organ... Agent: Sughrue Mion, PLLC

20100204331 - Prostaglandin deriative-containing aqueous liquid preparation: Provided is an aqueous liquid preparation comprising: (a) any one of a prostaglandin derivative being represented by the following formula (I), a pharmaceutically acceptable salt thereof and a hydrate thereof; and (b) at least one polyol of glycerin, propylene glycol, dipropylene glycol and 1,3-butylene glycol.... Agent: Sughrue Mion, PLLC

20100204333 - Novel pharmaceutical modified release dosage form cyclooxygenase enzyme inhibitor: Pharmaceutical modified release dosage form comprising at least one cyclooxygenase enzyme inhibitor or its pharmaceutically acceptable salts, esters, prodrugs, solvates, hydrates, or derivatives thereof as active agent, with a pharmaceutically acceptable carrier for controlling the release of the cyclooxygenase enzyme inhibitor is provided. The dosage form preferably provides a release... Agent: Ladas & Parry LLP

20100204334 - Intranasal delivery of modafinil: Modafinil is selectively delivered to the brain, minimizing delivery to the blood, of a person in need thereof by administering to the person a therapeutically-effective dosage of modafinil, wherein the dosage is less than 1 mg, formulated in a lipid microemulsion (LME) and selectively delivered to the upper third of... Agent: Richard Aron Osman

20100204335 - Kit and composition for eyelash growth: The invention provides a kit for enhancing the appearance of eyelashes, comprising an eyelash enhancing composition and delivery system. The eyelash enhancing composition comprises an effective amount of 0.03% bimatoprost. The delivery system comprises a plurality of applicator brushes designed to deliver a fraction of 1-drop bimatoprost dose to the... Agent: Allergan, Inc.

20100204336 - Formoterol tartrate process and polymorph: A method of preparation of a highly pure salt of R,R-formoterol L-tartrate is disclosed. The process provides the most thermodynamically stable polymorph by recrystallization of a novel polymorph.... Agent: Heslin Rothenberg Farley & Mesiti P.C.

20100204337 - Antibacterial s-heterosubstituted disulfides: Synthetically-derived S,S-heterodisubstituted disulfides that exhibit potent in vitro antibacterial activity against a variety of bacteria, including Staphylococcus aureus, methicillin-resistant Staphylococcus aureus and Francisella tularensis. The present invention provides compounds, methods and compositions effective to treat microbial/bacterial infections, and, especially, infections arising from bacteria which have developed resistance to conventional antibiotics.... Agent: Smith Hopen, Pa

20100204338 - Anti-angiogenic agents and methods of use: The present disclosure relates generally to treating or preventing diseases associated with angiogenesis by administering to a patient certain compounds found to inhibit or substantially reduce angiogenesis. Compounds employed according to the present disclosure exhibit good anti-angiogenic activity as well as demonstrate a prophylactic effect for preventing and substantially reducing... Agent: Connolly Bove Lodge & Hutz LLP

20100204339 - Orally bioavailable stilbenoids- compositions and therapeutic applications thereof: Disclosed is a novel sirtuin modulating composition comprising an orally bioavailable SIRT-1 enhancing compound 3,5-dimethoxy-3,4′-dihydroxystilbene represented by STR#I. Also disclosed is an anti-acne composition comprising 3,5-dimethoxy- 3,4′-dihydroxystilbenes represented by STR#I. Further, a novel sirtuin modulating composition comprising an orally bioavailable SIRT-1 enhancing compound 2,3′,5′, 6-tetrahydroxy-trans-stilbene represented by STR#II is also... Agent: Sabinsa Corporation

20100204340 - Orally bioavailable stilbenoids- compositions and therapeutic applications thereof: A novel, bioavailable and safe stilbenoid 3,5-dimethoxy-3,4′-dihydroxystilbene represented by STR#1 with an unexpected enhanced ability to prevent the accumulation of lipids accompanying the terminal differentiation of adipocytes, thereby inhibiting adipogenesis, and nutraceutical and cosmeceutical compositions comprising 3,5-dimethoxy-3,4′-dihydroxystilbene useful for anti-obesity and anti-cellulite therapy, are disclosed. Further the enhanced SIRT-1 activation... Agent: Sabinsa Corporation

20100204341 - Personal care dissolvable films: Personal care dissolvable films comprising a water soluble film forming agent, cosmetically acceptable plasticizer, and a thickener are described, along with methods of using the same.... Agent: Union Carbide Chemicals And Plastics Technology Corporation

20100204342 - Spherical organic polymer-silicon compound composite particles, hollow particles and their production methods: Hollow particles comprising a silicon compound, having an average particle size of from 5 to 65 nm and an average roundness of at least 0.90, and having a shell comprising the silicon compound and having a thickness of from 1 to 20 nm. Further, a method for producing hollow particles,... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, L.L.P.

20100204343 - 3-(4-hydroxy-3-methoxyphenyl)-1-(4-hydroxyphenyl)-1-propanone and its use as antioxidant: l

20100204344 - Macrocyclic lactones as fragrances:

20100204345 - Aqueous dispersion of low molecular weight polytetrafluoroethylene, low molecular weight polytetrafluoroethylene powder, and method for producing low molecular weight polytetrafluoroethylene: where X is H or F; m is an integer from 3 to 5; and Y is —SO3M, —SO4M, —SO3R, —SO4R, —COOM, —PO3M2 or —PO4M2, M being H, NH4 or an alkali metal, and R being an alkyl group having 1 to 12 carbons, and the low-molecular-weight PTFE has an... Agent: Sughrue Mion, PLLC

20100204346 - Novel sweetener having sucrose-like taste, method for producing the same, and use of the same: Means of Resolution: An isomerase and an epimerase are allowed to act on glucose liquid sugar produced in a glucose liquid sugar production plant to thereby produce D-psicose, thereby providing a novel sweetener (product) that maintains the degree and quality of sweetness of a glucose-fructose mixed solution and never causes... Agent: Westerman, Hattori, Daniels & Adrian, LLP

  
08/05/2010 > patent applications in patent subcategories. inventions list

20100197561 - Biomarkers for ovarian cancer: b2 microglobulin: The present invention provides protein-based biomarkers and biomarker combinations that are useful in qualifying ovarian cancer status in a patient. In particular, the biomarkers of this invention are useful to classify a subject sample as ovarian cancer or non-ovarian cancer. The biomarkers can be detected by SELDI mass spectrometry.... Agent: Edwards Angell Palmer & Dodge LLP

20100197563 - Compositions and methods for altering elastogenesis: Compositions and methods are provided for promoting elastin fiber formation (elastogenesis) in a cell, including methods that comprise contacting a cell that is capable of elastogenesis with (i) a mutated biglycan polypeptide that lacks chondroitin sulphate proteoglycan chains, (ii) a versican V3 isoform polypeptide that lacks most or all of... Agent: Seed Intellectual Property Law Group PLLC

20100197562 - Functionally selective alpha2c adrenoreceptor agonists: In its many embodiments, the present invention provides a novel class of biaryl compounds as inhibitors of ÿ2C adrenergic receptor agonists, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention,... Agent: Merck Patent Department (k-6-1, 1990)

20100197564 - Diaryl morpholines as cb1 modulators: The present invention provides compounds having the general structure of Formula (I) or a pharmaceutically acceptable salt, solvate, ester or prodrug thereof, which are useful as CB1 receptor antagonists. The compounds of the invention may be useful in treating diseases, disorders, or conditions responsive to CB1 receptor antagonists, including, but... Agent: Merck Patent Department (k-6-1, 1990)

20100197565 - Dry powder drug delivery system: A pulmonary drug delivery system is disclosed, including a breath-powered, dry powder inhaler, and a cartridge for delivering a dry powder formulation. The inhaler and cartridge can be provided with a drug delivery formulation comprising, for example, a diketopiperazine and an active ingredient, including, peptides and proteins such as insulin... Agent: K&l Gates LLP

20100197566 - Method and apparatus for preparing an acellular red blood cell substitute: A process is disclosed for the preparation of an essentially tetramer-free, substantially stroma-free, polymerized, pyridoxylated hemoglobin. Also disclosed is an essentially tetramer-free, substantially stroma-free, polymerized, pyridoxylated hemoglobin product capable of being infused into human patients in an amount of up to about 5 liters.... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20100197567 - Conus polypeptides: The invention relates to peptides (termed propeller peptides herein) and related peptides (termed peptides of the G12.2 family herein), about 60 to about 90 residues in length, which are naturally available in minute amounts in the venom of the cone snails or analogous to the naturally available peptides, and which... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20100197569 - Cross-linked glycopeptide-cephalosporin antibiotics: This invention provides cross-linked glycopeptide—cephalosporin compounds and pharmaceutically acceptable salts thereof which are useful as antibiotics. This invention also provides pharmaceutical compositions containing such compounds; methods for treating bacterial infections in a mammal using such compounds; and processes and intermediates useful for preparing such compounds.... Agent: Theravance, Inc.

20100197568 - Protective hydrocolloid for active ingredients: Partially deamidated rice endosperm protein or rice endosperm protein which is partially conjugated with mono-, di-, oligo- or polysaccharides is used as novel protective hydrocolloid for fat-soluble active ingredients and/or fat-soluble colorants. The present invention further includes compositions comprising that rice endosperm protein and at least one fat-soluble active ingredient/colorant,... Agent: Nixon & Vanderhye, PC

20100197570 - Cyclodepsipeptides with antineoplastic activity and methods of using to inhibit cancer and microbial growth: The present invention is directed to cyclodepsipeptide compounds having antineoplastic and/or antimicrobial activity, preferably Kitastatin 1. The present invention is further directed to methods of inhibiting cancer cell growth and/or microbial growth in a host inflicted therewith by administering cyclodepsipeptide compounds to the inflicted host.... Agent: Mcandrews Held & Malloy, Ltd

20100197571 - Extrudates with improved taste masking: The invention relates to extrudates comprising one or more pharmaceutically active substances, where the extrudates have a strand diameter of 0.5 mm or less, and to the use of these extrudates for the manufacture of medicaments.... Agent: Bayer Healthcare LLC

20100197572 - Use of somatostatin-14 as a therapeutic agent: The present invention is directed to the use of the peptide compound Ala-Gly-Cys-Lys-Asn-Phe-Phe-Trp-Lys-Thr-Phe-Thr-Ser-Cys-OH as a therapeutic agent for the prophylaxis and/or treatment of cancer, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurodegenerative diseases, infectious diseases, lung diseases, heart and vascular diseases and metabolic diseases. Moreover the present invention relates to pharmaceutical... Agent: Winstead PC

20100197590 - 4-amino-7,8-dihydropyrido[4,3-d]pyrimidin-5(6h)-one derivatives: e

20100197591 - 4-amino-7,8-dihydropyrido[4,3-d]pyrimidin-5(6h)-one derivatives:

20100197574 - Aquaretic and natriuretic polypeptides lacking vasodilatory activity: This document provides aquaretic and natriuretic polypeptides. For example, this document provides polypeptides having aquaretic and/or natriuretic activities. In some cases, a polypeptide provided herein can have aquaretic and natriuretic activities, while lacking the ability to lower blood pressure. This document also provides methods and materials for inducing aquaretic and/or... Agent: Fish & Richardson P.C.

20100197597 - Coagulation factor vii polypeptides: The present invention relates to novel coagulation Factor VII polypeptides, polynucleotide constructs encoding such polypeptides, as well as vectors and host cells comprising and expressing the polynucleotide, pharmaceutical compositions, uses and methods of treatment.... Agent: Novo Nordisk, Inc. Intellectual Property Department

20100197596 - Compositions and methods for diagnosis and treatment of type 2 diabetes: The present invention relates generally to the identification of biological markers associated with an increased risk of developing Diabetes, as well as methods of using such biological markers in diagnosis and prognosis of Diabetes. The biological markers of the invention may indicate new targets for therapy or constitute new therapeutics... Agent: David S. Resnick

20100197579 - Corticotropin releasing factor 2 receptor agonists: Isolated corticotropin releasing factor derivatives, and nucleic acids encoding the same, are effective for treating corticotropin releasing factor 2 receptor modulated disorders such as muscular dystrophy.... Agent: Fitzpatrick Cella Harper & Scinto

20100197578 - Demannosylated recombinant factor viii [[vii]] for the treatment of patients with haemophilia a: There is provided in accordance with the practice of this invention a demannosylated Factor VIII, the immunogenicity of which is substantially decreased or abolished in Human. The modified factor VIII is disclosed together with the modified amino acid sequence, changed by at least one substitution. The modified factor VIII is... Agent: Harness, Dickey & Pierce, P.L.C

20100197583 - Glycosaminoglycan-antagonising mcp-1 mutants and methods of using same: Novel mutants of human monocyte chemoattractant protein 1 (MCP-1) with increased glycosaminoglycan (GAG) binding affinity and knocked-out or reduced GPCR activity compared to wild type MCP-1, and their use for therapeutic treatment of inflammatory diseases.... Agent: Sheldon Mak Rose & Anderson PC

20100197582 - Growth hormone fusion proteins: We disclose growth hormone fusion proteins that have increased in vivo stability and activity; nucleic acid molecules encoding said proteins and methods of treatment of growth hormone deficiency that use said proteins.... Agent: Klarquist Sparkman, LLP

20100197594 - Methods for using soy peptides to inhibit h3 acetylation, reduce expression of hmg-coa reductase and increase ldl receptor and sp1 expression in a mammal: Controlled studies demonstrate that methods using soy related peptides inhibit H3 acetylation, reduce expression of HMG-CoA reductase and increase LDL receptor and Sp1 expression in mammals. The present disclosure is generally directed to using lunasin peptides and/or lunasin peptide derivatives to 1) inhibit H3 acetylation, 2) reduce expression of HMG-CoA... Agent: Kathryn P.wilke C/o Gaw Van Male

20100197589 - Modified growth hormone polypeptides: We describe modified growth hormone fusion proteins and dimers comprising said fusion proteins; nucleic acid molecules encoding said proteins and methods of treatment that use said proteins in the treatment of conditions that result from growth hormone excess.... Agent: Klarquist Sparkman, LLP

20100197593 - Modulators of the abc transporter family and methods for their use: An isolated factor derived from the bacterium Pseudomonas aeruginosa and confirmed by proteomics to be a protein that reduces expression of ABC transmembrane proteins and active fragments and mimetics thereof are provided. Also provided is a method for inhibiting expression of ABC transmembrane proteins in cells by administering to the... Agent: Licata & Tyrrell P.C.

20100197581 - Native gp41 assay:

20100197577 - Nitric oxide synthase activator: The object is to find a nitric oxide synthase activator, a method for the administration of the activator, and the amount of the activator to be administered. Disclosed is a nitric oxide synthase activator comprising a midkine family protein or a midkine derivative as an active ingredient. Specifically disclosed is... Agent: Morrison & Foerster LLP

20100197580 - Parstatin peptides and uses thereof: The invention provides parstatin peptides, particularly a mammalian parstatin peptide including amino acids 1-26 of full length mammalian parstatin, preferably a human parstatin. The invention provides parstatin peptides in appropriate pharmaceutical carriers and formulated for administration. The invention provides for the use of the peptide for example as a medicament... Agent: Edwards Angell Palmer & Dodge LLP

20100197576 - Polypeptides or fusion proteins thereof inhibiting transmigration of leucocytes or growth and/or metastasis of cancer cells: The present invention provides a polypeptide or its fusion protein derived from a paired immunoglobulin-like receptor α or β (PILRα or PILRβ), one of the transmembrane proteins, which inhibits the transmigration of leukocytes or the growth and/or metastasis of cancer cells. The present invention also provides a polynucleotide encoding the... Agent: The Nath Law Group

20100197575 - Soluble interleukin-20 receptor: A soluble receptor to IL-20 having two polypeptide subunits, IL-20RA (formerly called ZcytoR7) and IL-20RB (formerly called DIRS1). The two subunits are preferably linked together. In one embodiment one subunit is fused to the constant region of the light chain of an immunoglobulin, and the other subunit is fused to... Agent: Zymogenetics, Inc. Intellectual Property Department

20100197573 - Transglutaminase mediated conjugation of growth hormone: A method for PEGylating growth hormone, said method comprising reacting growth hormone with an amine comprising nucleophile which further comprises a first functional group in the presence og TGase to form a transaminated growth hormone, followed by a reaction of said transaminated growth hormone with a PEG which has been... Agent: Novo Nordisk, Inc. Intellectual Property Department

20100197595 - Treatment of melanoma with alpha thymosin peptides: A method of treating melanoma or a metastasis thereof in a human patient by administering a melanoma-treating effective amount of an alpha thymosin peptide to a human melanoma patient, wherein the human melanoma patient does not have a substantially elevated LDH blood level.... Agent: Cooley LLP Attn: Patent Group

20100197587 - Use of a peptide as a therapeutic agent: The present invention is directed to the use of the peptide compound His-Ala-Asp-Gly-Ser-Phe-Ser-Asp-Glu-Met-Asn-Thr-Ile-Leu-Asp-Asn-Leu-Ala-Ala-Arg-Asp-Phe-Ile-Asn-Trp-Leu-Ile-Gln-Thr-Lys-Ile-Thr-Asp-Arg-OH as a therapeutic agent for the prophylaxis and/or treatment of cancer, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurodegenerative diseases, infectious diseases, lung diseases, heart and vascular diseases and metabolic diseases. Moreover the present invention relates to pharmaceutical... Agent: Winstead PC

20100197588 - Use of a peptide as a therapeutic agent: The present invention is directed to the use of the peptide compound His-Ser-Asp-Gly-Ile-Phe-Thr-Asp-Ser-Tyr-Ser-Arg-Tyr-Arg-Lys-Gln-Met-Ala-Val-Lys-Lys-Tyr-Leu-Ala-Ala-Val-Leu-Gly-Lys-Arg-Tyr-Lys-Gln-Arg-Val-Lys-Asn-Lys-NH2 as a therapeutic agent for the prophylaxis and/or treatment of cancer, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurodegenerative diseases, infectious diseases, lung diseases, heart and vascular diseases and metabolic diseases. Moreover the present invention relates to pharmaceutical... Agent: Winstead PC

20100197585 - Use of a rgd-peptide and/or parathyroid hormone (1-34) as anti-hiv agent: The present invention is directed to the use of the peptide compound Gly-Arg-Gly-Asp-Asn-Pro as a therapeutic agent for the prophylaxis and/or treatment of cancer, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurodegenerative diseases, infectious diseases, lung diseases, heart and vascular diseases and metabolic diseases. Moreover the present invention relates to pharmaceutical... Agent: Winstead PC

20100197584 - Use of curcumin to block brain tumor formation in mice: The present invention provides compositions and methods of using curcumin or curcumin derivatives or analogs to activate the pro-apoptotic enzymes caspase-3/7 in cancer cells. The present invention also provides formulations of curcumin or derivatives or analogs with increased solubility or improved bioavailability. The formulations may be administered to a subject... Agent: Fish & Richardson P.C. / Cuny Research Foundation Of The City University Of New

20100197586 - Use of secretin and optionally urodilatin as therapeutic agents: The present invention is directed to the use of the peptide compound His-Ser-Asp-Gly-Thr-Phe-Thr-Ser-Glu-Leu-Ser-Arg-Leu-Arg-Glu-Gly-Ala-Arg-Leu-Gln-Arg-Leu-Leu-Gln-Gly-LeU-Val-NH2 as a therapeutic agent for the prophylaxis and/or treatment of cancer, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurodegenerative diseases, infectious diseases, lung diseases, heart and vascular diseases and metabolic diseases. Moreover the present invention relates to pharmaceutical... Agent: Winstead PC

20100197592 - Variant axmi-r1 delta endotoxin genes and methods for their use: Compositions and methods for conferring pesticidal activity to bacteria, plants, plant cells, tissues and seeds are provided. Compositions comprising a coding sequence for pesticidal polypeptides are provided. The coding sequences can be used in DNA constructs or expression cassettes for transformation and expression in plants and bacteria. Compositions also comprise... Agent: Athenix Corporation

20100197598 - Novel macromolecule transduction domains and methods for identification and uses thereof: The present invention discloses novel macromolecule transduction domain (MTD) peptides which facilitate the traverse of a biologically active molecule across the cell membrane. Also disclosed are polynucleotides encoding the MTD peptides, methods of identifying the MTD peptides; methods of genetically engineering a biologically active molecule to have cell permeability by... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, L.L.P.

20100197599 - Use of a peptide as a therapeutic agent: The present invention is directed to the use of the peptide compound Met-Ala-Pro-Arg-Gly-Phe-Ser-Cys-Leu-Leu-Leu-Leu-Thr-Ser-Glu-Ile-Asp-Leu-Pro-Val-Lys-Arg-Arg-Ala-OH as a therapeutic agent for the prophylaxis and/or treatment of cancer, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurodegenerative diseases, infectious diseases, lung diseases, heart and vascular diseases and metabolic diseases. Moreover the present invention relates to pharmaceutical... Agent: Winstead PC

20100197601 - Use of a fibrinogen receptor antagonist and/or follicular gonadotropin releasing peptide as a therapeutic agent in the treatment of streptococcus pneumonia infection: The present invention is directed to the use of the peptide compound Ac-Pen-Arg-Gly-Asp-Cys-OH as a therapeutic agent for the prophylaxis and/or treatment of cancer, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurode-generative diseases, infectious diseases, lung diseases, heart and vascular diseases and metabolic diseases. Moreover the present invention relates to pharmaceutical... Agent: Winstead PC

20100197602 - Use of follicular gonadotropin releasing peptide as a therapeutic agent in the treatment of streptococcus pneumoniae infection: The present invention is directed to the use of the peptide compound Thr-Asp-Thr-Ser-His-His-Asp-Gln-Asp-His-Pro-Thr-Phe-Asn-OH as a therapeutic agent for the prophylaxis and/or treatment of cancer, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurodegenerative diseases, infectious diseases, lung diseases, heart and vascular diseases and metabolic diseases. Moreover the present invention relates to pharmaceutical... Agent: Winstead PC

20100197600 - Use of the peptide his-ser-leu-gly-lys-trp-leu-gly-his-pro-asp-lys-phe alone or in combination with the peptide pro-gly-thr-cys-glu-ile-cys-ala-tyr-ala-ala-cys-thr-gly-cys-oh as a therapeutic agent: The present invention is directed to the use of the peptide compound His-Ser-Leu-Gly-Lys-Trp-Leu-Gly-His-Pro-Asp-Lys-Phe as a therapeutic agent for the prophylaxis and/or treatment of cancer, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurodegenerative diseases, infectious diseases, lung diseases, heart and vascular diseases and metabolic diseases. Moreover the present invention relates to pharmaceutical... Agent: Winstead PC

20100197603 - Use of rgdspasskp and optionally angiotensin ii as therapeutic agents in the treatment of eg s. pneumoniae infections: The present invention is directed to the use of the peptide compound Arg-Gly-Asp-Ser-Pro-Ala-Ser-Ser-Lys-Pro-OH as a therapeutic agent for the prophylaxis and/or treatment of cancer, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurodegenerative diseases, infectious diseases, lung diseases, heart and vascular diseases and metabolic diseases. Moreover the present invention relates to pharmaceutical... Agent: Winstead PC

20100197605 - Therapeutic use of peptide yglf and combination with kvlpvpq: The present invention is directed to the use of the peptide compound Tyr-Gly-Leu-Phe-OH as a therapeutic agent for the prophylaxis and/or treatment of cancer, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurodegenerative diseases, infectious diseases, lung diseases, heart and vascular diseases and metabolic diseases. Moreover the present invention relates to pharmaceutical... Agent: Winstead PC

20100197604 - Use of peptide as a therapeutic agent: The present invention is directed to the use of the peptide compound Asp-Arg-Val-Tyr-Ile-His-Pro-Phe-OH as a therapeutic agent for the prophylaxis and/or treatment of cancer, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurodegenerative diseases, infectious diseases, lung diseases, heart and vascular diseases and metabolic diseases. Moreover the present invention relates to pharmaceutical... Agent: Winstead PC

20100197607 - Mucin hypersecretion inhibitors and methods of use: Peptides are provided that comprise less than 24 amino acids. The peptides have an amino acid sequence selected from the group consisting of: (a) an amino acid sequence having from 4 to 6 contiguous amino acids of a reference sequence PEPTIDE 1; (b) an amino acid sequence substantially identical to... Agent: Cooley LLP Attn: Patent Group

20100197606 - Non-proteolysable oligopeptides that inhibit glycoprotein gp41 of the aids virus: The invention relates to non-proteolysable oligopeptides that inhibit glycoprotein 41 of the AIDS virus. More specifically, the invention relates to the identification of oligopeptides, particularly hexapeptides, (D), (L) or mixed, preferably D-hexapeptides, which inhibit the binding of a retrovirus to a target cell, thereby providing novel therapies against infection from... Agent: Ladas & Parry LLP

20100197608 - Use of melanotrophin-potentiating factor as a therapeutic agent: The present invention is directed to the use of the peptide compound Lys-Lys-GIy-Glu-OH as a therapeutic agent for the prophylaxis and/or treatment of cancer, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurodegenerative diseases, infectious diseases, lung diseases, heart and vascular diseases and metabolic diseases. Moreover the present invention relates to pharmaceutical... Agent: Winstead PC

20100197609 - Alkylamino-substituted dicyanopyridines and their amino acid ester prodrugs: The present application relates to novel 6-alkylamino-substituted dicyanopyridines, to their amino acid ester prodrugs, to processes for their preparation, to their use for the treatment and/or prophylaxis of diseases and to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, preferably for the treatment and/or prevention of... Agent: Barbara A. Shimei Director, Patents & Licensing

20100197611 - Alternative agent with vitamin d-like activity and an improving agent for intestinal function: The present invention relates to an alternative agent with vitamin D-like activity or an improving agent for age-related depression of intestinal function, comprising a sugar-phosphate ester or a salt thereof, as an active ingredient.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, L.L.P.

20100197610 - Fructose 1, 6 bisphosphate - a novel anticonvulsant drug: The present invention concerns methods and compositions for preventing one or more epileptic seizures in an individual by delivering fructose-1,6-bisphosphate to the individual. In certain cases, an additional therapy for epilepsy is provided to the individual.... Agent: Fulbright & Jaworski, LLP

20100197612 - Composition and methods for the treatment of cancer: wherein X is selected from the group consisting of: a nitro, an imidazole, a halide, sulfonate, a carboxylate, an alkoxide, and amine oxide; and R is selected from the group consisting of: OR′, N(R″)2, C(O)R′″, C1-C6 alkyl, C6-C12 aryl, C1-C6 heteroalkyl, a C6-C12 heteroaryl, H, and an alkali metal; where... Agent: Thorpe North & Western, LLP.

20100197613 - Methods for inhibition of nkt cells: Molecules that interact with the NKT cell antigen receptor and its counterpart antigen presenting molecule, but which inhibit the NKT cell immune function, are administered to a patient. Conditions of particular interest include the treatment of systemic lupus erythematosus (SLE), cancer, atherosclerosis, and allergic disease. In some embodiment of the... Agent: Wilson, Sonsini, Goodrich & Rosati

20100197617 - Process for the preparation of caralluma extract and a formulation prepared thereof: Processes for the preparation of Caralluma extract which includes shade-drying of Caralluma plant material; ii) treating the dried Caralluma plant material by at least one operation selected from a group consisting of sorting, cleaning and sizing to obtain Caralluma plant material meant for extraction or any combination thereof; iii) extracting... Agent: Lucas & Mercanti, LLP

20100197616 - Proliferation inhibitor of helicobacter pylori including alpha-n-acetyl-glucosaminyl bond-containing monosaccharide derivatives: (in the formula (1), Y is a straight-, branched- or cyclic-aliphatic hydrocarbon group having 1 to 27 carbon atoms or a straight-, branched- or cyclic-acyl group having 1 to 27 carbon atoms). The diet of the food, the beverage or the pharmaceutical preparation comprises the proliferation inhibitor of Helicobacter pylori.... Agent: Oliff & Berridge, PLC

20100197615 - Synthesis of compounds useful as modulators of amyloid-beta production: As described herein, the present invention provides methods for preparing compounds useful for treating or lessening the severity of a neurodegenerative disorder. The present invention also provides methods of treating or lessening the severity of such disorders wherein said method comprises administering to a patient a compound of the present... Agent: Choate, Hall & Stewart LLP

20100197614 - Treatment of urinary tract infections with a mixture of saponin and an antibiotic: Device for treating urinary infections comprising a catheter and a container, wherein the container comprises a cholesterol-binding agent. Patients who are using a urinary catheter to empty the bladder of urine are very prone to get an infection and the risk of getting a catheter associated Urinary Tract Infections (UTI)... Agent: Jacobson Holman PLLC

20100197619 - Cyclin-dependent protein kinases inhibitors of scutellaria flavonoid organic amine derivatives, synthesis and use thereof: The present invention provides a series of cyclin-dependent protein kinases (Cdks) inhibitors, Scutellaria flavonoid organic amine derivatives, synthesis and use thereof. The preparation method is as follows: taking Baicalein (or Wogonin) from Scutellaria baicalensis as lead compound, mixting it with formaldehyde solution and organic amine compounds based on the molar... Agent: Squire, Sanders & Dempsey L.L.P.

20100197618 - Extract of rehmannia glutinasa libosch for reducing blood sugar, reducing blood fat, treating leukemia, and preparation method uses thereof: The present invention relates to a Rehmannia glutinasa Libosch. extract for reducing blood glucose and lipid levels and treating hematologic diseases such as leukemia, and methods for preparing the same. The extract is prepared by subjecting fresh Rehmannia glutinasa Libosch. to flux extraction, concentrating the resultant extract, dissolving the concentrated... Agent: Frommer Lawrence & Haug

20100197620 - Pesticidal formulations: The present invention relates to an active composition for controlling or eradicating Phthiraptera, Siphonaptera and Acarina Pests, typically in domestic animals, comprising a synergistic combination of at least one A83543 compound and at least one macrocyclic lactone. The invention also relates to the use of the active composition in pesticidal... Agent: Eli Lilly & Company

20100197623 - Anti-infammatory macrolide: e

20100197621 - Methods of reducing the proliferation and viability of microbial agents: The invention relates to formulations of an antimicrobial agent, a lipid, and optionally a surfactant, and uses thereof for reducing the proliferation and viability of microbial agents.... Agent: Jones Day

20100197622 - Non-peptide macrocyclic histone deacetylase (hdac) inhibitors and methods of making and using thereof: e

20100197624 - Anthelmintic combination: A method is provided for the treatment of parasitic infestations in mammals, comprising the step of simultaneously or sequentially administering to the mammal effective amounts of (a) 2-desoxoparaherquamide; and (b) abamectin. Also provided is an anthelmintic composition comprising 2-desoxoparaherquamide and abamectin.... Agent: Pharmacia & Upjohn

20100197625 - Synthetic lipophilic inositol glycans for treatment of cancer and glucose-metabolism disorders: The present intervention related to materials and methods for the synthesis of lipophilic inositol glycan compounds, and salts, solvates and physiological functional derivatives thereof, and their use for the treatment of cancer and glucose-metabolism disorders, such as, for example, diabetes, obesity and metabolic syndrome.... Agent: Nutter Mcclennen & Fish LLP

20100197762 - Antisense compounds: Provided herein are gapmer oligomeric compounds for reduction of target RNA in vivo comprising different nucleotide modifications within one or both wing regions. Also provided are methods of using such oligomeric compounds, including use in animals. In certain embodiments, such compound have desirable potency and toxicity characteristics.... Agent: Woodcock Washburn LLP

20100197764 - Antisense modulation of acyl coa cholesterol acyltransferase-2 expression: Antisense compounds, compositions and methods are provided for modulating the expression of acyl CoA cholesterol acyltransferase-2. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding acyl CoA cholesterol acyltransferase-2. Methods of using these compounds for modulation of acyl CoA cholesterol acyltransferase-2 expression and for treatment of... Agent: Jones Day For Isis Pharmaceuticals, Inc.

20100197766 - Antisense oligonucleotides directed to ribonucleotide reductase r2 and uses thereof in the treatment of cancer: The present invention provides antisense oligonucleotides directed to a mammalian ribonucleotide reductase R2 gene and combinations of the antisense oligonucleotides with one or more chemotherapeutic agents for use in the treatment of cancer.... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20100197765 - Method for promoting the expression of p53, and p53 expression promoter for use in the method: A method for promoting expression of p53 mRNA and an expression promoting agent for use in the method are provided. The expression of the p53 gene can be promoted by inhibiting the binding between RNA transcribed from exon 1 of the vegf-A gene and mRNA transcribed from the p53 gene.... Agent: Hamre, Schumann, Mueller & Larson, P.C.

20100197763 - Rna interference mediated inhibition of cyclic nucleotide type 4 phosphodiesterase (pde4b) gene expression using short interfering nucleic acid (sina): The present invention relates to compounds, compositions, and methods for the study, diagnosis, and treatment of traits, diseases and conditions that respond to the modulation of cyclic nucleotide type 4 phosphodiesterase (PDE4B) gene expression and/or activity, including PDE4B1, PDE4B2, and PDE4B3 gene expression and/or activity. The present invention is also... Agent: Merck C/o Sirna Therapeutics, Inc.

20100197773 - Compositions and methods for inhibiting expression of ptp1b genes: This invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of a PTP1B gene. The invention also relates to a pharmaceutical composition comprising the dsRNA or nucleic acid molecules or vectors encoding the same together with a pharmaceutically acceptable carrier; methods for treating diseases caused by the... Agent: Hoffmann-la Roche Inc. Patent Law Department

20100197771 - Influenza virus vaccine composition and methods of use: The present invention is directed to enhancing the immune response of a human in need of protection against IV infection by administering in vivo, into a tissue of the human, at least one polynucleotide comprising one or more regions of nucleic acid encoding an IV protein or a fragment, a... Agent: Sughrue Mion, PLLC

20100197775 - Methods and compositions for treating & diagnosing mood disorders, schizophrenia, and neuro-psychiatric disorders: This invention provides: methods of determining a predisposition or susceptibility of a subject to a mood disorder, a schizophrenia, or a neuro-psychiatric disease or disorder, comprising detecting a presence of a polymorphism in a vesicular monoamine transporter 1 (VMAT1) gene or a haplotype comprising the polymorphism, and methods of treating... Agent: Pearl Cohen Zedek Latzer, LLP

20100197768 - Methods and compositions related to the structure and function of apobec3g: Disclosed are methods and compositions related to the structure and function of APOBEC3G.... Agent: Drinker Biddle & Reath Attn: Intellectual Property Group

20100197770 - Methods for determining heptocellular carcinoma subtype and detecting hepatic cancer stem cells: The invention provides a method of determining an HCC subtype in a subject comprising a) obtaining a sample from the subject, b) assaying the sample to detect the expression of 1 or more biomarkers, and c) correlating the expression of the biomarkers with an HCC subtype in a subject. The... Agent: Macmillan, Sobanski & Todd, LLC - Nih/osu

20100197774 - Microrna expression abnormalities in pancreatic endocrine and acinar tumors: The present invention provides novel methods and compositions for the diagnosis, prognosis and treatment of pancreatic cancer. The invention also provides methods of identifying anti-pancreatic cancer agent.... Agent: Macmillan Sobanski & Todd, LLC

20100197767 - Nucleic acid construct systems capable of daignosing or treating a cell state: Nucleic acid construct systems are disclosed capable of diagnosing and treating a cell state (e.g. disease state). Methods of diagnosing and treating disease states using the nucleic acid constructs described herein are also disclosed. In addition, methods of screening for agents capable of reversing a disease phenotype using the nucleic... Agent: Martin D. Moynihan D/b/a Prtsi, Inc.

20100197769 - Plasmid containing a sequence encoding a disintegrin domain of metargidin (rdd): The invention relates to a pORT plasmid containing a sequence encoding all or part of a disintegrin domain of metargidin (RDD) or a derivative thereof under the control of strong cytomegalovirus promoter, in particular a plasmid having the sequence shown in SEQ ID NO:2.... Agent: Stites & Harbison PLLC

20100197772 - Tissue-specific micrornas and compositions and uses thereof: The invention provides for isolated nucleic acid sequences of newly discovered micro RNAs that have been identified to exist in normal Human B cells and/or in tumor-related Human B cells, using an integrated bioinformatics method and pipeline described herein.... Agent: Wilmerhale/columbia University

20100197626 - Biomarkers for depression and methods using the same: The present invention provides various biomarkers of depression. The present invention also provides various methods of using the biomarkers, including methods for diagnosis of depression, methods of determining predisposition to depression, methods of monitoring progression/regression of depression, methods of assessing efficacy of compositions for treating depression, methods of screening compositions... Agent: Brinks, Hofer, Gilson & Lione

20100197628 - Methods of treating psychiatric, substance abuse, and other disorders using combinations containing omega-3 fatty acids: The invention provides methods for treating or preventing psychiatric disorders, substance abuse disorders, and other conditions, e.g., cardiovascular disease and cancer, involving administration of a therapeutically-effective amount of a cytosine-containing or cytidine-containing compound, creatine-containing compound, adenosine-containing, adenosine-elevating compound, omega-3 fatty acids, or combinations thereof to a mammal. The invention further... Agent: Clark & Elbing LLP

20100197627 - Pancreatic cancer treatment: N4 derivatives of the known antitumor compound CNDAC are useful in treatment of pancreatic cancer, especially as an adjuvant treatment and especially over long term administration.... Agent: Morrison & Foerster LLP

20100197629 - Oral pharmaceutical solutions containing telbivudine: A pharmaceutical solution suitable for oral administration comprising β-L-thymidine/2′-deoxy-L-thymidine (telbivudine), a pharmaceutically suitable solvent system, one or more taste-enhancing/masking agents, a preservative system, and a buffer system suitable to allow both drug stability and preservation.... Agent: Novartis Corporate Intellectual Property

20100197630 - Cetp inhibitors derived from benzoxazole arylamides: Compounds having the structure of Formula I, including pharmaceutically acceptable salts of the compounds, are potent CETP inhibitors, and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis. In formula I, A-B is an arylamide moiety.... Agent: Merck

20100197632 - Anti-inflammatory dermatological composition comprising corticosteroids and hyaluronate fragments, and uses thereof: Anti-inflammatory dermatological composition for topical administration, characterized in that it comprises 0.005% to 0.1%, preferably 0.01% to 0.05% by weight of a corticosteroid and 0.1% to 1%, preferably 0.5% to 1% by weight of hyaluronate fragments with an average molecular weight of between 20 and 500 kDa, preferably between 20... Agent: Birch Stewart Kolasch & Birch

20100197631 - Hyaluronic acid derivatives containing groups able to release no: Disclosed are hyaluronic acid derivatives functionalised with S-nitrosothiol groups of the general formula: wherein HA indicates hyaluronic acid and G indicates a suitable spacer.... Agent: Birch Stewart Kolasch & Birch

20100197633 - n-alkyl-heterocyclyl carboxamide derivatives: s

20100197634 - Inhibitors of janus kinases: The instant invention provides for compounds that inhibit the four known mammalian JAK kinases (JAK1, JAK2, JAK3 and TYK2) and PDK1. The invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting the activity of JAK1, JAK2, JAK3 TYK2 and PDK1 by administering the compound to a... Agent: Merck

20100197635 - Treatment of tardive dyskinesia with pyridoxal 5'-phosphate: This invention relates to treatment of Tardive Dyskinesia through the administration of pyridoxal 5′-phosphate. The treatment may be an oral administration of 100-4000 mg/day, for example, 100-750 mg/day or about 250 mg/day. Also provided is the use of pyridoxal 5′-phosphate for the preparation of a medicament for the treatment of... Agent: Merchant & Gould PC

20100197636 - Injectable calcium-phosphate cement releasing a bone resorption inhibitor: The present invention relates to a macroporous, resorbable and injectable apatitic calcium-phosphate cement with a high compressive strength useful as bone cement and releasing a bone resorption inhibitor, preparation method and uses thereof.... Agent: Stites & Harbison PLLC

20100197637 - Method of treatment using bisphosphonic acid: The present invention refers to a pharmaceutical composition of a bisphosphonic acid or salt thereof, and an excipient thereof, and a method of treating disorder characterized by pathologically increased bone resorption comprising orally administering at least 150% of the expected efficious daily dose of a bisphosphonic acid or a pharmaceutically... Agent: Hoffmann-la Roche Inc. Patent Law Department

20100197639 - Methods and devices for analysis of x-ray images: The present invention relates to methods and devices for analyzing x-ray images. In particular, devices, methods and algorithms are provided that allow for the accurate and reliable evaluation of bone structure from x-ray images.... Agent: Sunstein Kann Murphy & Timbers LLP

20100197638 - Skin beautifying agent: The present invention aims to provide a skin-beautifying agent, food, beverage, or feed for skin-beautification which has cosmetic effects such as moisturizing and beautifying the skin as well as preventing skin roughness and wrinkles by oral intake. The present invention further aims to provide a skin-beautifying agent containing a milk-derived... Agent: Townsend & Banta C/o Portfolio Ip

20100197640 - Novel sulfamoyl-phenyl-ureido compounds and their use as medicament: The present invention relates to novel sulfamoyl-phenyl-ureido compounds having the formula (I) or a physiologically acceptable salt or derivative thereof which are suitable for the therapy of infections caused by protozoa and in particular uncomplicated or severe malaria caused by plasmodia.... Agent: Millen, White, Zelano & Branigan, P.C.

20100197641 - Formulation for lipophilic agents: The invention relates to pharmaceutical formulations of lipophilic therapeutic agents in which such agents are solubilized in largely aqueous vehicles, and processes for preparing and using the same.... Agent: Michael Best & Friedrich LLP

20100197644 - Chemical compounds 572: e

20100197643 - Phytochemical-rich oils and methods related thereto: The invention relates to methods used in extracting oil from plants, plant fruits, and/or nuts, preferably fruits from plants of the family Arecaceae, or Palmae, even more preferably acai fruit. In some embodiments, the invention relates to methods of extracting the oil using an extraction solution comprising a volatile alcohol... Agent: Medlen & Carroll, LLP

20100197642 - Slow release misoprostol for obstetric and/or gynaecological applications: Described are medical applications of Misoprostol defined by a particular combination of sustained release or slow release dosage form and oral administration route for obstetric and/or gynaecological conditions and treatments. Further described are combination medications of Mifepristone with the aforementioned Misoprostol dosage form and administration.... Agent: Edwards Angell Palmer & Dodge LLP

20100197645 - Thioamide derivatives as progesterone receptor modulators: Thioamide compounds, and specifically, thioamide pyrrole compounds, and preparation thereof are provided. These thioamide compounds can be used as progesterone receptor modulators, in contraception, and in the treatment of progesterone-related maladies.... Agent: Howson & Howson LLP / Wyeth LLC

20100197646 - Solvent-based sterilisation of pharmaceuticals: A sterile composition of a pharmaceutical compound is prepared by combining solvent with a non-sterile pharmaceutical compound to form a solution and filtering to yield a sterile pharmaceutical compound, optionally removing all or part of the solvent, and under sterile conditions combining the compound with a pharmaceutically acceptable carrier.... Agent: Hedman & Costigan, P.C.

20100197647 - Compounds that inhibit oestrone sulphatase; compositions thereof; and methods employing the same: Disclosed and claimed are compounds suitable for use as an inhibitor of oestrone sulphatase in a subject in need thereof, as well as compositions containing such compounds and methods for using such compounds. Such compounds can be a sulphamate compound that has the Formula (X) and wherein X is a... Agent: Frommer Lawrence & Haug

20100197648 - Treatment of irritable bowel syndrome and related bowel disease: The present invention discloses a method of treating an individual having irritable bowel syndrome or a related disorder, comprising the step of administering to said individual a pharmacologically effective dose of a luminally active anti-inflammatory or immunosuppressive compound with minimal or no systemic side effects. Further provided is a method... Agent: Adler & Associates

20100197649 - Compositions and methods for diagnosing and treating community-acquired methicillin-resistant staphylococcus aureus: The present invention includes compositions and methods for diagnosing and treating CA-MRSA infections in patients. The methods are based on the finding that combining cefoxitin and a synthetic penicillin in a treatment regimen results in a synergistic effect of the two drugs, an effect that is related to PBP4 activity... Agent: Licata & Tyrrell P.C.

20100197650 - Compositions and methods of treatment comprising ceftaroline: The present invention provides compositions comprising ceftaroline or a pharmaceutically acceptable salt, solvate or a prodrug thereof alone or in combination with an antibacterial agent. The present invention provides methods of treating bacterial infection, which include administering an effective amount of ceftaroline or a pharmaceutically acceptable salt, solvate or a... Agent: Forest Laboratories, Inc. Attn: Charles S. Ryan

20100197651 - Pyridazinone compounds: e

20100197653 - Novel carbapenem derivatives: The present invention relates to novel carbapenem derivatives and belongs to pharmaceutical field. Specifically, the present invention relates to the compounds as represented by formulae (1) and (2), pharmaceutically acceptable salts, hydrolysable esters, isomers and intermediates thereof, wherein R1, R2, R3, R4 are described as in the description. The present... Agent: Brinks Hofer Gilson & Lione

20100197655 - Sulfonamide derivatives: e

20100197654 - Triazine kinase inhibitors:

20100197652 - Pyridine carboxamide orexin receptor antagonists: The present invention is directed to pyridyl carboxamide compounds which are antagonists of orexin receptors, and which are useful in the treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the... Agent: Merck

20100197656 - Compounds for the treatment of inflammatory diseases: and the pharmacologically acceptable salts, enantiomers, racemates, hydrates, or solvates thereof, which are suitable for the treatment of respiratory or gastrointestinal complaints or diseases, inflammatory diseases of the joints, skin, or eyes, diseases of the peripheral or central nervous system or cancers, as well as pharmaceutical compositions which contain these... Agent: Michael P. Morris Boehringer Ingelheim Usa Corporation

20100197657 - 2-aryl or heteroaryl indole derivatives: The present invention provides 2-aryl or heteroaryl indole derivatives which are ASIC channel modulators, maceutical compositions containing such compounds, and methods of using them as therapeutic agents.... Agent: Merck

20100197658 - Pharmaceutical use of fused 1,2,4-triazoles: Methods of using fused 1,2,4-triazoles for modulating the activity of 11β-hydroxysteroid dehydrogenase type 1 (11βHSD1) are described. The present compounds are modulators and more specifically inhibitors of the activity of 11βHSD1 and may be useful in the treatment, prevention and/or prophylaxis of a range of medical disorders where a decreased... Agent: High Point Pharmaceuticals, LLC

20100197659 - Biphenylcarboxamide derivatives as hedgehod pathway modulators: The invention provides a method for modulating the activity of the hedgehog signaling pathway. In particular, the invention provides a method for inhibiting aberrant growth states resulting from phenotypes such as Ptc loss-of-function, hedgehog gain-of-function, smoothened gain-of-function or Gli gain-of-function, comprising contacting a cell with a sufficient amount of a... Agent: Genomics Institute Of The Novartis Research Foundation

20100197660 - Azepine derivatives as gamma-secretase inhibitors: Compounds of formula (I), pharmaceutical compositions comprising them, and methods for their use are described.... Agent: Eli Lilly & Company

20100197661 - Method of treating neurological diseases and disorders: The present invention provides methods for treating neurological diseases and disorders. Compounds that replace or enhance the function of SMN or alleviate or reduce a phenotype of cells with low SMN protein levels are provided. Screening methods and kits for identifying such compounds also are provided.... Agent: Licata & Tyrrell P.C.

20100197662 - Heterocyclic compound having type i 11 beta hydroxysteroid dehydrogenase inhibitory activity: e

20100197663 - Method and compositions for treatment of painful disorders: Chronic pain is treated with a combination of a standard dose of a non-narcotic analgesic and a low dose of a tricyclic antidepressant compound. The invention is effective in the treatment of chronic pain associate with neuropathic or fibromuscular disorders, where such pain has been unresponsive to non-narcotic analgesics alone.... Agent: Barnes & Thornburg LLP

20100197664 - Novel b1-antagonists: r

20100197666 - (thio) -carbamoyl-cyclohexane derivatives and method for treating schizophrenia: The present invention relates to use of (thio)-carbamoyl-cyclohexane derivatives, particularly trans-4-{2-[4-(2,3-dichlorophenyl)-piperazin-1-yl]-ethyl}-N,N-dimethylcarbamoyl-cyclohexylamine and pharmaceutically acceptable salts thereof in the manufacture of a medicament for the treatment of schizophrenia. Furthermore, the present invention relates to the treatment of schizophrenia through the administration of (thio)-carbamoyl cyclohexane derivatives, particularly trans-4-{2-[4-(2,3-dichlorophenyl)-piperazin-1-yl]-ethyl}-N,N-dimethylcarbamoyl-cyclohexylamine and pharmaceutically acceptable salts... Agent: Fish & Richardson P.C.

20100197667 - Biphenyl compounds useful as muscarinic receptor antagonists: wherein a, b, c, m, s, t, W, Z, Ar, R1, R2, R3, R6, and R7 are as defined in the specification. The compounds of formula I are muscarinic receptor antagonists. The invention also provides pharmaceutical compositions containing such compounds, processes and intermediates for preparing such compounds and methods of... Agent: Theravance, Inc.

20100197665 - Indazole derivatives as kinase inhibitors for the treatment of cancer: Substituted indazole derivatives of formula (I) and pharmaceutically acceptable salts thereof, as defined in the specification, process for their preparation and pharmaceutical compositions comprising them are disclosed; the compounds of the invention may be useful in therapy in the treatment of diseases associated with a dysregulated protein kinase activity, like... Agent: Scully Scott Murphy & Presser, PC

20100197668 - 1,2,3,4-tetrahydropyrrolo[1,2-a]pyrazine-6-carboxamide and 2,3,4,5-tetrahydropyrrolo[1,2-a][1,4]-diazepine-7-carboxamide derivatives, preparation and therapeutic use thereof: The present invention relates to derivatives of 1,2,3,4-tetrahydropyrrolo-[1,2-a]pyrazine-6-carboxamides and of 2,3,4,5-tetrahydropyrrolo[1,2-a][1,4]diazepine-7-carboxamides, to the preparation thereof and to the therapeutic use thereof.... Agent: Andrea Q. Ryan Sanofi-aventis U.s. LLC

20100197669 - Kappa selective opioid receptor antagonist: A selective kappa opioid receptor antagonist useful for treating ethanol use disorder withdrawal and anxiety, and/or depression, or schizophrenia as independent comorbid conditions.... Agent: Eli Lilly & Company

20100197670 - Amidine, thiourea and guanidine derivatives of 2-aminobenzothiazoles and aminobenzothiazines for their use as pharmacological agents for the treatment of neurodegenerative pathologies: s

20100197671 - Phenyl amino pyrimidine compounds and uses thereof: The present invention relates to phenyl amino pyrimidine compounds which are inhibitors of protein kinases including JAK kinases. In particular the compounds are selective for JAK2 kinases. The kinase inhibitors can be used in the treatment of kinase associated diseases such as immunological and inflammatory diseases including organ transplants; hyperproliferative... Agent: Morrison & Foerster LLP

20100197672 - Pyrrole compounds as inhibitors of mycobacteria, synthesis thereof and intermediates thereto: The present invention relates to a compound having the general formula (3): synthesis, intermediates and uses thereof.... Agent: Lucas & Mercanti, LLP

20100197673 - Indole and indazole compounds as an inhibitor of cellular necrosis: The present invention relates to indole or indazole compounds, pharmaceutically acceptable salts or isomers thereof which are useful for the prevention or treatment of cellular necrosis and necrosis-associated diseases. The present invention also relates to a method and a composition for the prevention or treatment of cellular necrosis and necrosis-associated... Agent: Birch Stewart Kolasch & Birch

20100197674 - Oxopyrazine derivative and herbicide: e

20100197675 - Cyclic urea and carbamate inhibitors of 11 beta-hydroxysteroid dehydrogenase 1: This invention relates to novel compounds of the Formula (I), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful for the therapeutic treatment of diseases associated with the modulation or inhibition of 11 β-HSD1 in mammals. The invention further relates to pharmaceutical compositions of the novel compounds and... Agent: Foley & Lardner LLP

20100197676 - 5-substituted-2-phenylamino benzamides as mek inhibitors: i

20100197677 - Oxadiazoanthracene compounds for the treatment of diabetes:

20100197679 - Compounds: Bicyclic nitrogen containing compounds and their use as antibacterials... Agent: Glaxosmithkline Global Patents -us, Uw2220

20100197678 - Glucocorticoid mimetics, methods of making them, pharmaceutical compositions and uses thereof: wherein R1, R2, R3, A, B, C, D, E, G, X, Y, and Z are as defined herein, or a tautomer, prodrug, solvate, or salt thereof; pharmaceutical compositions containing such compounds, and methods of modulating the glucocorticoid receptor function and methods of treating disease-states or conditions mediated by the glucocorticoid... Agent: Michael P. Morris Boehringer Ingelheim Usa Corporation

20100197680 - Lactam-substituted dicarboxylic acids and use thereof: The present application relates to novel lactam-substituted dicarboxylic acid derivatives, processes for their preparation, their use for the treatment and/or prophylaxis of diseases, and their use for producing medicaments for the treatment and/or prophylaxis of diseases, especially for the treatment and/or prevention of cardiovascular disorders.... Agent: Barbara A. Shimei Director, Patents & Licensing

20100197683 - Fused ring compound and use thereof: Wherein each symbol is as defined in the specification, or a salt thereof, which has an angiotensin II receptor antagonistic activity and a peroxisome proliferator-activated receptor γ agonistic activity, and is useful as an agent for the prophylaxis or treatment of circulatory diseases such as hypertension and the like and/or... Agent: Foley And Lardner LLP Suite 500

20100197682 - Organic compounds: Phosphatidylinositol (PI) 3-kinase inhibitor compounds, their pharmaceutically acceptable salts, and prodrugs thereof; compositions of the new compounds, either alone or in combination with at least one additional therapeutic agent, with a pharmaceutically acceptable carrier; and uses of the new compounds, either alone or in combination with at least one additional... Agent: Novartis Institutes For Biomedical Research, Inc.

20100197684 - Substituted heterocyclic compounds: o

20100197681 - Triazolopyridine compounds and their use as ask inhibitors: The present invention relates to triazolopyridine compounds according to Formula (I), their use as medicament, for treating autoimmune disorders, inflammatory diseases, cardiovascular diseases and/or neurodegenerative diseases and a process for their preparation.... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20100197685 - Novel benzofuran type derivatives, a composition comprising the same for treating or preventing cognitive dysfunction and the use thereof: The present invention relates to the novel benzofuran derivatives, the preparation thereof and the composition comprising the same. The benzofuran derivatives of the present invention showed potent inhibiting activity of beta-amyloid aggregation and cell cytotoxicity resulting in stimulating the proliferation of neuronal cells as well as recovering activity of memory... Agent: Kirk Hahn

20100197686 - Therapeutic compounds: The invention provides compounds of Formula (I) and (IV): as described herein, as well as salts thereof. The compounds have anti-cancer properties and/or chemosensitization properties.... Agent: Viksnins Harris & Padys Pllp

20100197688 - Epha4 rtk inhibitors for treatment of neurological and neurodegenerative disorders and cancer: e

20100197687 - Indoles useful in the treatment of inflammation: wherein T, Y, X1, R1, R2, R3, R4 and R5 have meanings given in the description, and pharmaceutically-acceptable salts thereof, which compounds are useful in the treatment of diseases in which inhibition of the activity of a member of the MAPEG family is desired and/or required, and particularly in the... Agent: Morgan Lewis & Bockius LLP

20100197689 - Novel processes for the preparation of piperazinyl and diazapanyl benzamide derivatives: The present invention is directed to novel processes for the preparation of substituted piperazinyl and diazepanyl benzamides, useful for the treatment of disorders and conditions mediated by the histamine receptor.... Agent: Philip S. Johnson Johnson & Johnson

20100197690 - Pyrimidinyl pyridazinone derivatives: Compounds selected from the group according to Claim 1 are inhibitors of tyrosine kinases, in particular of Met kinase, and can be employed, inter alia, for the treatment of tumours.... Agent: Millen, White, Zelano & Branigan, P.C.

20100197692 - Bicyclic heteroaromatic compounds as inhibitors of stearoyl-coenzyme a delta-9 desaturase: Bicyclic heteroaromatic compounds of structural formula I are inhibitors of stearoyl-coenzyme A delta-9 desaturase (SCD). The compounds of the present invention are useful for the prevention and treatment of conditions related to abnormal lipid synthesis and metabolism, including cardiovascular disease; atherosclerosis; obesity; diabetes; neurological disease; metabolic syndrome; insulin resistance; liver... Agent: Merck

20100197694 - Compositions and methods for treatment of diseases and conditions with increased vascular permeability: The invention provides compositions and methods for treating diseases and conditions through reducing vascular permeability, selectively inhibiting VEGF-induced postcapillary venular leakage, and/or selectively reducing spread of viral and/or bacterial pathogens. The provided compositions and methods utilize low concentrations of selective α-2 adrenergic receptor agonists having a binding affinity of 300... Agent: Wood, Phillips, Katz, Clark & Mortimer

20100197693 - Novel benzenesulfonamides as calcium channel blockers: e

20100197691 - Soluble epoxide hydrolase inhibitors, compositions containing such compounds and methods of treatment: Compounds of the Formula: (I) as well as pharmaceutically acceptable salts and hydrates thereof, that are useful for treating hypertension, diabetes, inflammation, atherosclerosis, pain, and the like are disclosed. Pharmaceutical compositions and methods of use are also included.... Agent: Merck

20100197695 - Antitumoral derivatives of et-743: m

20100197697 - Piperidine derivatives as nk3 receptor antagonists: A, Ar1, Ar2, R1, R2, R3, R4, R5, R6, m, n, o, p, s, t, and u are as defined herein or to a pharmaceutically active salt, a racemic mixture, an enantiomer, an optical isomer or a tautomeric form thereof. the present compounds are high potential NK-3 receptor antagonists for... Agent: Hoffmann-la Roche Inc. Patent Law Department

20100197698 - 5-phenyl-3-pyridazinone derivative:

20100197699 - I-oxa-3-azaspiro (4.5) decan-2-one and 1-oxa-3, 8-diazaspiro (4.5) decan-2-one derivatives for the treatment of eating disorders: processes for their preparation, intermediates used in these processes, pharmaceutical compositions containing them and their use in therapy, as NPY Y5 receptor antagonists and as agents for the treatment and/or prophylaxis of eating disorders such as a binge eating disorder.... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B482

20100197696 - Pesticidal heterocyclic dihaloallyl compounds: Het, A1, A2, A3, A4, D, W, T, Q, Y, X1, X2, R1, R2, R3, R4, k and m are as defined hereinabove, and, where applicable, to possible E/Z isomers, mixtures of E/Z isomers and/or tautomers thereof, in each case in free form or in salt form, to a process... Agent: Syngenta Crop Protection , Inc. Patent And Trademark Department

20100197700 - 5-ht7 receptor antagonists: t

20100197701 - Method of treating diabetes: Methods are provided for treating diabetes, lowering plasma level of HbA1c, glucose plasma levels, total cholesterol plasma level, and/or triglyceride plasma level while increasing HDL cholesterol levels and delaying onset of diabetic retinopathy in a diabetic, pre-diabetic, or non-diabetic mammal while minimizing undesirable side effects.... Agent: Cv Therapeutics, Inc. Gilead Palo Alto, Inc.

20100197702 - Ophthalmic composition with nitric oxide donor compound and method of forming and using same: The present invention is directed to the provision of ophthalmic compositions such as multi-dose, topical, ophthalmic compositions. The compositions include a nitric oxide (NO) donor compound.... Agent: Alcon

20100197703 - N-sulfonyl thiazolylpiperazine derivatives and related n-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases: This invention provides thiazolylpiperazine derivatives, and N-sulfonyl heterocyclic derivatives including phenyl- and benzyl-thiazolylpiperidine derivatives, and pharmaceutically acceptable salts thereof, which are useful active ingredients for administration in a method for the treatment of an α-synucleopathy such as Parkinson's disease, diffuse Lewy body disease, traumatic brain injury, amyotrophic lateral sclerosis, Niemann-Pick... Agent: Clark & Elbing LLP

20100197704 - Pharmaceutical compositions and method for treating acute mania: The present invention relates to use of (thio)-carbamoyl-cyclohexane derivatives, particularly trans-4-{2-[4-(2,3-dichlorophenyl)-piperazin-1-yl]-ethyl}-N,N-dimethylcarbamoyl-cyclohexylamine and pharmaceutically acceptable salts thereof in the manufacture of a medicament for the treatment of acute mania. Furthermore, the present invention relates to the treatment of acute mania through the administration of (thio)-carbamoyl cyclohexane derivatives, particularly trans-4-{2-[4-(2,3-dichlorophenyl)-piperazin-1-yl]-ethyl}-N,N-dimethylcarbamoyl-cyclohexylamine and pharmaceutically... Agent: Fish & Richardson P.C.

20100197706 - Derivatives of 1-oxo-1,2-dihydroisoquinoline-5-carboxamides and of 4-oxo-3,4-dihydroquinazoline-8-carboxamides, preparation thereof and application thereof in therapeutics: The present invention relates to derivatives of 1-oxo-1,2-dihydroisoquinoline-5-carboxamides and of 1-oxo-3,4-dihydroquinazoline-8-carboxamides, to the preparation thereof and to the therapeutic use thereof.... Agent: Andrea Q. Ryan Sanofi-aventis U.s. LLC

20100197705 - Quinazolinone derivatives useful as vanilloid antagonists: e

20100197707 - Platelet manipulation to reduce the incidence of and treat endovascular disease and its sequelae, to reduce the incidence of and treat arrhythmias and to reduce the incidence of malignancy: Manipulation of total body platelet activity via pharmacologic, mechanical, electrical or electronic means, or any combination thereof, or any other means, alone or in conjunction with manipulation of the activity of the coagulation cascade, for the purpose of reducing the incidence and severity of vascular disease in at risk populations,... Agent: Attila Mady

20100197708 - Indole compounds: Indole derivatives that are useful for treating pain, inflammation and other conditions are described. Certain of the compounds are benzyl derivatives and others are benzoyl derivatives. The compounds are substituted at least at the 3 position of the indole.... Agent: Honigman Miller Schwartz & Cohn LLP/iron

20100197709 - Non-sedating barbiturate compounds as neuroprotective agents: Methods of providing neuroprotection are disclosed comprising administering a non-sedative barbiturate compound in an amount sufficient to achieve neuroprotection in a mammalian subject. Preferred compounds are in the family of diphenylbarbituric acid and analogs. Preferred doses for a neuroprotective effect exceed the dosage of a corresponding sedative barbiturate without sedative... Agent: Taro Pharmaceuticals U.s.a., Inc. C/o Venable LLP

20100197711 - Benzothiazole compounds: The present invention relates to benzothiazole compounds that mimic the activity of BH3 only proteins and are capable of binding to and neutralizing pro survival Bcl 2 proteins. The invention also relates to the use of such compounds in the regulation of cell death or cell survival and the treatment... Agent: Wilmerhale/boston

20100197710 - Methods of activating irs-1 and akt: The present invention provides methods of activating IRS-1 and/or AKT and methods of treating or preventing IRS-1- and/or AKT-related disease, condition, or disorder.... Agent: Pepper Hamilton LLP

20100197713 - Butone derivatives useful as cooling agents: Cooling compounds of formula (I) wherein R1 is selected from the group consisting of hydrogen, methyl, C1-C3 alkoxy, phenyl, C1-C3 alkylphenyl, C1-C3 alkoxyphenyl, thienyl, pyridyl, furyl, and indoyl; R2 is selected from the group consisting of hydrogen and hydroxyl, or R2 forms together with the carbon atom to which it... Agent: Curatolo Sidoti Co., Lpa

20100197712 - Use of dopamine stabilizers: At least one embodiment of the present invention relates to the use of a dopamine stabilizing substance in an oral, subcutaneous or intramuscular daily dose of 1-20 mg or in an intravenous daily dose of 0.1-2 mg in treatment of a neurological or psychiatric disorder characterized by a hypofunction of... Agent: Harness, Dickey & Pierce, P.L.C

20100197716 - N-linked heterocyclic antagonists of p2y1 receptor useful in the treatment of thrombotic conditions:

20100197715 - Piperidine derivatives:

20100197714 - Spiro-pyrano-pyrazole derivatives: The present invention relates to compounds of formula (I) below having pharmacological activity towards the sigma (σ) receptor, and more particularly to spiro-pyrano-pyrazole compounds, to processes of preparation of such compounds, to pharmaceutical compositions comprising them, and to their use in therapy and prophylaxis, in particular for the treatment of... Agent: Cooper & Dunham, LLP

20100197717 - Combination of a 5ht7 receptor ligand and an opioid receptor ligand: The present invention refers to a combination of a 5HT7 receptor ligand and an opioid receptor ligand, especially of a 5HT7 receptor agonist and an opioid receptor agonist, a medicament comprising this combination, or the use of this combination for the treatment of the symptoms of pain, the prevention or... Agent: Cooper & Dunham, LLP

20100197718 - Treatment of pediatric tumors: A subclass of camptothecin derivatives is disclosed to be useful for the preparation of a medicament for the treatment of pediatric tumors such as for examplerhabdomyosarcoma, primitive neuroectodermal tumors (PNET) and neuroblastoma.... Agent: Lucas & Mercanti, LLP

20100197719 - Medicament compositions containing anticholinergically-effective compounds and betamimetics: s

20100197720 - Heteroaryl-substituted diazatricycloalkanes and methods of use thereof: The present invention relates to amide and urea derivatives of heteroaryl-substituted diazatricycloalkanes, pharmaceutical compositions including the compounds, methods of preparing the compounds, and methods of treatment using the compounds. More specifically, the methods of treatment involve modulating the activity of the α7 nAChR subtype by administering one or more of... Agent: Womble Carlyle Sandridge & Rice, PLLC

20100197721 - Pyrrolo [3, 4-h] isoquinoline compounds and methods for modulating gated ion channels: The present invention relates to compositions and methods to modulate the activity of gated ion channels.... Agent: Lahive & Cockfield, LLP Floor 30, Suite 3000

20100197722 - Treatment for basal cell carcinoma: The present invention provides a method of treating basal cell carcinoma in a subject. Generally, the method includes administering to the subject an amount of IRM compound effective for treating basal cell carcinoma in a treatment cycle that includes at least two consecutive days in which the IRM compound is... Agent: Edwards Angell Palmer & Dodge LLP

20100197724 - 6.5 -pyrrolopiperidine tachykinin receptor antagonists: The present invention is directed to certain hydroxymethyl ether hydroisoindoline compounds which are useful as neurokinin-1 (NK-1) receptor antagonists, and inhibitors of tachykinin and in particular substance P. The invention is also concerned with pharmaceutical formulations comprising these compounds as active ingredients and the use of the compounds and their... Agent: Merck

20100197723 - Bicyclic compounds and methods of making and using same: Disclosed herein are compounds that may be modulators of 5-HT receptors, and methods of making and using same.... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20100197725 - 1-oxo-isoindoline-4-carboxamide and 1-oxo-1,2,3,4-tetrahydroisoquinoline-5-carboxamide derivatives, preparation and therapeutic use thereof: The present invention relates to derivatives of 1-oxo-isoindoline-4-carboxamides and of 1-oxo-1,2,3,4-tetrahydroisoquinoline-5-carboxamides, to the preparation thereof and to the therapeutic use thereof.... Agent: Andrea Q. Ryan Sanofi-aventis U.s. LLC

20100197726 - Inhibitor of the differentiation of t cells into th1 cells: e

20100197728 - Crystalline form of a quinolinone-carboxamide compound: The invention provides a crystalline hydrochloride salt of 1-isopropyl-2-oxo-1,2-dihydroquinoline-3-carboxylic acid {(1S,3R,5R)-8-[(R)-2-hydroxy-3-(methanesulfonyl-methyl-amino)propyl]-8-azabicyclo[3.2.1]oct-3-yl}amide or a solvate thereof. The invention also provides pharmaceutical compositions comprising such crystalline salt forms, methods of using such crystalline salt forms to treat diseases associated with 5-HT4 receptor activity, and processes useful for preparing such crystalline salt forms.... Agent: Theravance, Inc.

20100197727 - Quinoline derivatives as antibacterial agents: wherein Y is CH2, O, S, NH or N-alkyl; R3 is alkyl, Ar, Ar-alkyl, Het or Het-alkyl; q is 0 to 4; R4 and R5 each independently are hydrogen, alkyl or benzyl; or R4 and R5 may be taken together including the N to which they are attached; R6 is... Agent: Philip S. Johnson Johnson & Johnson

20100197730 - Methods for treating anxiety: Disclosed are methods of treating anxiety by administering to a patient in need of such treatment a compound having the following formula (I).... Agent: Allergan, Inc.

20100197729 - Therapeutic ((phenyl)imidazolyl)methylquinolinyl compounds: Disclosed herein is a compound of the formula (I) therapeutic methods, compositions, and medicaments related thereto are also disclosed.... Agent: Allergan, Inc.

20100197731 - kind of piperphentonamine hydrochloride lyophilized powder for injection and preparation and use thereof: A kind of piperphentonamine hydrochloride lyophilized powder for injection and a preparation method thereof. The injection is prepared by one portion of piperphentonamine hydrochloride, 2.5-30 parts of excipient and 400-600 parts of water for injection with pH 1.5-5.5 via freeze-drying. The excipient is mannitol, dextran, lactose, saccharose, polyethylene glycol, poloxamer,... Agent: Buchanan, Ingersoll & Rooney PC

20100197732 - Repaglinide substantially free of dimer impurity: The present invention provides highly pure repaglinide substantially free of dimer impurity, and process for the preparation thereof. The present invention also relates to 2-ethoxy-N-[(1S)-3-methyl-1-[2-(1-piperidinyl)phenyl]butyl]-4-[2-[[(1S)-3-methyl-1-[2-(1-piperidinyl)phenyl]butyl]amino]-2-oxoethyl]benzamide, an impurity of repaglinide, and a process for preparing and isolating thereof. The present invention further relates to pharmaceutical compositions comprising solid particles of pure... Agent: Cantor Colburn, LLP

20100197733 - Pyrrolidines and piperidines as orexin receptor antagonists: The invention relates to compounds of formula (I) wherein Y, A, N and R1 are as described in the description, to salts, especially pharmaceutically acceptable salts, of such compounds and to the use of such compounds as medicaments, especially as orexin receptor antagonists.... Agent: Hoxie & Associates LLC

20100197734 - Pleuromutilin derivatives and their use as antimicrobials: A compound of formula (I) or of formula (II) wherein X is oxygen or sulfur, and Y is a residue of pipecolic acid or a residue of an amino acid, preferably a naturally occurring amino acid.... Agent: Workman Nydegger 1000 Eagle Gate Tower

20100197735 - Novel phenylurea inhibitors of the enzyme soat-1 and pharmaceutical/cosmetic compositions comprised thereof: c

20100197736 - Cetp activity inhibitors: wherein R represents a straight chain or branched alkyl group; a straight chain or branched alkenyl group; a lower haloalkyl group; a substituted or unsubstituted cycloalkyl group; a substituted or unsubstituted cycloalkenyl group; a substituted or unsubstituted cycloalkylalkyl group; a substituted or unsubstituted aryl group, or a substituted or unsubstituted... Agent: Leydig Voit & Mayer, Ltd

20100197737 - Active agent combinations having insecticidal and acaricidal properties: e

20100197738 - Fly control method: This invention relates to a method of controlling or preventing infestations of flies on an animal by applying to the animal a composition comprising an parasiticidally effective amount of a compound of Formula 1, (3-bromo-N-[4-chloro-2-methyl-6-[(methylamino)carbonyl]phenyl]-1-(3-chloro-2-pyridinyl)-1H-pyrazole-5-carboxamide), or an N-oxide, or a salt thereof,... Agent: E I Du Pont De Nemours And Company Legal Patent Records Center

20100197739 - Stable suspension concentrate formulation for water-soluble compounds: The present invention is directed to an insecticidal water based suspension concentrate formulation comprising a water-soluble insecticide selected from the group consisting of N-cyanomethyl-4-(trifluoromethyl)nicotinamide and (EZ)-1-(6-chloro-3-pyridylmethyl)-N-nitroimidazolidin-2-ylidineamine and at least one water-soluble salt selected from the group consisting of magnesium sulfate (hydrated and anhydrous forms) and sodium sulfate, wherein the water-soluble... Agent: Patent Administrator Fmc Corporation

20100197740 - Method of screening compounds having anti-amyloid properties: The invention relates to a method of screening compounds having anti-amyloid properties. The method of screening compounds that are capable of dissociating or preventing high-affinity complexes between β-amyloid peptides and nicotinic acetylcholine receptors of human cortical tissues makes it possible to rapidly identify compounds intended for the curative and/or preventive... Agent: The Firm Of Hueschen And Sage

20100197741 - Ternary fungicidal compositions comprising boscalid and chlorothalonil: in a synergistically effective amount, methods for controlling phytopathogenic harmful fungi using compositions of boscalid, chlorothalonil and at least one active compound III, the use of boscalid and chlorothalonil with at least one active compound III for preparing such compositions, and also agents and seed comprising such compositions.... Agent: Brinks, Hofer, Gilson & Lione

20100197742 - New formulations and use thereof: A pharmaceutical formulation comprising one or more active pharmaceutical ingredients (APIs) suitable for intraoral uptake, that comprises cocoa powder, a process for manufacturing the formulation and use of the formulation for medical treatment.... Agent: Woodcock Washburn LLP

20100197744 - Organic compounds: Novel compounds that are inhibitors of protein tyrosine phosphatases (PTPases) and, thus, may be employed for the treatment of conditions mediated by PTPase activity. The compounds of the present invention may also be employed as inhibitors of other enzymes characterized with a phosphotyrosine binding region such as the SH2 domain.... Agent: Novartis Institutes For Biomedical Research, Inc.

20100197743 - Use of sulphur-containing heteroaromatic acid analogues: v

20100197745 - Gamma-glutamyl transpeptidase inhibitors and methods of use: The present invention enhances the effects of antitumor agents and increases the sensitivity of therapy-resistant tumor cells to antitumor agents such as chemotherapeutic agents and radiation. The present invention is thus directed to compositions and methods for inhibiting and killing neoplastic cancer cells, for example for the treatment, inhibition or... Agent: Dunlap Codding, P.C.

20100197747 - Synergistic insecticidal mixtures: The invention relates to insecticide mixtures comprising thiodicarb and at least one other known active ingredient from the category of chloronicotinyls, as well as the use of these mixtures to control animal pests.... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20100197746 - Synthesis of epothilones, intermediates thereto and analogues thereof: e

20100197748 - Anti-microbial composition: The present invention provides an anti-microbial composition comprising (i) an antimicrobial agent with surfactant properties; (ii) a siloxane selected from those having the formulae (H3C)[SiO(CH3)2]nSi(CH3)3, and (H3C)[SiO(CH3)H]nSi(CH3)3, and mixtures thereof, wherein n is from 1 to 24; and (iii) a polar solvent; wherein the ratio of (i) to (ii) is... Agent: Nelson Mullins Riley & Scarborough LLPIPDepartment

20100197749 - Chemical compounds: or pharmaceutically acceptable salts thereof, which possess Edg-1 antagonistic activity and are accordingly useful for their anti-cancer activity and thus in methods of treatment of the human or animal body. The invention also relates to processes for the manufacture of said chemical compounds, to pharmaceutical compositions containing them and to... Agent: Astrazeneca R&d Boston

20100197750 - Preservation of ergothioneine: Compositions comprising ergothioneine and a trimethylamine absorber are provided. Also provided are methods for preventing, reducing or minimizing the fishy, amine odor, due to trimethylamine, that is associated with the processing and/or storage of a preparation containing ergothioneine, by combining with the ergothioneine, during processing or prior to storage, a... Agent: The Estee Lauder Cos, Inc

20100197751 - Compositions of pegylated soluble tumor necrosis factor receptors and methods of preparing: The present invention provides for improved compositions comprising a PEGsTNF-R1 which, in addition to having useful higher concentrations, demonstrate decreased viscosity (<400 cP) and improved stability.... Agent: Amgen Inc. Law Department

20100197752 - Urocanic acid derivatives useful for the treatment of immune-related and inflammatory diseases: The invention relates to derivatives of urocanic acid that have improved efficacy and/or tissue penetration properties. The invention further provides use of these derivatives in a medicament for modulating an immune-related disease in an individual. Imidazole derivative, or a salt thereof, selected from O I1 W—C—R1 H— (formula 1); o... Agent: Renner Otto Boisselle & Sklar, LLP

20100197753 - Benzamides useful as s1p receptor modulators: e

20100197754 - Crystalline n--5-chloro-4-(4-chloro-1-methyl-1h-pyrazol-5-yl)-2-thiophenecarboxamide hydrochloride: An improved AKT inhibiting compound, crystalline N-{(1S)-2-amino-1-[(3-fluorophenyl)methyl]ethyl}-5-chloro-4-(4-chloro-1-methyl-1H-pyrazol-5-yl)-2-thiophenecarboxamide hydrochloride.... Agent: Glaxosmithkline Global Patents -us, Uw2220

20100197755 - Hydrazone modulators of cannabinoid receptors: Hydrazone compounds which modulate cannabinoid receptors are presented. Pharmaceutical compositions containing these compounds, methods of using these compounds as modulators of cannabinoid receptors and processes for synthesizing these compounds are also described herein.... Agent: NielsenIPLaw LLC

20100197756 - Indole-3-sulphur derivatives: The present invention relates to substituted indoles useful as pharmaceutical compounds for treating respiratory disorders. (I)... Agent: Fish & Richardson P.C.

20100197757 - Oxindoles as kinase inhibitors: The present invention relates to oxindoles of the formula I, their use as protein kinase activators or inhibitors, a method for their manufacture, their use for the preparation of a medicament for the treatment of diseases and their use for the manufacture of a pharmaceutical composition.... Agent: Millen, White, Zelano & Branigan, P.C.

20100197758 - Ischemia/reperfusion protection compositions and methods of using: The invention provides for ischemia/reperfusion protection compositions having one or more ketone bodies and melatonin. The invention also provides for methods of using such compositions to reduce or prevent ischemia/reperfusion injury due to blood loss, stroke or cardiopulmonary arrest or surgery.... Agent: Fish & Richardson P.C.

20100197759 - Administration of dithiolane compounds for photoprotecting the skin: e

20100197760 - Disubstituted phenylpyrrolidines as modulators of cortical catecholaminergic neurotransmission: The present invention provides compounds which increase extracellular levels of catecholamines, dopamine and norepinephrine, in cerebral cortical areas of the mammalian brain, and more specifically to the use of 3-(disubstituted aryl)-pyrrolidines for the treatment of central nervous system disorders.... Agent: Birch Stewart Kolasch & Birch

20100197761 - Fused cyclic compounds: e

20100197776 - Direct dissolution of docetaxel in a solvent in polysorbate 80: The disclosure relates to the solubilization of docetaxel in an organic solvent, to the mixture thereof with polysorbate 80, and to the evaporation of the solvent.... Agent: Andrea Q. Ryan Sanofi-aventis U.s. LLC

20100197777 - Synergistic combination of analgesic compounds: e

20100197779 - Phytoestrogenic isoflavone compositions, their preparation and use thereof for protection against and treatment of radiation injury: The present invention provides compositions and methods for the prophylactic and therapeutic treatment of animals, including humans from radiation injury. In particular, the present invention provides methods and compositions comprising the isoflavone genistein (4′,5,7-trihydroxyflavone) or phytoestrogenic isoflavonoids.... Agent: Woodcock Washburn LLP

20100197778 - Proanthocyanidins for the treatment of amyloid and alpha-synuclein diseases: A method of treating an amyloid disease, or a disease characterized by IAPP amyloid fibrils or islet amyloid deposits, in a mammalian subject. The method includes administering to the mammal a therapeutically effective amount of a various disclosed procyanidins or proanthocyanidins characterized by disclosed general formulae. A pharmaceutical composition and... Agent: Proteotech, Inc.

20100197780 - Compounds extracted from palm oil mill effluent for the treatment of cancer, compositions thereof and methods therewith: The present invention describes a composition and methods for prevention and treatment of cancer comprising compounds extracted from Palm oil mill effluent. Also, the invention describes effective therapeutic dosages of the compounds and their combinations. The present invention can be prepared independently or as a combination product.... Agent: Foley & Lardner LLP

20100197781 - Anti-malarial compound isolated from gomphostema niveum: e

20100197782 - Therapeutic agent for virus-associated malignancy: A therapeutic agent comprising fucoxanthin or fucoxanthinol as an active component is disclosed. The therapeutic agent is effective and high clinical utility for medical treatment and prevention of virus-associated malignancy such as adult T-cell leukemia and Burkitt lymphoma.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, L.L.P.

20100197783 - Radiation protection using single wall carbon nanotube derivatives: A method of reducing side effects of damage in a human subject exposed to radiation includes administering to the human subject carbon nanotubes in a pharmaceutically acceptable carrier after or prior to exposure to radiation. A composition for reducing radical damage includes a carbon nanotube which is functionalized (1) for... Agent: Winstead PC

20100197784 - Novel curcumin analogues and uses thereof: The present invention relates to compounds capable of acting as androgen receptor antagonists, pharmaceutical formulations containing the same, and methods of use thereof. Such uses include, but are not limited to, use as antitumor agents, particularly for the treatment of cancers such as colon, skin and prostate cancer and to... Agent: Myers Bigel Sibley & Sajovec

20100197785 - Omega-3 fatty acid fortified composition: The present invention relates to an omega-3 fortified composition, method for its production and use of said composition as a nutritional, food or pharmaceutical composition.... Agent: Volpe And Koenig, P.C.

20100197786 - Insect-repellent formulations: An insect repellent aqueous formulation comprising a combination of at least two essential oils, citrus peel tincture, and vinegar.... Agent: Dr. D. Graeser Ltd.

20100197787 - Composition for prevention of hypoglycemic condition: Disclosed is a composition for use in the prevention of a hypoglycemic condition, which comprises at least one compound selected from a branched amino acid, a pharmaceutically acceptable salt thereof and a derivative of the amino acid or salt as an active ingredient. The composition can promote the uptake of... Agent: Wenderoth, Lind & Ponack, L.L.P.

20100197789 - Anti-obesity agent and use thereof: Disclosed is a novel anti-obesity agent. Also disclosed is a therapeutic method using the anti-obesity agent. The anti-obesity agent comprises a GABAB receptor agonist or a pharmacologically acceptable salt thereof as an active ingredient.... Agent: Edwards Angell Palmer & Dodge LLP

20100197790 - Container for pharmaceutical use for the quantitative release of a single dose for oral administration of t3 and t4 thyroid hormones in solution: The present disclosure relates to a container for pharmaceutical use for the quantitative release of a single-dose for oral administration of the T3 and T4 thyroid hormones in solution, characterized by the fact of being formed with a plastic material having a Young's modulus between 10 and 80 MPa.... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20100197791 - Pharmaceuticals for transdermal use on animals: The invention relates to pharmaceutical preparations for use on animals, which are applied to the fur or the skin of the animal and whose active ingredient subsequently undergoes transdermal absorption.... Agent: Bayer Healthcare LLC

20100197788 - Preventive or therapeutic agent for disease caused by decrease in lacrimal fluid: The present invention provides pharmaceuticals for the prevention or treatment of diseases associated with decrease in tear. That is, the present invention provides pharmaceuticals for the prevention or treatment of diseases associated with decrease in tear such as dry eye, dry disorders of cornea and conjunctiva, disorders of the keratoconjunctival... Agent: Stuart D. Frenkel Frenkel & Associates, P.C.

20100197792 - 1-amino-alkylcyclohexane derivatives for the treatment of inflammatory skin diseases: The present invention relates to the treatment of an individual afflicted with inflammatory skin diseases comprising administering to the individual an effective amount of a 1-amino-alkylcyclohexane derivative.... Agent: The Firm Of Hueschen And Sage

20100197793 - Solid state forms of aliskiren compounds: The invention relates to solid states of pharmaceutically acceptable compounds of aliskiren, and processes for preparation thereof. The invention further provides pharmaceutical formulations comprising the amorphous or crystalline forms of pharmaceutically acceptable compounds of aliskiren and processes thereof; and a method of inhibiting renin for treating hypertension.... Agent: Kenyon & Kenyon LLP

20100197794 - Fluorine-containing organosulfur compound and pesticidal composition comprising the same: There is provided a fluorine-containing organosulfur compound having an excellent controlling effect on arthropod pests represented by the formula (I): wherein G represents an oxygen atom or a sulfur atom; R2 represents a C1-C4 chain hydrocarbon group which is optionally substituted with a halogen atom, etc.; R3 and R4 independently... Agent: Birch Stewart Kolasch & Birch

20100197795 - Transdermal compositions: The present invention is directed to transdermal compositions and the uses thereof. These compositions include at least one of the following components: a C1-C6 dialkyl, C12-C30 dialkyl quaternary ammonium salt, a C12-C30 fatty acid, a nitrogenous organic base, C12-C30 fatty alcohol, monoglyceride or the reaction products thereof.... Agent: Scully Scott Murphy & Presser, PC

20100197797 - Methods of managing fibromyalgia using milnacipran: The present invention relates to compositions comprising milnacipran or a pharmaceutically acceptable salt thereof (e.g., milnacipran hydrochloride) and methods for managing fibromyalgia comprising administering milnacipran or a pharmaceutically acceptable salt thereof (e.g., milnacipran hydrochloride). The present invention also relates to titration packs comprising dosage forms (e.g., tablets) comprising milnacipran or... Agent: Forest Laboratories, Inc. Attn: Charles S. Ryan

20100197796 - Methods of treating fibromyalgia syndrome, chronic fatigue syndrome and pain: The present invention provides a method of treating fibromyalgia syndrome (FMS), chronic fatigue syndrome (CFS), and pain in an animal subject. The method generally involves administering a therapeutically effective amount of a dual serotonin norepinephrine reuptake inhibitor compound or a pharmaceutically acceptable salt thereof, wherein said dual serotonin norepinephrine reuptake... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20100197798 - Abuse-resistant amphetamine prodrugs: The invention describes compounds, compositions, and methods of using the same comprising a chemical moiety covalently attached to amphetamine. These compounds and compositions are useful for reducing or preventing abuse and overdose of amphetamine. These compounds and compositions find particular use in providing an abuse-resistant alternative treatment for certain disorders,... Agent: Mcdermott Will & Emery LLP

20100197799 - Hydroxylamine derivatives: wherein n is 0, 1 or 2; R1 and R2, independently of each other, are H, OH or OCH3; R3 is H or CH3; R4 is H, C1-C3 straight or branched alkyl or, together with R3, forms a five to seven-membered carbocyclic ring; and R5 and R6, independently of each... Agent: Young & Thompson

20100197800 - Treatment and/or prevention of presbycusis by modulation of metabotropic glutamate receptor 7: The invention relates to the treatment and/or prevention of age-related hearing loss (presbycusis) with a modulator of a metabotropic glutamate receptor 7 (mGluR7).... Agent: Wilson, Sonsini, Goodrich & Rosati

20100197801 - Volatile distillate by-product of mint oil that promotes absorption and/or bioavailability of compounds of bio-medical and nutritional interest: Disclosed is an adjuvant for improving the bioavailability of bioactive compositions. The adjuvant is prepared from a byproduct of mint flavor production. In vitro and in vivo testing confirms effectiveness. The adjuvant contains a mixture of compounds which is effective to improve the oral bioavailability of a bioactive composition normally... Agent: Thaddius J. Carvis

20100197802 - Skin dressings: Improvements relating to skin dressing A skin dressing adapted, on activation, to generate one or more S-nitrosothiols by reaction between a thiol and a nitrate salt in the dressing, the skin dressing comprising a source of Cu2+, Zn2+ and/or Fe2+ ions for delivery of nitric oxide to a body site... Agent: Marshall, Gerstein & Borun LLP

20100197803 - Method for obtaining a sequoyitol-containing extract from a plant of the genus of trifolium, leguminosae or ginkoaceae and uses thereof: The method for obtaining a sequoyitol-containing extract from a plant of the genus of Trifolium, Leguminosae or Ginkgoaceae, an extract obtained by the method and the use of the extract for the preparation of medicaments for treating diabetes and its complications, the method comprises the steps of extracting with a... Agent: Harness, Dickey & Pierce, P.L.C

20100197804 - Pharmaceutical compositions comprising terbinafine: Pharmaceutical compositions for oral administration comprising terbinafine, a buffering component and a disintegrant. The compositions show rapid disintegration and having taste-masking properties.... Agent: Novartis Corporate Intellectual Property

20100197805 - Composition for improving the surface appearance of the skin: The present invention relates to a cosmetic composition in the form of a paste, containing, in a physiologically acceptable medium, at least 10% by weight, relative to its total weight, of filler(s), at least one silicone polyamide block copolymer (PSPA) and at least one wax having a starting melting point... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, L.L.P.

20100197806 - Method involving 1-benzotriazolyl carbonate esters of polymers: The invention provides a method comprising the steps of (i) reacting a water-soluble and non-peptidic polymer having two or more terminal hydroxyl groups with di(1-benzotriazolyl)carbonate to form a water-soluble and non-peptidic polymer having two or more 1-benzotriazolylcarbonate ester groups; and (ii) reacting the water-soluble and non-peptidic polymer having two or... Agent: Nektar Therapeutics

20100197807 - Compositions comprising reaction products of alkylamidoamines, alkylaminoimidazolines and free amine and their use: Compositions comprising reaction products of alkylamidoamines, alkylaminoimidazolines and free amine and also processes for their preparation and their use as solvents in agrochemical formulations.... Agent: Frommer Lawrence & Haug

20100197808 - Method for identifying mhc alleles in dogs: A method for identifying one or more MHC alleles present in a dog, the method comprising: (a) determining the nucleotide present at the or each polymorphic position specified for the one or more MHC alleles in any one of Tables 4 to 6 or determining the nucleotide(s) present at a... Agent: Fulbright & Jaworski, LLP

20100197810 - Oil-in-water emulsions: m

20100197809 - Skin solution and preparation method thereof: A skin solution for transporting molecules with high molecular weight to the skin, and/or moisturizing the epidermal tissues of the skin, and/or alternating the membrane permeability of the skin, and/or softening any type of callus, corns, nail folds or dry skin and facilitating the removal of the same. A method... Agent: Conley Rose, P.C. David A. Rose

20100197811 - Aqueous composition: The viscosity of the composition of the present invention is abruptly increased when heated at a temperature near the body temperature, but it is rapidly reduced when applying weak force thereto, for instance, by lightly shaking the same. When the medicament obtained by incorporating a drug into the composition of... Agent: Nixon & Vanderhye, PC

20100197812 - Compositions and methods for enhancing the stability of foods, beverages, nutritional supplements and cosmetics: The present invention provides metal-chelating or sequestering antioxidant compositions, derived from edible herbs, spices, fruits, vegetables and/or grains, useful for incorporating into foods, beverages, nutritional supplements and cosmetics for the purpose of enhancing the stability of said food, beverage or cosmetic. This invention provides processes for preparing these antioxidant, stability-enhancing... Agent: The Firm Of Hueschen And Sage

20100197813 - Heterocyclic compounds as sweetener enhancers: and physiologically acceptable salts thereof wherein G1, G2, G3, R1, R2, R7, R3, R4, and R5 are defined herein. Compounds according to Formula I can be used to enhance a sweet taste produced by a tastant. The invention is also directed to compositions comprising a compound according to the above... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

Previous industry: Perfume compositions
Next industry: Colloid systems and wetting agents; subcombinations thereof; processes of


######

RSS FEED for 20141002: xml
Integrate FreshPatents.com into your RSS reader/aggregator or website to track weekly updates.
For more info, read this article.

######

Thank you for viewing Drug, bio-affecting and body treating compositions patents on the FreshPatents.com website. These are patent applications which have been filed in the United States. There are a variety ways to browse Drug, bio-affecting and body treating compositions patent applications on our website including browsing by date, agent, inventor, and industry. If you are interested in receiving occasional emails regarding Drug, bio-affecting and body treating compositions patents we recommend signing up for free keyword monitoring by email.



Results in 6.8056 seconds

PATENT INFO